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Studies on Application of Silyl Groups in  
Ring-Closing Metathesis Reactions  
and Fragment-Based Probe Discovery 
 
Abstract 
In efforts to search for tool compounds that are capable of probing normal and 
disease-associated biological processes, both quality and identity of the screening 
collection are very important. Towards this goal, diversity-oriented synthesis (DOS) has 
been explored for a decade, which aims to populate the chemical space with diverse sets 
of small molecules distinct from the traditional ones obtained via combinatorial 
chemistry. 
 
In the practice of DOS, macrocyclic ring-closing metathesis (RCM) reactions 
have been widely used. However, the prediction and control of stereoselectivity of the 
reaction is often challenging; chemical transformation of the olefin moiety within the 
product is in general limited. Chapter I of this thesis describes a methodology that 
addresses both problems simultaneously and thus extends the utility of the RCM 
reactions. 
 
 iv 
By installing a silyl group at the internal position of one of the olefin termini, the 
RCM reaction could proceed with high stereoselectivity to afford the (E)-alkenylsiloxane 
regardless of the intrinsic selectivity of the substrate. The resulting alkenylsiloxane can 
be transformed to a variety of functionalities in a regiospecific fashion. The conversion of 
the (E)-alkenylsiloxanes to alkenyl bromides could proceed with inversion of 
stereochemistry for some substrates allowing the selective access of both the E- and Z-
trisubstituted macrocyclic alkenes. It was also found that the silyl group could trap the 
desired mono-cyclized product by suppressing nonproductive pathways. 
 
Chapter II of this thesis describes the application of the concept of DOS in the 
area of fragment-based drug discovery. Most fragment libraries used to date have been 
limited to aromatic heterocycles with an underrepresentation of chiral, enantiopure, sp3-
rich compounds. In order to create a more diverse fragment collection, the 
build/couple/pair algorithm was adopted. Starting from proline derivatives, a series of 
bicyclic compounds were obtained with complete sets of stereoisomers and high sp3 ratio. 
Efforts are also described toward the generation of diverse fragments using methodology 
described in Chapter I. The glycogen synthase kinase (GSK3β) was selected as the proof-
of-concept target for screening the DOS fragments.  
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Chapter I. 
Extending the Utility of Ring-Closing 
Metathesis Reactions through the 
Introduction of a Silyl Group 
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Chapter I-1. Introduction 
1. Application and limitations of metathesis reactions in the build/couple/pair 
strategy for the generation of optimal small-molecule screening collections 
One of the most challenging problems that organic chemists face is the need to generate 
optimal small-molecule screening collections capable of probing normal and disease-
associated biological processes. As described in a recent review,1 “the development of 
effective small-molecule probes and drugs entails at least three stages: 1) a discovery 
phase, often requiring the synthesis and screening of candidate compounds, 2) an 
optimization phase, requiring the synthesis and analysis of structural variants, 3) and a 
manufacturing phase, requiring the efficient, large-scale synthesis of the optimized probe 
or drug”. Therefore, a new type of synthetic chemistry aimed at yielding small molecules 
that increases the probability of success in all three phases should be developed. 
Although such transformative chemistry has historically proven difficult to achieve, a 
novel strategy in diversity-oriented synthesis (DOS)2 called build/couple/pair (B/C/P) has 
emerged, which may have the potential to achieve these goals. 
 
In the “build” phase (Scheme I-1), building blocks containing orthogonal sets of 
functional groups suitable for subsequent coupling and pairing reactions are bought or 
synthesized. For chiral building blocks, obtaining all possible stereoisomers in their 
enantiopure form is a requirement. In the “couple” phase, intermolecular coupling 
reactions are performed to join the building blocks together either without the creation of 
new stereogenic elements or with complete control of all possible stereochemical 
outcomes. In the “pair” phase, intramolecular functional-group-pairing reactions3 are 
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performed. In this strategy, molecular complexity is generated in pairing reactions and 
sometimes in coupling reactions as well. Stereochemical diversity is incorporated in the 
build and couple phases, while skeletal diversity is achieved through the different 
combinations of pairing reactions between polar and polar, polar and nonpolar, or 
nonpolar and nonpolar functional groups. Overall, this strategy integrates complexity-
generating reactions with diversity-generating processes4 by focusing on making the 
product of one reaction the substrate of a diverse range of subsequent pairing reactions.5  
 
Scheme I-1. Illustration of the build/couple/pair strategy (adapted from ref. 1). 
 
 
In practice, when applying the build/couple/pair strategy to generate diverse, small-
molecule screening collections, it is necessary to consider the qualities of an ideal 
functional group pairing reaction. There are two criteria by which such a reaction can be 
 4 
evaluated. First, the reaction used for pairing should be highly general over a wide range 
of substrates. By carefully studying previous works, we recognized that ring-closing 
metathesis (RCM) was widely used as a pairing reaction due to its generality and 
robustness. Besides forming cyclic structures with various ring sizes, metathesis reactions 
can provide skeletal diversity starting from different substrates (Scheme I-2). RCM 
produces a cyclic alkene from a diene (eq. 1,6 eq. 2,7 eq. 38), a cyclic diene from an ene-
yne (eq. 4,9 eq. 5,10 eq. 611) and a bicyclic diene from an ene-yne-ene (eq. 710). Moreover, 
a ring-opening/ring-closing cascade can generate polycyclic structures (eq. 812).  
 
Scheme I-2. Skeletal diversity generated from different types of RCM reactions. 
 
 
In addition to substrate generality and diversity, reactions yielding products that are in 
turn poised for further transformations are also desired. The ideal situation arises when 
the functional group(s) created by a highly general reaction is itself a substrate for an 
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array of synthetic transformations. For example, a β-hydroxy carbonyl moiety generated 
from an aldol reaction can be dehydrated, alkylated, reduced, or oxidized to provide 
different functionalities and the potential for further transformations. The diversification 
potential of such intermediates allows the efficient generation of analogues that are useful 
for the study of structure-activity relationships. Moreover, this potential also facilitates 
the medicinal chemistry effort to tune the physicochemical properties of a hit compound. 
Following this criterion, we became conscious of the fact that RCM products offer 
relatively few opportunities for further modification. We therefore initiated several 
research projects with the goal of expanding the diversification potential of the RCM 
products to further increase the utility of this reaction. 
 
2. RCM of dienes to build naturally occurring and novel macrocyclic compounds 
We initially focused on macrocyclic RCM of diolefinic substrates. Macrocyclic 
compounds (with ring sizes larger than or equal to 8) are important naturally occurring 
small molecules produced by various organisms during the course of evolution.  These 
macrocycles usually display interesting biological activities.13-33 A number of them and 
their analogues have been in use as therapeutics for years and include antibiotics 
(erythromycin,34 rifamycins,35,36 colistin37,38, daptomycin39, and vancomycin40-42), 
antifungals (amphotericin B43), immunosuppressants (sirolimus,44,45 and 
cyclosporine46,47), and cancer therapies (azaepothilone B48 and sirolimus49-51). Due to the 
biological activity and structural complexity of macrocyclic compounds, they represent 
an attractive and challenging class of compounds for organic chemists to synthesize.  
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Figure I-1. Summary of typical macrocyclization reactions. 
 
 
There are indirect ways to form macrocycles,52 yet the most efficient method is 
macrocyclization. In theory, any reaction that couples two parts of a linear molecule 
together can be used as a macrocyclization reaction. However in practice, only a small 
number of reactions have been developed and extensively used by organic chemists in 
this respect. Typical macrocyclization reactions (Figure I-1) include lactonization,53-57 
lactamization,56,58-63 alkylation,64-70 SNAr reactions,71-74 Horner-Wadsworth-Emmons or 
Wittig reactions,75-77 transition metal-catalyzed coupling reaction,78-90 and alkene ring-
closing metathesis.91-116 Other types of reactions such as ring-closing alkyne metathesis 
(RCAM),92,94,95,117 cycloaddition,118-122 oxidative lactonization,123,124 Prins-type 
reactions,125 and multicomponent cyclizations126-128 have also been recently explored. 
Among these transformations, RCM of diolefinic compounds is an attractive 
methodology for three major reasons. First, olefins are orthogonal to a number of 
common reactions and so rarely require protection. Second, reaction conditions of RCM 
are relatively mild, thus common functional groups (as well as protecting groups) are 
compatible under these conditions. Third, RCM is a catalyzed reaction that does not 
typically need any activating reagents. Therefore, since the commercialization of 
metathesis catalysts,129-131 the applications of RCM in synthesizing macrocyclic 
compounds have been extensively explored.   
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Figure I-2. Representative bioactive synthetic macrocycles made from RCM reactions. 
 
 
In addition to the total synthesis of macrocyclic natural products and their analogues, 
there has been interest in accessing non-naturally occurring macrocycles using RCM 
reactions in search for novel biological activities.98,99,101,107,109,111,114,132-136 Screening of 
such compounds has successfully yielded compounds that have novel antibiotic 
activities137-139 as well as activities against different types of biological targets including 
histone deacetylases8,140,141 and sonic hedgehog7 (Figure I-2). Moreover, macrocyclic 
RCM reactions have been extensively used in medicinal chemistry to cyclize precursors 
in order to improve target affinity and selectivity, as well as bioavailability and 
stability.142-150 Within our own laboratories, macrocyclic RCM has proven to be an 
enabling methodology toward the goal of assembling small-molecule screening 
collections to probe normal and disease-associated biological processes.7,8,12,151-153 
 
3. Limitations of ring-closing metathesis towards the generation of macrocyclic 
compounds and previous approaches to address them 
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In efforts to synthesize macrocyclic compounds via RCM reactions, we have recognized 
two major limitations: lack of control over the stereochemistry of olefin product and 
limited potential for further transformations on the olefin moiety (Scheme I-3).  
 
First, controlling the stereochemistry of the resulting olefin is often problematic.103,105,106 
Under the circumstances when the olefin moiety is not required for further transformation 
or in the final compound, the stereoselectivity generally will not be an issue after 
reduction of the double bond. On the contrary when the olefin moiety is crucial, it is often 
challenging to separate the desired stereoisomer from the mixture at the cost of the 
undesired isomer.154-161 In some extreme cases when the RCM reactions only generated 
the undesired stereoisomers, extra synthetic steps to produce the desired alkene 
configuration are required162 or the synthetic route has to be redesigned.77,163 Since a 
variety of factors can determine the stereochemical outcome in RCM reactions,76,103,106 
general strategies that give rise to either Z or E olefins remain a significant challenge. 
 
Scheme I-3. Limitations in macrocyclic RCM of diolefinic compounds.  
 
 
Two major advances that address the stereoselectivity of macrocyclic RCM reactions 
have been achieved.  One approach involves ring-closing alkyne metathesis and selective 
reduction of the macrocyclic alkyne intermediate to yield Z or E olefins (Scheme I-4, 
A).164-167 However, this approach is only applicable to ring sizes of 12 and larger due to 
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the ring strains of cyclic alkynes.168,169 Another approach is based on the development of 
Z-selective catalysts that have been successfully applied in cross-metathesis (CM) 
reactions and macrocyclic RCM reactions (Scheme I-4, B);170-174 however, catalysts that 
yield the E olefin product selectively have yet to be discovered. 
 
Scheme I-4. Two approaches to solve the stereoselectivity issue of macrocyclic RCM 
reactions. 
 
 
The second limitation of macrocyclic RCM is that, as mentioned above, there are few 
opportunities for further modification. The sp2 carbon atoms in a cyclic 1,2-disubstituted 
olefin (the typical RCM product) are not easily chemically differentiated. In the absence 
of a dominant steric or electronic bias within the substrate, achieving regioselectivity on 
such a product is problematic (e.g. in a hydroboration reaction). Due to this drawback, 
post-metathesis functionalizations have predominantly been confined to “symmetrical” 
transformations (Scheme I-3) such as hydrogenation, dihydroxylation,175-177 
epoxidation,154,177,178 and aziridination.179,180  
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4. Our proposed approach to address both the stereoselectivity and the post-RCM 
functionalization simultaneously by using a versatile silyl group (the major focus of 
this chapter) 
To address both limitations, we investigated the introduction of a chemical handle at the 
internal position of one of the olefins.  Such geminal-disubstituted olefins could generate 
cyclic trisubstituted alkenes upon the treatment with a RCM catalyst. First, the sterics of 
the exocyclic chemical handle would be expected to favor formation of the E product 
(assuming it is larger than a methylene group). Second, it would allow subsequent 
functionalization of the product that is not limited to “symmetrical” transformations. 
 
Aryl groups,181-184 carbonyl groups,185-193 silicon groups,194-199 boron groups,200,201 alkoxy 
groups,202-207 halogens,208-213 nitrogen,214,215 and phosphinate216 can be incorporated into 
the internal position of one of the olefins yielding a variety of trisubstituted alkene 
products. Yet to our knowledge, most of these precedents were limited to making small 
rings (5-, 6-, or 7-membered) and not macrocycles. It has been shown that alkyl groups (a 
methyl or ethyl group) can be installed to access trisubstituted macrocycles. However, 
they failed to control the stereoselectivity of the reaction154,161,217  
 
Among these explorations, we are especially interested in the cases when a non-carbon 
substituent was employed (Scheme I-5).  Advantages of having exocyclic silicon (eq. 
9,197,198 eq. 10196), bromide (eq. 11,213 eq. 12212), or boron (eq. 13,200 eq. 14201) attached to 
the alkenes in the product are due to the versatile nature of such groups. Ipso-protonation 
reactions (protodesilylation, protodebromination, protodeboronation) generate simple 
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disubstituted alkenes. Oxidation of alkenylsiloxanes and alkenylboronates yields ketones; 
of alkenyl bromide yields α-bromoketones. Most importantly, all of these functional 
groups can participate in transition-metal catalyzed coupling reactions, which enables 
diversification of the substituted alkenes in a regiospecific manner. 
 
Scheme I-5. RCM of vinyl halides, vinylboronates, and vinylsilanes to make 
trisubstituted cyclic alkenes. 
 
 
Our detailed proposal is described in Scheme I-6. Silyl groups were selected in our study 
owing to several reasons. First, the inclusion of a silyl group at the internal carbon of one 
of the olefins could be easily achieved via a regioselective hydrosilylation reaction of a 
terminal alkyne. A ruthenium-based catalyst developed in the Trost group is able to 
achieve this transformation with high chemo- and regio-selectivity, good functional 
group compatibility, and broad silyl group generality.197,198 Second, silylalkene groups 
are, in general, compatible with metathesis catalysts compared to bromoalkenes.218 Third, 
silyl groups are easier to handle and more stable than boryl groups. We also hypothesized 
that the steric bulk of the silyl group would likely control the stereoselectivity of the 
RCM reaction yielding the E product (Scheme I-6, the 1st goal). Moreover, if the (E)-
alkenylsiloxane can be transformed to the Z-trisubstituted alkenyl bromide (the 2nd goal), 
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we would not only obtain both stereoisomers, but also introduce great potential for 
further diversification of both stereoisomers.  
 
Scheme I-6. Expanding the scope of RCM reations through silyl group incorporation. 
 
 
5. Applications of silyl groups in other types of RCM reactions 
Given the versatility of the silyl group, another research project was also launched in our 
group to explore its potential in ene-yne RCM reactions. 
 
Scheme I-7. Extension of the ene-yne RCM reaction by the introduction of a silyl group.  
 
 
Ene-yne RCM reactions are powerful transformations to generate cyclic dienes. Without 
a functional group on the resulting diene, the most common way of further transforming 
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it was a Diels-Alder reaction (Scheme I-7, A). The incorporation of a silyl group on the 
alkyne moiety for ene-yne RCM was already reported but not well studied.219-226 The silyl 
group that ends up on the diene can be oxidized to generate an enone moiety (Scheme I-
7, B), which serves as a dienophile or hetero-diene as well as a Michael accepter. In 
addition, metal-catalyzed cross-coupling reactions can convert the silyl group to a variety 
of aromatic groups. The Diels-Alder reaction is still applicable but with the benefit of 
leaving a valuable alkenylsiloxane moiety for further transformations. 
 
Concurrent with our studies of macrocyclic RCM of vinylsiloxanes, the Fürstner group 
demonstrated the use of silyl groups in macrocyclic diene-ene RCM.227 By installing the 
silyl group on the C3 position of a terminal butadiene (Scheme I-8, eq. 15), they were 
able to control the stereochemical outcome of the macrocyclic RCM reaction (in this case 
E-selective) and prevent ring contraction to form the 10-membered ring (the reaction with 
the internal alkene of the diene) observed in the absence of the silyl group. 
 
Scheme I-8. An example of the use of silyl groups in macrocyclic diene-ene RCM. 
 
 
 
 
 
 14 
Chapter I-2. Ring-Closing Metathesis of  
Vinylsilanes and Vinylsiloxanes 
1. Initial attempt of RCM of vinylsilanes and vinylsiloxanes to form small rings and 
macrocycles 
As shown in Table I-1, Dr. Masaaki Hirano pioneered the RCM of trimethylvinylsilane 
1g’ to form a 5-membered ring.  Mr. Miguel Jimenez and I explored the RCM of 
dimethylphenylsilanes 1e’ or 2e’ and tert-butyldimethylsilanes 1h’ or 2h’ to form 5- or 6-
membered rings.  In accordance with previous reports, all substrates were successfully 
closed although the yields of different substrates varied. However, 8-membered rings 
bearing either silyl group, substrate 3e’ and 3h’ failed to undergo ring-closing metathesis. 
 
At the same time, Mr. Anders S. Hansen and Dr. Eun-Ang Raiber were attempting the 
RCM of vinylsilanes 6’ or 7’ to form 12- or 14-membered rings. Various reaction 
conditions were applied, but none of them were effective. Next they tried to introduce a 
rigidifying element to favour the ring closure. Substrates 8’ and 9’ were synthesized and 
subjected to various reaction conditions. However, no desired 15-membered products 
were observed under any condition. In most of the unsuccessful cases, incomplete 
conversion and decomposition of starting materials were observed.  
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Table I-1. Initial exploration on RCM of vinylsilanes and vinylsiloxanes to make small 
rings and macrocycles with various silyl groups and reaction conditions. 
Substrate Product Y.
[b] 
(%) 
Rxn 
cond.[a
] 
Substrate Product Y.
[b] 
(%) 
Rxn 
cond.[a
] 
  
95 A 
 
not observed - 
C, D, 
E, F, 
G, H, 
I 
  
92 A 
 
not observed - H, I, J 
  
81 B 
 
not observed - H, I, K 
  
95 A 
 
not observed - B, L 
  
44 B 
 
not observed - B, L 
 
not 
observed - B 
 
not observed - B 
 
not 
observed - B 
 
not observed - B 
  
20[c] B 
  
27[c] C 
 
not 
observed - B 
  
2[c] C 
a Reaction conditions: A. Grubbs II 10 mol%, DCM (20 mM), r.t., 18 h; B. Grubbs II 20 mol%, DCM (3 
mM), reflux, 18 h; C. Grubbs II 10 mol%, DCM (2 mM), reflux, 10 h; D. Hoveyda-Grubbs II 20 mol%, 
DCM (1.7 mM), reflux, 24 h; E. Grubbs II 10 mol%, toluene (2 mM), 65 °C, 18 h; F. Grubbs I 10 mol%, 
DCM (1.8 mM), reflux, 18 h; G. Grubbs II 20 mol%, toluene (3 mM), 300 W Microwave, 100 °C, 30 
min/cycle, 3 cycles; H. Schrock’s Mo-based catalyst 50 mol%, DCM (2.6 mM), r.t., 18 h; I. Schrock’s 
Mo-based catalyst 50 mol%, toluene (2.6 mM), 45 °C, 18 h; J. Hoveyda-Grubbs II 20 mol%, toluene (1.7 
mM), 60 °C, 24 h; K. Hoveyda-Grubbs II 20 mol%, toluene (1 mM), 300 W Microwave, 100 °C, 30 
min/cycle, 3 cycles; L. the isolated homodimers were resubmitted to condition C with 6 mol% Grubbs II 
catalyst added in 2 times. b Isolated yield unless otherwise indicated. c Yield determined by 1H NMR 
analysis. 
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Table I-2. Influence of the silyl group in CM reactions. 
 
Entry -[Si] -R Yield (%) 
1 Si(OEt)3 Ph 80 
2 SiCl3 Ph 83 
3 Si(OAc)3 Ph 75 
4 Si(OEt)2Me Ph 6 
5 Si(OEt)Me 2 Ph 5 
6 SiMe3 Ph 0 
7 SiPh3 C4H9 0 
8 Si(C6H4-Me-p)3 C4H9 0 
9 Si(C6H4-CF3-p)3 C4H9 97 
 
This result drew our attention the role of the silyl group. Although the influence of 
different silyl groups had not been extensively studied for RCM, there were ample 
precedents in the area of cross metathesis (CM). Pietraszuk et al. demonstrated that the 
influence of the silyl groups on CM largely originates from an electronic effect of the 
substituents on silicon (Table I-2).228-235 Silyl groups with electronegative substituents 
such as EtO-, AcO-, Cl- gave better yields than with Me- and/or Ph- groups (entry 1-3 
versus 6, 7). The use of (p-CF3Ph)3Si- led to quantitative yield in the CM reaction with 1-
hexene (entry 9) while the use of Ph3Si- or (p-MePh)3Si- did not produce any detectable 
product (entry 7 and 8). With this knowledge, we decided to pursue a substrate, that had 
been shown to undergo RCM to give a trisubstituted macrocycle (Scheme I-9),217 with 
alkoxysilyl groups (10a’ and 10b’) instead of the original methyl group (10-Me’). 
 
The initial attempts to close substrate 10a’ and 10b’ were not successful under condition 
B and only homodimers were isolated. Through personal contact with Prof. Fürstner by 
Dr. Raiber, it was found out that in order to close substrate 10-Me’, homodimers needed 
to be separated and resubmitted to the RCM reaction using Grubbs II as catalyst. 
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However following this procedure (Table I-1, condition L), they were still unable to 
cyclize either substrate. 
 
Scheme I-9. Reported RCM to form macrocyclic trisubstituted alkenes (adapted from ref 
181). 
 
 
Despite those unsuccessful attempts, Mr. Miguel Jimenez and I were able to obtain an 8-
membered ring 4a with a triethoxysilyl group. In contrast, substrate 5’ failed to yield the 
12-membered product.  Dr. Eun-Ang Raiber and I decided to revisit the salicylate-based 
substrates. Compounds 11a’ and 11b’ were made separately and submitted to RCM 
reactions.  However, both failed to give any cyclized products.  We then increased the 
ring size from 12 to 14 by inserting an ethylene group into the substrates.  Finally, 
substrate 12a’ with a triethoxysilyl group was successfully closed to generate the 14-
membered macrocyclic alkenylsiloxane 12a under un-optimized reaction conditions with 
27% 1H NMR yield. Surprisingly, the analogue 12b’ with a diethoxyphenylsilyl group 
yielded only 2% of the desired product 12b under the same reaction conditions. 
 
This initial exploration taught us several lessons.  First, macrocyclic RCM of 
vinylsiloxanes is possible. However, typical RCM conditions are not optimal. Second, 
ring sizes of the products seem to affect the outcome of the reaction, and so far only 8- 
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and 14-membered macrocycles were formed. Finally, the silyl groups played an 
important role in this reaction, which might be more complicated than a purely electronic 
effect in CM reactions. With this knowledge in mind, I decided to move forward to 
systematic optimization of the reaction conditions. 
 
2. Screening catalysts and optimizing reaction conditions for RCM of vinylsiloxanes 
to make macrocycles 
Substrate 13a’ (an analogue of 12a’ with an extra methylene group) was synthesized and 
subjected to the initial conditions. Not surprisingly, the yield of the 15-membered product 
13a dropped to 3% (Table I-3, Entry 2). This demanding substrate was then used to 
optimize the reaction conditions. 
 
Among commercially available ruthenium-based metathesis catalysts, catalyst A was able 
to increase the yield from 3% to 19% under the original reaction conditions. In contrast to 
the second-generation Grubbs catalyst, A bears one methyl group on the ortho-position of 
each phenyl ring, making it less sterically hindered and more reactive.236 After varying 
solvent, temperature, and concentration we found that optimal results (63%, 1H NMR 
yield) were obtained using benzene or toluene as solvent at 35 °C and with 20 mol% of 
catalyst A (Table I-3, Entry 11 and 12). 
 
Under the optimal reaction conditions, unreacted starting material was still observed, 
indicating that the catalyst was deactivated before the reaction went to completion. It is 
very likely that C(sp2)-H bond insertion of the N-aryl ring on the ligand by ruthenium can 
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lead to fast deactivation of catalyst A,237 in addition to the commonly observed 
decomposition pathways of Grubbs II.238 
 
Table I-3. Catalysts screening and reaction condition optimization. 
 
Entry Catalyst Solv. Temp. (oC) Conc. (mM) Yield (%)[a] 
1 Grubbs I DCM reflux 2 < 2 
2 Grubbs II DCM reflux 2 3 
3 Hoveyda-Grubbs I DCM reflux 2 < 2 
4 Hoveyda-Grubbs II DCM reflux 2 < 2 
5 A DCM reflux 2 19 
6 B DCM reflux 2 3 
7 A ClCH2CH2Cl 50 2 15 
8 A benzene 50 2 54 
9 A toluene 50 2 50 
10 A benzene 23 2 42 
11 A benzene 30 2 63 
12 A benzene 40 2 63 
13 A benzene 60 2 45 
14 A benzene 35 1 52 
15 A benzene 35 5 39 
16 A benzene 35 10 20 
17 A benzene 35 20 12 
a Yield determined by 1H NMR analysis. 
 
3. Influence of silyl groups on the reaction outcome 
We next examined the influence of different silyl groups on the yield of the RCM 
reaction (Table I-4). The results are in alignment with those of CM reactions. Generally, 
ethoxy substituents promote the formation of product and lead to higher yields compared 
to alkyl and/or aryl substituents (compare a-d with e, f). More ethoxy substituents are 
preferred over less (compare c with d). Pietraszuk et al. noted that electron-withdrawing 
substituents shut down an undesired pathway that leads to catalyst deactivation.228,230 We 
suggest that these unproductive processes are operative in macrocyclization reactions as 
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well and require the appropriate siloxane group to suppress them. However, in contrast to 
the CM precedents, the sterics of the silyl group also influenced the yield of the reaction. 
This effect is seen with the more demanding substrates 13a’-13f’, while substrates 12a’-
12f’ show the same trend but to a lesser degree. When one of the ethoxy substituents was 
changed to a methyl group (13a’ versus 13c’), the yield was improved while a change to 
a phenyl group (13c’ versus 13b’) resulted in the yield being halved. Our results indicate 
that the diethoxymethylsilyl group delivers the best reaction outcomes by maintaining a 
balance between both steric and electronic effects. 
 
Table I-4. Influence of the silicon substituents on the yield of RCM. 
Substrate Entry Silyl group 12[a] 13[a] 
a Si(OEt)3 92 60 
b Si(OEt)2Ph 69[b] 35[b] 
c Si(OEt)2Me 95 76 
d Si(OEt)Me2 81 62[b] 
e SiMe2Ph 54 (71[b]) 32  
f SiEt3 10[b] < 2 
a Isolated yield (%) unless otherwise indicated; b yield calculated based 
on 1H NMR analysis of reaction mixtures. 
 
Vinylsiloxanes and alkenylsiloxanes are stable toward column chromatography and can 
be stored at -20 °C for 6 months without significant decomposition. 
 
4. Substrate generality study and protodesilylation 
Using the diethoxymethylsilyl group, macrocyclic alkenyl siloxane products with a wide 
range of ring sizes were obtained in moderate to excellent yields (Scheme I-10). 
Diastereomers gave differing yields of purified products. For some substrates, silyl 
groups were incorporated into each of the alkene termini of the diene substrates. The 
trans-cyclohexanediols with silyl groups on different termini behaved similarly (21 and 
 
 
21 
23); while the silyl regioisomers of cis-cyclohexanediols behaved differently (22 and 24). 
To test the generality of this method in more complex molecules, two substrates inspired 
by previous work8 were prepared, incorporating vinylsiloxanes on either alkene termini. 
The 16-membered rings were both formed in moderate yields (32 and 33). 
 
Scheme I-10. Isolated yields of the RCM of various substrates and protodesilylation of 
the alkenyl siloxane products (in parentheses). 
 
 
All corresponding Z-disubstituted olefins were obtained by protodesilylation with good to 
excellent yields while maintaining the geometry of the olefins. As envisaged, the tri-
substituted olefins in the macrocyclic products have the E configuration (except for 30 
and 32 that are mixtures of both stereoisomers with high E selectivity).  
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Scheme I-11. Substrates that failed to be cyclized under sub-optimal reaction conditions 
with ring sizes of desired products (in parentheses). 
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Substrates with silyl groups that failed to be closed are listed in Scheme I-11.  Although 
these substrates were not subjected to the optimum reaction conditions (50 °C for some 
substrates, and Si(OEt)3 instead of Si(OEt)2Me), the introduction of the silyl group did 
not result in productive RCM. We do not know whether the non-silylated analogues of 
these substrates are competent to undergo RCM to generate the desired macrocycles if 
the ring strains associated with the formation of the macrocycles are intrinsically high 
(see discussion in Chapter I-2-7). Regarding instances when the silyl group thwarts ring 
closure, it may result from transannular interactions introduced by the silyl group which 
disfavor the formation of the macrocycle. A more comprehensive mechanistic 
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investigation into the factors governing the outcomes of these reactions is warranted. In 
order to close these recalcitrant substrates, higher reaction temperature might be required. 
However, the catalyst decomposes faster at higher temperatures. Therefore, future work 
or collaboration should involve the development of more stable catalyst that can improve 
the generality of this methodology. 
 
5. Role of silyl groups in controlling stereochemistry of the reaction 
We next sought to understand the role of the silyl group in controlling the stereochemical 
outcome of the reaction. For comparison, most of the corresponding simple (non-silyl 
containing) RCM precursors were synthesized in order to determine the intrinsic 
stereoselectivity of the substrates (Table I-5). Upon treatment with the optimized reaction 
conditions as well as typical RCM conditions using Grubbs II, Z-selective, E-selective, 
and non-selective outcomes were all observed. For the Z-selective (33’, 34’, 38’, 39’, 40’, 
43’, and 14’) or non-selective (42’) simple olefin substrates, the introduction of the silyl 
group was found to reinforce the intrinsic stereoselectivity. More dramatically, for the E-
selective substrates (36’, 37’, 41’, 44’, and 45’), the introduction of silyl groups in the 
substrates (17’, 18’, 22’, 24’, 30’, 31’, and 32’) can completely override the intrinsic 
preferences and generate the E-trisubstituted products (with Z configuration after 
protodesilylation). This confirmed our initial hypothesis that a silyl group serves as an 
effective controlling group favoring the formation of the E product in macrocyclic RCM 
reactions. During this comparative study, it was noticed that the RCM of simple olefin 
substrate gave rise to complex mixture of products in some cases. This observation 
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promoted us to explore and understand another important role of the silyl group. For a 
detailed explanation, see Chapter I-2-7. 
 
Table I-5. Influence of the silyl group on the specificity and stereoselectivity of RCM 
reactions. 
Substrate # R Cond. I[a] 
Cond. 
II[a] Substrate # R 
Cond. 
I[a] 
Cond. 
II[a] 
     R1 R2   
4c’ [Si][b] Z [c] - 24’ Si H Z - 
33’ H Z Z 22’ H Si Z - 
 
N
Ts
R      
O
O
O
R2
(±)
R1
 41’ H H c. mix. (19:81) 
c. mix. 
(19:81) 
        
15’ [Si] Z - 19’ [Si] Z - 
34’ H 38’ H O
O
R
(±)    
c. 
mix.[d] 
(Z)[e] 
c. mix. 
(Z) 
N
O
O
R
(±)    
c. mix. 
(Z) 
c. mix. 
(Z) 
        
16’ [Si] Z - 29’ [Si] Z - 
35’ H c. mix. c. mix. 43’ H O
O
R
(±)      
O
O
O R
(±)
   
c. mix. 
(76:24) 
c. mix. 
(76:24) 
        
17’ [Si] Z - 12c’ [Si] Z - 
36’ H 14’ H 81:19[f] 80:20[g] O
O
R
O
(±)    
c. mix. 
(24:76) 
c. mix. 
(24:76) 
O
O
O R
     
        
18’ [Si] Z - 30’ [Si] 90:10 - 
37’ H E E 44’ H 28:72 24:76 O
O
R
O
(±)      
O
O
O R
(±)
     
        
20’ [Si] Z - 13c’ [Si] Z - 
39’ H 42’ H 57:43[f] 54:46[g] O
O
R
(±)    
c. mix. 
(Z) 
c. mix. 
(Z) 
O
O
O R
     
 R1 R2    R1 R2   
23’ Si H Z - 31’ Si H Z - 
21’ H Si Z - 32’ H Si 86:14 - 
O
O
O
R2
(±)
R1
 40’ H H c. mix. (Z) 
c. mix. 
(Z) 
PMBO
N O
Me
O
O
O2N
N
Me
Me
Boc
R1
R2  45’ H H 36:64 - 
a Cond. I: cat. A (20 mol%), toluene, 35 °C; Cond. II: Grubbs II (10 mol%), 1,4-benzoquinone (20 mol%), 
toluene, 35 °C; b [Si] equals diethoxymethylsilyl. For silylated substrates, Z:E assignment is based on the 
protodesilylated products; c Single stereoisomer reported for Z:E ratios >98:2, otherwise Z:E ratio was 
determined by 1H NMR analysis of the crude mixture; d c. mix.: complex mixture of products (cyclized and 
uncyclized oligomers); e stereochemistry of cyclized monomer reported in parentheses whenever its 
proportion within the complex mixture was sufficient for determination; f reactions performed at room 
temperature; g reactions performed in refluxing DCM. 
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6. Proposed models to explain the stereoselectivity controlled by the silyl group 
Scheme I-12. Two proposed models to explain the stereoselectivity of the RCM reaction. 
 
 
Based on previous studies on CM by Grubbs and coworkers239 as well as our own 
observations, the initiation of the reaction would most likely happen on the simple olefin 
(for detailed discussion, see Chapter I-2-7). After the formation of I, we propose 
metallocyclobutane intermediates II is preferably formed leading to the E product 
(Scheme I-12). There are two models that can explain the high selectivity observed. As 
shown in model A, the allylic carbon in transition state (TS) IIa avoids steric interactions 
with the bulky silyl group as in TS IIIa. Thus the formation of intermediate II is favored. 
To support this model, CM of a geminal-disubstituted vinylsiloxane and a simple mono-
substituted olefin was performed (see Chapter I-5-2). Without the influence imposed by 
the macrocycle, the stereoselectivity of the CM reaction will only reflect the interaction 
between the silyl group and the allylic carbon. Unfortunately, the CM reactions that we 
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performed so far were not successful. Therefore, we looked for evidence that is consistent 
or in conflict with what can be inferred from model A. No matter which olefin terminus 
the silyl group is installed on, the stereoselectivity should be the same according to model 
A. However, for the complex substrate, putting the silyl group on one side, 31’, yielded 
only the E isomer, yet putting the silyl group on the other side, 32’, yielded mixture of 
both stereoisomers with E:Z ratio of 86:14 (see Table I-5). Based on this result, we 
concluded that the first model might be operative to some degree but not exclusive. 
 
We then proposed model B that can explain the stereoselectivity of the reaction from a 
different perspective. Macrocycles are known to have transannular interactions especially 
when an alkene is present.240 Depending on the macrocyclic conformation of each 
substrate, the energy of transition states leading to both intermediates is differentiated by 
transannular interactions between the silyl group and the backbone or substituent of the 
macrocycle. The transition state IIIb leading to III is more likely to have transannular 
interactions than the transition state IIb leading to II because in transition state IIIb, the 
backbone has to connect the two allylic carbons which will be on opposite faces of the 
metallocyclobutane ring. If this model is operating, larger rings will be able to 
accommodate the transition state leading to the (Z)-macrocycle without having severe 
transannular interactions. This prediction is in accordance with the results. Substrates 30’ 
and 32’ that form 15- or 16-membered rings gave rise to little amount of the (Z)-
macrocycle, although the dominant products are still the E isomer. This model also 
explains that silyl groups on different olefin termini resulted in different 
stereoselectivities. However, model B is dependent on the macrocyclic conformation that 
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varies with different substrates. The prediction of stereoselectivity for a novel substrate 
will therefore not be straightforward. 
 
7. Role of silyl groups in trapping the desired product 
It is also noteworthy that several of the simple substrates gave rise to a complex mixture 
of products (Table I-5, substrates 34’, 36’, 38’, 39’, 40’, 41’, and 43’), sometimes without 
a detectable level of cyclized monomer (substrate 35’). The LC-MS analysis of the crude 
reaction indicated the formation of cyclized dimers and other polymeric by-products. 
This is a general problem for macrocyclic RCM reactions of simple olefins.241-243 While 
the reaction conditions for the simple substrates were not optimized, these results point to 
the additional ability of the silyl group to suppress the formation of undesired products. 
 
Scheme I-13. Possible reaction pathways of macrocyclic RCM with and without a 2-silyl 
group (A); route to compound 35 from RCM of the vinylsiloxane (B). 
 
 
Based on our data, we propose a model for the reaction pathways depicted in Scheme I-
13, A. Several unproductive pathways are involved in RCM reactions of simple olefins 
including re-opening of the monocyclized product (A-), CM to generate an acyclic dimer 
or oligomer (B, C), and potential cyclization at either of these stages (C, D). In contrast, 
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when the silyl group is incorporated in one of the olefins, pathway A leading to the 
desired product is no longer reversible. When we re-subjected the purified trisubstituted 
silylalkene product to the reaction conditions, no ring-opening product was observed. 
Pathway B exists to generate the acyclic dimers, but only through the CM between the 
simple olefins – the 2-silyl alkene remains a spectator to CM under our reaction 
conditions.239 However, when re-subjected to the reaction conditions, the purified acyclic 
cross-dimers (E and Z) of the silylated substrates 13a’ yielded macrocyclic products with 
60% 1H NMR yield comparable to that starting from monomer (Scheme I-14). 
Additionally, since the 2-silyl alkene remains a spectator to CM, pathway C is shut down. 
Pathway D is also blocked because the formation of a tetrasubstituted alkene with two 
silyl groups is highly disfavored.  
 
Scheme I-14. RCM of acyclic dimers of 13a’ compared to the reaction with monomer 
13a’. 
 
 
Overall, the silyl group is able to lower the reactivity of the attached olefin, thereby 
suppressing non-productive pathways while still allowing the pathways to yield the 
desired product. In agreement with this analysis, for the substrates that gave low yields, 
only unreacted starting material, the acyclic cross-dimers, and a styrene derivative were 
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observed along with the product. To explore the “trapping” role of the silyl group, the 
monocyclized (Z)-alkene 35 (not observed from the RCM of the simple olefin substrate 
35’, Scheme I-13, B) obtained from protodesilylation of compound 16 was subjected to 
reaction condition II. Not surprisingly, it was almost completely consumed to generate 
dimers and oligomers. Owing to the fact that the silyl group can be removed, this method 
offers a means to cyclize some recalcitrant substrates using RCM. 
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Chapter I-3. Diversification of  
Alkenylsiloxanes and Alkenylsilanes 
1. Further transformation of macrocyclic alkenylsiloxanes 
As a principle goal of this project, we aimed to demonstrate the synthetic versatility of 
alkenylsiloxanes by directly transforming them into a variety of different products 
(Scheme I-15). Alkenyl siloxanes are capable of undergoing a wide range of 
transformations. Accordingly, the simple Z-disubstituted olefin 46-Z was obtained by 
protodesilylation.165 This two-step process affords Z olefins selectively from RCM 
reactions. Oxidation of the alkenyl siloxane generated ketone 47 at the carbon bearing the 
siloxyl group.244 Ketones, which are found in many biologically active and naturally 
occurring small molecules, have not typically been obtained from metathesis products in 
the past except from the RCM product of enol ethers. Our methodology should permit the 
synthesis of ketones at either of the alkenyl carbons.  
 
Scheme I-15. Further transformation of the alkenyl siloxane 31. 
 
 
The direct synthesis of trisubstituted macrocyclic olefins using RCM is generally 
challenging.154,161,217,245 The siloxyl-substituted macrocycles provide an effective solution 
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to this synthetic objective. An ipso-iodination of the alkenyl siloxane provided alkenyl 
iodide 48, a substrate with considerable synthetic potential in transition metal-catalyzed 
cross-coupling reactions. We also achieved several carbon-carbon bond-forming 
reactions using the macrocyclic alkenyl siloxane directly. A palladium-catalyzed cross-
coupling enabled direct C-C bond formation with an aryl halide, affording the aryl-
appended macrocycle 49.246 The alkenyl siloxane also underwent a conjugate addition to 
an α,β-unsaturated ketone in the presence of a rhodium catalyst to generate a C(sp2)-
C(sp3) bond in compound 50 as a mixture of diastereomers.247,248 
 
2. An effective way to synthesize cyclic α-silyl carbonyl compounds via silapinacol 
rearrangement 
Compounds containing α-silyl carbonyl moieties are versatile synthetic intermediates 
because the silyl group differentiates the two α-positions of a carbonyl moiety that are 
hard to be selectively transformed otherwise.249-264 Three conventional ways of accessing 
the α-silyl carbonyl moiety include α-silylation of carbonyl compounds,265-268 oxidation 
of β-silyl alcohols,269-272 and the addition of silyl-containing organolithium or 
organomagnesium to esters and acid chlorides.273-275 It was also reported that α,β-
dihydroxysilanes can undergo “silapinacol” rearrangement upon the treatment of an acid 
to generate α-silyl ketones or aldehydes.276 Cunico reported that when α,β-
dihydroxysilane 51 was dissolved in CDCl3 (without the addition of extra acid), the 
intermediate α-silyl aldehyde 52 could be observed, coexisting with the starting material 
for some hours, but slowly collapsing to the desilylated aldehyde product 53 (Scheme I-
16, A). If the appropriate silyl group was selected that is stable at the α position of a 
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carbonyl moiety under acidic conditions (a TBS group in contrast with a TMS group, 
Scheme I-16, B), α-silyl ketones, or aldehydes, can be obtained. 
 
Scheme I-16. Silapinacol rearrangement of acyclic α,β-dihydroxysilanes. 
 
 
Enabled by the RCM of vinylsilanes and the following syn-dihydroxylation catalyzed by 
OsO4, cyclic α,β-dihydroxysilanes can be easily accessed. Mr. Miguel Jimenez and I 
explored the application of the silapinacol rearrangement in these cyclic substrates to 
obtain cyclic α-silyl ketones that serve as another versatile functionality for further 
diversification in addition to the direct transformation of vinylsilanes.  
 
Precursors 56, 57, 61, and 62 with two silyl groups were synthesized. Upon treatment of 
an acid, only the 6-membered ring with a TBS group 62 was able to yield the desired α-
silyl ketone 64. We speculate that the 5-membered ring is not flexible enough to provide 
the required conformation for the silyl group to migrate (assuming a antiperiplanar 
relationship between the migrating silyl group and the leaving protonated or borylated β-
hydroxy group, Scheme I-18, C). Unlike the acyclic substrate, 1 equivalent of acid and 
higher reaction temperatures are required for the rearrangement to occur. Additionally, 
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stronger acid than TFA is required such as HCl or BF3·Et2O. Finally, the 
dimethylphenylsilyl group is not stable enough to stay at the α position of ketone. 
 
Table I-6. Silapinacol rearrangement of 5- and 6-membered alkenylsilanes under 
different acids and reaction conditions. 
 
Product, yield (conversion) Substrate TFA[a] HCl[b] BF3·Et2O[c] Zn(OTf)2[d] TMSOTf[e] MgBr2[f] 
56 no rxn 60 71% 
60 
54% 
60 
37% 
60 
(>95%) no rxn 
57 no rxn 61 17% 
60 
26% decomposition 
60 
(>95%) no rxn 
61 65 24% 
65 
53% 
65 
55% decomposition 
65 
(>95%) no rxn 
62 64 20% 
64 
54% 
64 
48% decomposition 
65 
(>95%) no rxn 
a Reaction conditions: 1 eq. TFA, 80 °C for substrate 56 and 57, 50 °C for substrate 61 and 62, toluene (25 
mM), 16 h. b Reaction conditions: 1 eq. HCl (1 M solution in Et2O), 80 °C for substrate 56 and 57, 50 °C 
for substrate 61 and 62, toluene (25 mM), 16 h. c Reaction conditions: 1 eq. BF3·Et2O, 50 °C for substrate 
56 and 57, toluene (25 mM); 0 °C for substrate 61 and 62, DCM (25 mM), 16 h. d Reaction conditions: 1.1 
eq. Zn(OTf)2, 80 °C for substrate 56 and 57, 50 °C for substrate 61 and 62, dioxane (25 mM), 16 h. e 
Reaction conditions: 1 eq. TMSOTf, 0 °C, toluene (25 mM), 2 h. f Reaction conditions: 1.2 eq. MgBr2, 80 
°C for substrate 56 and 57, 50 °C for substrate 61 and 62, toluene (25 mM), 16 h. 
 
We halted further exploration because we could not access tert-butyldimethylsilylalkenes 
with ring sizes larger than 6 by RCM reaction under our current reaction conditions. 
Nevertheless, this methodology would greatly increase the diversification potential of the 
product from RCM of vinylsilanes. 
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Chapter I-4. Conversion of Macrocyclic (E)-Alkenylsiloxanes  
to the Corresponding (Z)-Alkenyl Bromides  
Inspired by early studies of Jarvie et al.277 and Miller et al.,278 acyclic alkenylsilanes can 
be transformed to alkenyl bromides with inversion of stereochemistry. It is desirable to 
apply this transformation to the macrocyclic alkenylsiloxane obtained from RCM 
reactions because not only the stereochemistry can be inverted, but the alkenyl bromide 
also serves as a versatile synthetic intermediate. 
 
Using substrate 12c, Mr. Miguel Jimenez and I tried some mild dihalogenation reagents 
such as pyridinium tribromide and phenyltrimethylammonium tribromide. None of them 
provided complete consumption of starting material or clean reaction without 
decomposition. We then turned our focus to bromine. Treatment of substrate 12c in DCM 
at -78 °C with dropwise addition of bromine solution showed complete consumption of 
starting material and formation of a dibromide intermediate along with a small amount of 
alkenyl bromide product suggested by LC-MS analysis. It was found that the dibromide 
intermediate could convert into the alkenyl bromide on silica gel when running TLC 
analysis. So instead of isolating the intermediate, a two-step, one-pot procedure was 
adopted. TBAF was chosen as the bromodesilylation reagent.  Upon the addition of up to 
4 equivalents of TBAF as solution in THF, the dibromide intermediate completely 
collapsed to the desired alkenyl bromide after warming up to room temperature. The E 
isomer was assigned by confirming the NOE effect between the two groups of allylic 
protons.  The Z:E ratio was determined with 1H NMR analysis.    
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Table I-7. Influence of reaction conditions on the stereoselectivity of converting 
alkenylsiloxane to alkenyl bromide. 
 
Entry Solvent Temp. (°C) 
Time[a] 
(min) 
Reaction 
outcome[b] 
Stereoselectivity[c] 
(E:Z) 
1 DCM 40 5 94% 15:85 
2 DCM 0 5 91% 8:92 
3 DCM -78 5 95% 3:97 
4 DCM -100 15 95% 2:98 
5 toluene 23 5 94% 17:83 
6 toluene 0 5 94% 13:87 
7 toluene -78 5 79% 8:92 
8 CS2 23 5 94% 13:87 
9 CS2 0 5 73% 15:85 
10 CS2 -78 5 95% 3:97 
11 THF 23 5 full conv., minor decomp. 31:69 
12 THF 0 5 full conv., minor decomp. 22:78 
13 THF -78 5 incompl. conv., minor decomp. 67:33 
14 THF -100 15 incompl. conv., minor decomp. 84:16 
15 Et2O 23 5 >95%[d] 20:80 
16 Et2O 0 5 92% 13:87 
17 Et2O -78 5 30% 55:45 
18 DMF 23 5 incompl. conv., decomp. n. d.
[e] 
19 DMF 0 5 incompl. conv., decomp. n. d.
[e] 
20 DMF -78 5 incompl. conv., decomp. n. d.
[e] 
a Time between addition of Br2 and TBAF. b Isolated yield unless otherwise 
indicated. c Determined by 1H NMR analysis of reaction mixture after 
workup. d Yield determined by 1H NMR analysis. e Ratio not determined. 
 
Next we explored the influence of solvent and temperature on the stereoselectivity of this 
transformation (Table I-7).  It was found that nonpolar solvents (DCM, CS2, and toluene) 
generally favored inversion of stereochemistry leading to the desired (Z)-alkenyl 
bromide.  In these solvents, lowering temperature could increase the selectivity towards 
the Z isomer, and reactions could reach complete conversion in most cases.  On the 
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contrary, polar solvent such as DMF favored the retention of stereochemistry yielding the 
E isomer as the major product independent of reaction temperature. Also, side reactions 
that led to decomposition became significant in DMF. Interestingly, when the reaction 
was performed in ether or THF, the reaction proceeded slower at lower temperature (-100 
°C to -78 °C) with higher E selectivity. As temperature was elevated, both the conversion 
and Z selectivity were increased. Reaction mechanisms leading to the formation of either 
stereoisomers and the role of solvents are not fully clear at this point. 
 
Table I-8. Stereoselectivity of converting (E)-alkenylsiloxane substrates to the 
corresponding alkenyl bromide. 
Substrate[a] Alkenyl bromide, (E:Z)[b] Substrate 
Alkenyl bromide, 
(E:Z) 
 
67, 87:13 
 
66, 3:97 
 
68, 44:56 
 
72, 6:94 
 
69, > 98:2 
 
73, 2:98 
 
70, 86:14 
 
74, 2:98 
 
71, > 98:2 
 
75, 12:88 
a [Si] equals diethoxymethylsilyl. b Reaction condition: alkenylsiloxane (1 eq.), Br2 
(1.05 eq.), DCM (40 mM), -78 °C, 5 min; TBAF (4 eq.), warmed up to r.t., 15 min. 
E:Z ratio was determined by 1H NMR analysis of crude extract. 
 
The stereoselectivity of the product is further complicated by the fact that macrocyclic 
substrates may have intrinsic conformational constraints that affect stereochemistry of 
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each step in the reaction sequence. As shown in Table I-8, 11- or 12-membered rings 
gave retention of stereochemistry, while 14- and 15-membered rings yielded almost 
complete inversion.  
 
Scheme I-17. Proposed reaction mechanism of dibromination/bromodesilylation leading 
to either stereoisomer. 
 
 
A general model that explains the dependency of stereochemistry on the ring size of the 
macrocycle is proposed in Scheme I-17. In the ideal situation, once the bromonium ion I 
is formed, the bromide (Br−) attacks from the back to generate the anti-dibromide 
(pathway A). The issue of which carbon the bromide attacks (II or III) is inconsequential 
as long as the relative stereochemistry of the dibromide is anti. Upon treatment with 
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TBAF, bromodesilylation happens only when the β-bromo group is antiperiplanar to the 
silyl group via rotation about the C-C bond (transition state VI and VII) following an E2 
mechanism. The products from both intermediates are the same (Z)-alkenyl bromide 
(XI). 
 
This explains the high selectivity observed for the 14- or 15-membered substrates when 
reactions are performed in nonpolar solvents at low temperature. However at higher 
temperatures, the Z selectivity decreases because the E2 process is eroded by the E1 
process (pathway C via the fully formed carbocation or D via rearrangement of the 
bromonium ion). Additionally, at these temperatures syn-dibromination may occur also 
leading to the E product (pathway B). 
 
In polar solvents the situation is reversed since the solvent can stabilize either the 
bromonium ion or the fully formed carbocation. When the reaction of substrate 12c was 
performed in solvents such as THF or ether, a critical temperature exists, below which 
pathways leading to the E product (B, C, or D) become dominant (observed at -100 °C) 
potentially because the solvent-stabilized cation does not easily undergo a back-side 
attack by another bromide; however above this critical temperature pathways leading to 
the Z product (A) become dominant (observed at 0 °C) because the desired anti 
dibromide can readily form as with nonpolar solvents but with lower selectivity.  
 
For 11- or 12-membered substrates, pathway A becomes disfavored even in nonpolar 
solvent (Table I-8, substrate 17, 18, 21, 22, and 25). It is possible that in these smaller 
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ring-sizes, even though the reactivity of the bromonium ion is maintained, the back side 
of the bromonium ion is blocked by the backbone and the substituents of the macrocycle 
transannularly so that anti-dibromination is largely prohibited at the temperatures 
reported. Another possibility is that the (E)-alkenyl bromide product is higher in energy 
than the Z isomer. So even if the anti-dibromide is initially formed, it may revert to the 
bromonium ion and eventually form the Z product through the pathways mentioned 
above. Further mechanistic study is warranted to understand the stereoselectivity with 
different substrates. 
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Chapter I-5. Applications of the Silyl Group  
in Other Types of Metathesis Reactions 
1. Enyne RCM of alkynylsilanes and alkynylsiloxanes 
Mr. Michele Melchiorre and Ms. Cinzia Botta initiated the enyne RCM study. They used 
a model substrate to show the importance of the silyl groups in the enyne metathesis 
(Table I-9). A number of silyl groups could be installed on the terminal alkyne with 
moderate to excellent yields. However, three silyl groups (Entry 1, 2, and 4) failed to 
afford the desired butadiene product under optimized reaction conditions.  
 
Table I-9. Influence of the silyl group on the enyne RCM reactions. 
 
Entry [Si] 
Silylation 
Product, 
Yield (%) 
Enyne RCM 
Product, 
Yield (%) 
Entry R group 
Silylation 
Product, 
Yield (%) 
Enyne RCM 
Product, 
Yield (%) 
1 SiClMe2 79’, 80 no rxn 5 SiMe2Ph 83’, 72 83, 74 
2 Si(OMe)Me2 80’, 32 no rxn 6 SiMe3 84’, 91 84, 77 
3 Si(OtBu)Ph2 81’, 95 81, 49 7 SiBnMe2 85’, 76 85, 93 
4 SiHMe2 82’, 76 no rxn 8 SiMePh2 86’, 75 86, 96 
 
Ms. Cinzia Botta and Mr. Brandon Silverman then studied the generality of the enyne 
RCM reaction to form different sized products. It was found that when the ring sizes 
become larger, the yield for the enyne RCM dropped significantly (Scheme I-18). 
Especially substrate 89’ and 90’ failed to generate any detectable amount of 7-membered 
ring products. 
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Scheme I-18. Reaction outcome of enyne RCM yielding products with different ring 
sizes. 
 
 
Based on the initial study on this reaction and our understanding of the role of silyl 
groups in the RCM reaction, I explored the reaction to form the 7-membered product 
using a triethoxysilyl group (Scheme I-19). Initial efforts to separate the alkynylsiloxane 
92’ failed because it decomposes on silica gel. Instead, a one-pot procedure was adopted. 
After silylation of the terminal alkyne 91, the reaction was concentrated and then a 
solution of Hoveyda-Grubbs second-generation catalyst in toluene was added. The 
resulting mixture was charged with ethylene gas and left at room temperature for 12 
hours. The overall yield of desired silyl-diene 92 after workup and flash chromatography 
was 14% without any optimization. Further effort is required to find the optimal silyl 
group that is compatible with the enyne RCM reaction and at the same time suitable for 
following transformations especially the Fleming-Tamao oxidition. 
 
Scheme I-19. Initial exploration on synthesis and enyne RCM of triethoxysilyl-
containing substrate to form a 7-membered product. 
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2. Cross metathesis and relay cross metathesis of vinylsiloxanes 
In order to understand the role of the silyl group in determining stereochemistry of the 
macrocyclic RCM reaction, CM of geminal-disubstituted silanes or siloxanes with a 
monosubstituted olefin was performed. Without any intrinsic preference toward Z or E 
imposed by macrocyclic comformation and transannular interactions, the stereoselectivity 
of the CM reaction would reflect the influence of the sterics of the silyl group.  However, 
we failed to observe any desired product forming in any of the reactions listed in Scheme 
I-20. Difficulties in achieving CM of geminal-disubstituted siloxanes categorized them in 
the spectator class for CM reaction under current reaction conditions, which is in 
accordance with our analysis of the reaction pathway mentioned in Chapter I-2-7.  
 
In order to overcome the low reactivity of sterically hindered geminal-disubstituted 
olefins, we have explored a strategy called relay metathesis used in RCM reaction.279-282 
Compound 95e was synthesized and subjected to the CM reaction with allyl acetate. We 
failed to observe any desired product under these conditions (Scheme I-20). Only 
homodimers of allyl acetate were observed. The effort to synthesize compound 95a with 
a Si(OEt)3 group instead of a SiPhMe2 was more challenging. An inseparable mixture of 
both regioisomers (95a and 96a) was obtained and the desired isomer is the minor 
product. Although we did not observe any desired CM product upon treatment of the 
mixture with catalyst A and allyl acetate, the result was inconclusive. Further 
investigation into the relay CM is warranted. 
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Scheme I-20. Attempted CM between geminal-disubstituted vinylsiloxanes and a 
monosubstituted olefin; attempted relay CM reactions. 
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Chapter I-6. Conclusion and Future Directions 
In summary, the introduction of silyl groups into several types of metathesis reactions has 
been extensively explored. The macrocyclic RCM was the primary focus. Under 
optimized reaction conditions, a series of 8- to 16-membered macrocyclic rings 
containing trisubstituted olefins and other useful functionality, including rings having 
complex substitution patterns, can be accessed. The results demonstrated that the silyl 
group plays three roles: control of the stereoselectivity of the reaction favoring formation 
of the E product, trapping the desired product by preventing the undesired reaction 
pathways, and providing the diversification potential with regiochemical control. 
However, introduction of the silyl group compromises the generality of the RCM reaction 
to some extent, which is compounded by the instability of the optimal catalyst. Future 
works on development of metathesis catalyst can be done to increase the generality of 
this methodology. 
 
In addition, it has been shown that (E)-alkenyl siloxanes can be transformed to (Z)-
alkenyl bromides with inversion of stereochemistry. The alkenyl bromide can also serve 
as a versatile chemical handle for further diversification. The stereoselectivity of this 
transformation is substrate-dependent, however, we have not fully understood the 
reaction mechanism. Both Z/E isomers of a variety of trisubstituted macrocyclic alkenes 
are accessible for substrates that give complete inversion of stereochemistry from 
alkenylsiloxane to alkenyl bromide. 
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To utilize the diversification potential of the silyl group, enyne RCM of alkynylsiloxanes 
were studied yielding limited success thus far. Further exploration is required to 
understand the stability of the alkynylsiloxane, the compatibility of the silyl group in the 
RCM reaction, the optimal catalyst and reaction conditions, and substrate generality of 
this reaction. 
 
Attempts to effect a CM between a vinylsiloxane and a simple alkene were made to 
understand the role of silyl groups in determining stereoselectivity of the RCM reaction. 
Different substrates and reaction conditions as well as the relay strategy were tried but 
failed to generate a detectable amount of products. It is likely that novel catalysts will be 
required for this transformation. 
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Experimental section 
1. Material and Methods 
Except as otherwise noted, reactions were carried out under argon. All reaction solvents 
except acetone and pyridine were dispensed from a solvent purification system wherein 
solvents are passed through a packed activated alumina column. Acetone was Aldrich 
99.5+% histological grade. Pyridine was Aldrich 99.8% histological grade. NMR spectra 
were recorded at 500 MHz using a Varian I-500 instrument. Chemical shifts for proton 
NMR spectra are reported in parts per million downfield from tetramethylsilane and were 
referenced to residual protonated solvent (CHCl3: d 7.26, C6H6: d 7.15). Chemical shifts 
for carbon NMR spectra are reported in parts per million downfield from 
tetramethylsilane and referenced to protonated solvent (CHCl3: d 77.0, C6H6: d 128.0). 
Data are represented as follows: chemical shift (multiplicity [bs = broad singlet, s = 
singlet, d = doublet, t = triplet, q = quartet, m = multiplet], coupling constants in Hertz, 
integration). High-resolution mass spectra were obtained through the Harvard University 
mass spectrometry facility. Infrared spectra were obtained with a Nicolet IR100 FTIR 
from Thermo Scientific. Optical rotations were obtained using digital polarimeter 
Autopol IV (Rudolph research Analytical) with a 1 mL cell and a 1 dm path length. All 
reactions were magnetically stirred and monitored by thin-layer chromatography (TLC) 
using E. Merck silica gel 60 F254 precoated plates (0.25 mm). Flash chromatography was 
performed either with the indicated solvent on E. Merck silica gel 60 (230-400 mesh) or 
using a CombiFlash companion system (Teledyne ISCO, Inc.) with pre-packed FLASH 
silica gel columns (Teledyne ISCO, Inc.). SFC/MS chromatography was performed with 
a Berger analytic SFC (Waters ZQ Mass Spectometer) using CO2 and isopropanol as the 
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mobile phase and using a Chiralpak® AD-H column purchased from Chiral Technology 
Inc. (column length: 4.6x250mm, particle size: 5um). HPLC purification was performed 
on a Waters mass-directed autopurification system.  The system consisted of 2767 
injection/collection sample manager, a 2525 binary gradient high pressure LC pump, two 
515 pumps to deliver makeup and dilution flow, a column fluidic organizer (CFO), a 
2996 photodiode array detector, and a ZQ quadropole MS equipped with an electrospray 
interface.  All of the instrumentation was controlled by MassLynx and FractionLynx 
software versions 4.1. All reagents were obtained from commercial sources and used 
without further purification.  
 
2. Experimental procedures 
Note on compound numbering: ring-closed products are designated as the parent 
compound and numerated with just a number with or without a letter. Whenever 
necessary, Z or E is used to distinguish between both stereoisomers. Substrates (simple, 
silyl-containing, or enyne) for RCM reactions are designated with a prime after the 
compound name. The undesired regioisomer of the vinylsiloxane from the 
hydrosilylation reaction is designated with double primes after the name. The styrene 
derivative from the RCM reaction is labeled with ‘s’ after the name of the substrate. For 
the same scaffold that has different silyl groups, letters are used to differentiate: ‘a’ 
Si(OEt)3; ‘b’ Si(OEt)2Ph; ‘c’ Si(OEt)2Me; ‘d’ Si(OEt)Me2; ‘e’ SiMe2Ph; ‘f’ SiEt3; ‘g’ 
SiMe3; ‘h’ SitBuMe2. 
 
A. Synthesis and RCM of vinylsilane 
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Scheme I-21. Synthetic route toward cyclic alkenylsilanes. 
 
 
As shown in Scheme I-21, it takes three steps to access the silyl-containing diolefinic 
substrates for RCM reactions. According to the literature,283 the first step involves a 
dibromination and HBr elimination of a vinylsilane to generate the bromovinylsilane. The 
second step starts with a lithium-bromo exchange of the bromovinylsilane, which is 
subsequently quenched with paraformaldehyde. Then the allyl alcohol is subjected to a 
Mitsunobu reaction with tosylamine serving as a nucleophile. The general procedures of 
these three steps are described as follows. 
 
Bromine (1 equiv.) in carbon tetrachloride (1.2 M) was added dropwise, via a cannula, to 
a stirred solution of vinylsilane (1 equiv.) in carbon tetrachloride (1.2 M) at 0 °C. The 
solution was stirred for 10 min at 0 °C, washed sequentially with saturated aqueous 
sodium hydrogen carbonate containing some sodium hydrogen sulfite (3 × 50 ml) and 
brine (50 ml), dried over magnesium sulfate and concentrated in vacuo to give the crude 
dibromide. This crude product was dissolved in diethylamine (0.6 M) and refluxed for 12 
h. After cooling to room temperature, the dark brown reaction mixture was diluted with 
diethyl ether and washed with water. The organics were then washed with brine, dried 
over sodium sulfate and concentrated in vacuo, which was then purified by flash column 
chromatography (hexane) to give the bromovinylsilane. 
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To a stirred solution of bromovinylsilane in diethyl ether (0.3 M) at -78 °C, tert-
butyllithium (1.7 M solution in pentane, 2.1 equiv.) was added dropwise. After complete 
addition, the reaction was stirred for 1 h at -78 °C. A solution of paraformaldehyde (2 
equiv.) in diethyl ether (2.5 M) was then added dropwise via a cannula. After stirring for 
1 hour at -78 °C, the reaction was allowed to warm to room temperature. Water was 
added, the mixture was separated and the aqueous layer was extracted with diethyl ether 
for 3 times. The organics were then washed with brine, dried over sodium sulfate and 
concentrated in vacuo, which was purified by flash column chromatography (5% ethyl 
acetate in hexane) to give the vinylsilane-containing alcohol. 
 
The vinylsilane-containing alcohol was dissolved in THF (0.1 M). PPh3 (1.2 equiv.) was 
added to the solution.  Then N-alkenyl-4-methylbenzenesulfonamide (1.1 equiv.) was 
added.  The reaction was cooled to 0 °C.  DIAD (1.1 equiv.) was added dropwise.  The 
reaction was warmed to r.t. and stirred for 12h. The reaction mixture was concentrated in 
vacuo. The residue was purified via flash column chromatography (10% ethyl acetate in 
hexane) to give the RCM substrate. 
 
Initial RCM reaction conditions: substrate (1 equiv.) was dissolved in anhydrous DCM at 
a concentration of 20 mM (for compound 1e’ and 2e’) or 3 mM (for compound 1h’, 2h’, 
3e’, 3h’, 4a’, 5’, 11a’, and 11b’) under argon. Grubbs II (10 mol% for 1e’ and 2e’; 20 
mol% for others) was added to the solution. The reaction was kept at room temperature 
for 18 hours (for 1e’ and 2e’) or heated up to 40 °C for 18 hours (for other substrates).  
The resulting mixture was concentrated under reduced pressure and the residue was 
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analyzed by 1H NMR or purified by silica gel column chromatography using 
Hexanes/EtOAc as eluent. 
 
 
N-allyl-N-(2-(dimethyl(phenyl)silyl)allyl)-4-methylbenzenesulfonamide (1e’) 
Yield 46% (colorless oil); 1H-NMR (500 MHz, CDCl3) δ 7.66-7.64 (m, 2 H), 7.61-7.49 
(m, 2 H), 7.37-7.33 (m, 3 H), 7.27-7.25 (m, 2 H), 5.83-5.82 (m, 1 H), 5.54-5.53 (m, 1 H), 
5.39-5.30 (m, 1 H), 4.96-4.94 (m, 1 H), 4.90-4.86 (m, 1 H), 3.83 (s, 2 H), 3.66 (d, J = 7.0 
Hz, 2 H), 2.41 (s, 3 H), 0.41 (s, 6 H); 13C-NMR (125 MHz, CDCl3) δ 144.1,143.0, 137.3 
137.1, 133.9, 132.0, 129.6, 129.2, 128.1, 127.8, 127.2, 119.3, 51.0, 49.6, 21.5, -3.4. 
 
 
3-(dimethyl(phenyl)silyl)-1-tosyl-2,5-dihydro-1H-pyrrole (1e) 
Yield 92% (colorless oil); 1H-NMR (500 MHz, CDCl3) δ 7.67 (d, J = 8.5 Hz, 2 H), 7.39-
7.26 (m, 7 H), 5.82 (t, J = 1.0 Hz, 1 H), 4.17-4.13 (m, 4 H), 2.43 (s, 3 H), 0.33 (s, 6 H); 
13C-NMR (125 MHz, CDCl3) δ 143.3, 138.9, 136.2, 135.3, 134.4, 133.6, 129.7, 129.5, 
127.9, 127.3, 58.5, 56.6, 21.5, -3.4. 
 
  
3-(tert-butyldimethylsilyl)-1-tosyl-2,5-dihydro-1H-pyrrole (1h) 
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Yield 86% (colorless oil); 1H-NMR (500 MHz, CDCl3) δ 7.71 (d, J = 8.5 Hz, 2 H), 7.31 
(d, J = 8.5 Hz, 2 H), 5.78 (t, J = 1.3 Hz, 1 H), 4.20-4.18 (m, 2 H), 4.14-4.12 (m, 2 H), 
2.42 (s, 3 H), 0.80 (s, 9 H), 0.01 (s, 6 H; 13C-NMR (125 MHz, CDCl3) δ 143.3, 138.4, 
135.1, 134.4, 129.7, 127.3, 59.4, 56.5, 26.3, 21.5, 16.6, -6.4. 
 
N-(but-3-en-1-yl)-N-(2-(dimethyl(phenyl)silyl)allyl)-4-methylbenzenesulfonamide 
(2e’) 
Yield 69% (colorless oil); 1H-NMR (500 MHz, CDCl3) δ 7.64 (d, J = 8.0 Hz, 2 H), 7.52-
7.50 (m, 2 H), 7.38-7.26 (m, 3 H), 7.26 (d, J = 8.0 Hz, 2 H), 5.85-5.84 (m, 1 H), 5.55-
5.47 (m, 2 H), 4.92-4.85 (m, 2 H), 3.83 (s, 2 H), 3.06-3.03 (m, 2 H), 3.41 (s, 3 H), 2.02-
1.98 (m, 2 H), 0.43 (s, 6 H); 13C-NMR (125 MHz, CDCl3) δ 144.5, 143.0, 137.1, 137.0, 
134.7, 133.9, 129.6, 129.3, 128.2, 127.9, 127.1, 116.7, 52.3, 47.1, 32.1, 21.5, -3.4. 
 
 
5-(dimethyl(phenyl)silyl)-1-tosyl-1,2,3,6-tetrahydropyridine (2e) 
Yield 82% (colorless oil); 1H-NMR (500 MHz, CDCl3) δ 7.61 (d, J = 6.0 Hz, 2 H), 7.45-
7.43 (m, 2 H), 7.39-7.32 (m, 3 H), 7.27 (d, J = 8.0 Hz, 2 H), 6.03-6.01 (m, 1 H), 3.62-
3.61 (m, 2 H), 3.16 (t, J = 6.0 Hz, 2 H), 2.42 (s, 3 H), 2.25-2.22 (m, 2 H), 0.33 (s, 6 H); 
13C-NMR (125 MHz, CDCl3) δ 143.3, 136.7, 135.0, 133.8, 133.7, 133.5, 129.5, 129.2, 
127.8, 127.5, 46.4, 42.2, 26.6, 21.4, -3.6. 
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N-(but-3-en-1-yl)-N-(2-(tert-butyldimethylsilyl)allyl)-4-methylbenzenesulfonamide 
(2h’) 
Yield 76% (colorless oil); 13C-NMR (125 MHz, CDCl3) δ 143.3, 143.0, 137.3, 134.7, 
129.6, 127.4, 127.1, 116.9, 53.2, 47.5, 32.7, 26.7, 21.5, 16.9, -6.2. 
 
 
5-(tert-Butyldimethylsilyl)-1-tosyl-1,2,3,6-tetrahydropyridine (2h) 
Yield 18% (colorless oil); 1H-NMR (500 MHz, CDCl3) δ 7.67 (d, J = 8.5 Hz, 2 H), 7.31 
(d, J = 8.5 Hz, 2 H), 5.99-5.97 (m, 1 H), 3.63 (dt, J = 2.3, 2.3 Hz, 2 H), 3.15 (t, J = 5.5 
Hz, 2 H), 2.43 (s, 3 H), 2.28-2.24 (m, 2 H), 0.84 (s, 9 H), 0.02 (s, 6 H). 
 
B. Initial synthesis and RCM of vinylsiloxane 
Hydrosilylation: following the literature procedure,197,198 to a solution of the alkyne 
substrate (1 equiv.) in DCM (0.5 M) was added the diethoxymethylsilane (1.1 equiv.). 
The flask was cooled to 0 °C and catalyst [Cp*Ru(MeCN)3]PF6 (5 mol%) was added. 
The ice bath was immediately removed and the solution was stirred for 30 min.  The 
resulting mixture was concentrated in vacuo and the residue was purified by silica gel 
column chromatography using Hexanes/EtOAc as eluent to give the RCM substrate. 
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4-methyl-N-(pent-4-en-1-yl)-N-(3-(triethoxysilyl)but-3-en-1-yl)benzenesulfonamide 
(4a’) 
Yield 68% (colorless oil); 1H-NMR (500 MHz, CDCl3) δ 7.69 (d, J = 8.0 Hz, 2 H), 7.28 
(d, J = 8.0 Hz, 2 H), 5.81-5.73 (m, 2 H), 5.67-5.66 (m, 2 H), 5.03-4.99 (m, 2 H), 4.98-
4.96 (m, 2 H), 3.83-3.78 (m, 6 H), 3.23-3.20 (m, 2 H), 3.14 (t, J = 7.6 Hz, 2 H), 2.41 (s, 3 
H), 2.37-2.33 (m, 2 H), 2.05 (dt, J = 7.0, 7.0 Hz, 2 H), 1.69-1.63 (m, 2 H), 1.23-1.20 (m, 
9 H); 13C-NMR (125 MHz, CDCl3) δ 142.9, 140.2, 137.5, 137.2, 131.7, 129.5, 127.1, 
115.2, 58.6, 48.0, 47.9, 35.6, 30.8, 27.7, 21.5, 18.2. 
 
 
(E)-1-tosyl-6-(triethoxysilyl)-1,2,3,4,7,8-hexahydroazocine (4a) 
Yield 71% (colorless oil); 1H-NMR (500 MHz, CDCl3) δ 7.67 (d, J = 8.5 Hz, 2 H), 7.28 
(d, J = 8.5 Hz, 2 H), 6.37 (t, J = 8.2 Hz, 1 H), 3.82-3.75 (m, 6 H), 3.16 (bs, 2 H), 3.04-
3.02 (m, 2 H), 2.44-2.30 (m, 7 H), 1.79-1.75 (m, 2 H), 1.21-1.18 (m, 9 H). 
 
 
5-(Triethoxysilyl)hex-5-en-1-yl 2-(pent-4-en-1-yloxy)benzoate (12a’) 
 54 
Yield 72% (colorless oil); IR (neat, cm-1) 3077, 2974, 2927, 2890, 2736, 1729, 1705, 
1641, 1601, 1583, 1492, 1469, 1452, 1390, 1301, 1251, 1165, 1080, 1016, 958; 1H-NMR 
(500 MHz, CDCl3) δ 7.78-7.76 (m, 1 H), 7.44-7.40 (m, 1 H), 6.97-6.93 (m, 2 H), 5.85 
(ddt, J = 17.0, 10.5, 6.8 Hz, 1 H), 5.74-5.73 (m, 1 H), 5.65-5.65 (m, 1 H), 5.08-5.04 (m, 1 
H), 4.99 (d, J = 10.0 Hz, 1 H), 4.30 (t, J = 6.8 Hz, 2 H), 4.04 (t, J = 6.5 Hz, 2 H), 3.82 (q, 
J = 6.8 Hz, 6 H), 2.28 (dt, J = 7.2, 7.2 Hz, 2 H), 2.21 (t, J = 7.8 Hz, 2 H), 1.93 (tt, J = 7.0, 
7.0 Hz, 2 H), 1.76 (tt, J = 7.2, 7.2 Hz, 2 H), 1.65-1.59 (m, 2 H), 1.22 (t, J = 6.5 Hz, 9 H); 
13C-NMR (125 MHz, CDCl3) δ 166.6, 158.5, 143.3, 137.7, 133.1, 131.5, 129.4, 120.1, 
120.0, 115.2, 113.1, 68.0, 64.8, 58.5, 35.6, 30.0, 28.5, 28.3, 25.1, 18.2; HRMS (ESI-
TOF) calcd. for C24H38O6Si [M+Na]+ 473.23299, found 473.23204. 
 
 
(E)-6-(triethoxysilyl)-3,4,7,8,9,10-hexahydrobenzo[b][1,5]dioxacyclotetradecin-
12(2H)-one (12a) 
Yield 92% (pale yellow oil) with optimized reaction conditions; IR (neat, cm-1) 3076, 
2972, 2927, 2735, 1705, 1602, 1582, 1491, 1453, 1387, 1302, 1252, 1166, 1128, 1080, 
1025, 996, 958; 1H-NMR (500 MHz, C6D6) δ 7.79-7.77 (m, 1 H), 7.44-7.41 (m, 1 H), 
6.97 (dd, J = 7.5, 7.5 Hz, 1 H), 6.92 (d, J = 8.5 Hz, 1 H), 6.21 (t, J = 8.0 Hz, 1 H), 4.43 
(t, J = 5.2 Hz, 2 H), 4.06 (t, J = 5.0 Hz, 2 H), 3.83 (q, J = 7.0 Hz, 6 H), 2.43-2.38 (m, 2 
H), 2.23-2.19 (m, 2 H), 1.90-1.85 (m, 2 H), 1.83-1.78 (m, 2 H), 1.71-1.65 (m, 2 H), 1.24 
(t, J = 6.8 Hz, 9 H); 13C-NMR (125 MHz, C6D6) δ 168.1, 158.1, 145.2, 134.1, 132.9, 
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132.8, 122.1, 120.1, 112.1, 67.0, 63.5, 58.6, 30.1, 28.6, 27.7, 26.0, 25.5, 18.6; HRMS 
(ESI-TOF) calcd. for C22H34O6Si [M+Na]+ 445.20169, found 445.20168. 
 
C. Catalysts screening 
To a round-bottomed flask equipped with magnetic stir bar and armed with a condenser 
was added substrate 13a’ (1.0 equiv.) in anhydrous dichloromethane (2 mM) under 
argon. The catalyst (0.2 equiv.) was then added and the reaction was refluxed for 18 
hours.  The mixture was cooled to room temperature, concentrated under reduced 
pressure. The conversion was analyzed by crude proton NMR study using CDCl3 as 
solvent (Table I-10).  Representative NMR spectrum (olefinic proton area) of the RCM 
reaction of substrate 13a’ with catalyst A was shown in Figure I-3. The peak at 6.23 ppm 
(t) was the resonance of olefin proton within product 13a (the overlap of product peak 
with one of the styrene olefin proton was corrected by subtracting integration of the other 
styrene olefin proton (6.42-6.39 ppm) from the integration of 6.26-6.20 ppm).  Unreacted 
starting material, acyclic cross-dimmers, and the styrene derivative share the common 
moiety of vinylsiloxane which gives two terminal olefin proton peaks at 5.73 and 5.65 
ppm.  Integration for one of them and the corrected integration of desired product were 
then used for determination of the conversion of the reaction. After catalyst A was 
discovered, reaction conditions for RCM of substrate 13a’ were then optimized (see 
Table I-3 in Chapter I-2-2).  
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Table I-10. Conversion of the RCM reaction of substrate 13a’ with various catalysts to 
desired product. 
Entry Catalyst Conversion to product (%) Entry Catalyst 
Conversion to 
product (%) 
A 
 
19 J 
 
< 2 
B 
 
3 K 
 
< 2 
C 
 
< 2 L 
 
< 2 
D 
 
< 2 M 
 
< 2 
E 
 
< 2 N 
 
< 2 
F 
 
< 2 O 
 
< 2 
G 
 
< 2 P 
 
< 2 
H 
 
< 2 Q 
 
< 2 
I 
 
< 2    
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Figure I-3. Representative crude proton NMR spectrum (olefinic proton area) of RCM 
reaction for catalysts screening, reaction condition optimization, and catalyst 
decomposition studies.  
 
Reaction condition: substrate 13a’ with catalyst A, DCM, reflux, 18 hours. 
 
Optimized reaction conditions for RCM of vinyl siloxane substrates: substrate (1 equiv.) 
was dissolved in anhydrous toluene (or other solvent when indicated) at a concentration 
of 2 mM under argon. Catalyst A (20 mol%) was added to the solution.  High vacuum 
was applied to the reaction flask for 5 min and charged with argon. This operation cycle 
was repeated for 5 times. The reaction was then heated up to 35 °C and left for 12 hours.  
The resulting mixture was concentrated under reduced pressure and the residue was 
analyzed by 1H NMR or purified by silica gel column chromatography using 
Hexanes/EtOAc as eluent. 
 58 
 
 
5-(Triethoxysilyl)hex-5-en-1-yl 2-(hex-5-en-1-yloxy)benzoate (13a’) 
Yield 72% (colorless oil); IR (neat, cm-1) 3076, 2974, 2929, 2736, 1729, 1705, 1641, 
1601, 1583, 1491, 1452, 1389, 1301, 1249, 1165, 1079, 995, 958; 1H-NMR (500 MHz, 
CDCl3) δ 7.76 (d, J = 8.0 Hz, 1H), 7.44-7.40 (m, 1 H), 6.96-6.93 (m, 2 H), 5.82 (ddt, J = 
17.0, 10.5, 6.5 Hz, 1 H), 5.73-5.73 (m, 1 H), 5.65-5.65 (m, 1 H), 5.05-5.01 (m, 1 H), 4.97 
(d, J = 10.5 Hz, 1 H), 4.30 (t, J = 6.8 Hz, 2 H), 4.03 (t, J = 6.2 Hz, 2 H), 3.82 (q, J = 6.8 
Hz, 6 H), 2.21 (t, J = 7.5 Hz, 2 H), 2.13 (dt, J = 7.2, 7.2 Hz, 2 H), 1.84 (tt, J = 7.1, 7.1 Hz, 
2 H), 1.76 (tt, J = 7.1, 7.1 Hz, 2 H), 1.64-1.57 (m, 4 H), 1.22 (t, J = 7.0 Hz, 9 H); 13C-
NMR (125 MHz, CDCl3) δ 166.6, 158.5, 143.3, 138.5, 133.1, 131.5, 129.4, 120.9, 119.9, 
114.7, 113.0, 68.6, 64.8, 58.5, 35.5, 33.4, 28.6, 28.4, 25.2, 25.1, 18.2; HRMS (ESI-TOF) 
calcd. for C25H40O6Si [M+Na]+ 487.24864, found 487.24889. 
 
 
(E)-7-(Triethoxysilyl)-4,5,8,9,10,11-hexahydro-2H-
benzo[b][1,5]dioxacyclopentadecin-13(3H)-one (13a) 
Yield 60% (pale yellow oil) with optimized reaction conditions; IR (neat, cm-1) 2972, 
2927, 1700, 1602, 1491, 1453, 1388, 1302, 1250, 1166, 1102, 1078, 1018, 958; 1H-NMR 
(500 MHz, CDCl3) δ 7.75-7.74 (m, 1 H), 7.42-7.39 (m, 1 H), 6.96 (dd, J = 7.5, 7.5 Hz, 1 
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H), 6.91 (d, J = 8.5 Hz, 1 H), 6.23 (t, J = 7.5 Hz, 1 H), 4.40 (t, J = 5.5 Hz, 2 H), 4.07 (t, J 
= 5.0 Hz, 2 H), 3.80 (q, J = 6.8 Hz, 6 H), 2.27-2.21 (m, 4 H), 1.87-1.77 (m, 4 H), 1.68-
1.58 (m, 4 H), 1.22 (t, J = 6.8 Hz, 9 H); 13C-NMR (125 MHz, C6D6) δ 167.8, 158.2, 
145.0, 134.9, 132.6, 132.2, 122.3, 120.1, 112.4, 68.1, 64.3, 58.6, 29.1, 28.9, 28.9, 28.7, 
27.1, 26.9, 18.5; HRMS (ESI-TOF) calcd. for C23H36O6Si [M+Na]+ 459.21734, found 
459.21736. 
 
D. Study of influence of silyl groups 
Different vinyl silane or vinyl siloxane substrates were synthesized following general 
procedure for hydrosilylation using the respective silanes.  The RCM reaction was then 
performed following the general procedure for RCM.  
 
 
5-(Diethoxy(phenyl)silyl)hex-5-en-1-yl 2-(pent-4-en-1-yloxy)benzoate (12b’) 
Yield 91% (colorless oil); IR (neat, cm-1) 3071, 2973, 2940, 2881, 1728, 1704, 1641, 
1601, 1583, 1491, 1469, 1452, 1430, 1389, 1301, 1251, 1164, 1119, 1101, 1079, 1016, 
952; 1H-NMR (500 MHz, CDCl3) δ 7.76-7.74 (m, 1 H), 7.64-7.62 (m, 2 H), 7.44-7.33 
(m, 4 H), 6.96-6.93 (m, 2 H), 5.88-5.79 (m, 2 H), 5.67-5.66 (m, 1 H), 5.06-5.03 (m, 1 H), 
4.98 (d, J = 10.0 Hz, 1 H), 4.23 (t, J = 6.5 Hz, 2 H), 4.03 (t, J = 6.5 Hz, 2 H), 3.81 (q, J = 
7.0 Hz, 4 H), 2.26 (dt, J = 7.2, 7.2 Hz, 2 H), 2.22 (t, J = 8.0 Hz, 2 H), 1.91 (tt, J = 6.9, 6.9 
Hz, 2 H), 1.70 (tt, J = 7.2, 7.2 Hz, 2 H), 1.56 (tt, J = 7.6, 7.6 Hz, 2 H), 1.23 (t, J = 7.2 Hz, 
6 H); 13C-NMR (125 MHz, CDCl3) δ 166.6, 158.4, 145.5, 137.7, 134.6, 133.3, 133.1, 
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131.5, 130.0, 129.4, 127.7, 120.8, 120.0, 115.2, 113.1, 68.0, 64.8, 58.7, 35.2, 30.0, 28.4, 
28.3, 25.1, 18.3; HRMS (ESI-TOF) calcd. for C28H38O5Si [M+Na]+ 505.23807, found 
505.24127. 
 
 and  
RCM reaction of compound 12b’ gave rise to an inseparable mixture of product 12b and 
styrene derivative 12b’-s as well as acyclic dimer and unreacted starting material. The 
NMR yield was calculated to be 69% based on analysis of crude 1H NMR spectrum. 
 
 
5-(Diethoxy(methyl)silyl)hex-5-en-1-yl 2-(pent-4-en-1-yloxy)benzoate (12c’) 
Yield 85% (colorless oil); IR (neat, cm-1) 3077, 2972, 2943, 2879, 2763, 2735, 1728, 
1705, 1641, 1601, 1583, 1491, 1452, 1389, 1301, 1253, 1164, 1130, 1103, 1079, 1016, 
951; 1H-NMR (500 MHz, CDCl3) δ 7.77 (d, J = 7.0 Hz, 1 H), 7.42 (dd, J = 7.2, 7.2 Hz, 1 
H), 6.97-6.93 (m, 2 H), 5.85 (ddt, J = 17.2, 10.2, 7.0 Hz, 1 H), 5.69 (bs, 1 H), 5.57-5.56 
(m, 1 H), 5.06 (d, J = 17.5 Hz, 1 H), 4.99 (d, J = 10.0 Hz, 1 H), 4.30 (t, J = 6.5 Hz, 2 H), 
4.04 (t, J = 6.5 Hz, 2 H), 3.76 (q, J = 6.8 Hz, 4 H), 2.27 (dt, J = 7.0, 7.0 Hz, 2 H), 2.21 (t, 
J = 7.5 Hz, 2 H), 1.93 (tt, J = 6.9, 6.9 Hz, 2 H), 1.76 (tt, J = 7.2, 7.2 Hz, 2 H), 1.60 (tt, J = 
7.6, 7.6 Hz, 2 H), 1.21 (t, J = 7.0 Hz, 6 H), 0.19 (s, 3 H); 13C-NMR (125 MHz, CDCl3) δ 
166.6, 158.4, 147.0, 137.7, 133.1, 131.5, 127.7, 120.8, 120.0, 115.2, 113.0, 67.9, 64.8, 
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58.2, 35.1, 30.0, 28.5, 28.3, 25.1, 18.3, -4.6; HRMS (ESI-TOF) calcd. for C23H36O5Si 
[M+H]+ 421.24048, found 421.24067. 
 
 
(E)-6-(Diethoxy(methyl)silyl)-3,4,7,8,9,10-
hexahydrobenzo[b][1,5]dioxacyclotetradecin-12(2H)-one (12c) 
Yield 95% (pale yellow oil); IR (neat, cm-1) 3076, 2970, 2927, 2873, 1705, 1602, 1582, 
1491, 1453, 1386, 1356, 1303, 1253, 1165, 1129, 1103, 1079, 1051, 1024, 995; 1H-NMR 
(500 MHz, CDCl3) δ 7.79-7.77 (m, 1 H), 7.44-7.41 (m, 1 H), 6.97 (dd, J = 7.2, 7.2 Hz, 1 
H), 6.92 (d, J = 8.0 Hz, 1 H), 6.11 (t, J = 8.0 Hz, 1 H), 4.43 (t, J = 5.2 Hz, 2 H), 4.06 (t, J 
= 5.0 Hz, 2 H), 3.77 (q, J = 7.0 Hz, 4 H), 2.40 (dt, J = 6.0, 6.0 Hz, 2 H), 2.21-2.18 (m, 2 
H), 1.90-1.84 (m, 2 H), 1.83-1.78 (m, 2H), 1.69-1.62 (m, 2 H), 1.23 (t, J = 7.2 Hz, 6 H), 
0.19 (s, 3 H); 13C-NMR (125 MHz, CDCl3) δ 168.5, 157.6, 143.5, 136.8, 133.1, 132.2, 
121.1, 120.1, 112.0, 67.4, 63.8, 58.2, 29.9, 28.4, 26.9, 25.7, 25.3, 18.3, -4.9; HRMS (ESI-
TOF) calcd. for C21H32O5Si [M+H]+ 393.20918, found 393.20943. 
 
 and  
Hydrosilylation reaction gave rise to a 14.4:1 mixture of two regioisomers with the 
desired regioisomer 12d’ being the major one.  Yield 84% (colorless oil). 
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(E)-6-(Ethoxydimethylsilyl)-3,4,7,8,9,10-
hexahydrobenzo[b][1,5]dioxacyclotetradecin-12(2H)-one (12d) 
Yield 81% (pale yellow oil); IR (neat, cm-1) 2959, 2926, 2865, 1704, 1602, 1491, 1453, 
1386, 1303, 1250, 1164, 1131, 1102, 1080, 1049, 1023, 993; 1H-NMR (500 MHz, 
CDCl3) δ 7.79-7.77 (m, 1 H), 7.44-7.41 (m, 1 H), 6.97 (dd, J = 7.5, 7.5 Hz, 1 H), 6.92 (d, 
J = 8.5 Hz, 1 H), 5.97 (t, J = 8.0 Hz, 1 H), 4.43 (t, J = 5.2 Hz, 2 H), 4.06 (t, J = 5.0 Hz, 2 
H), 3.65 (q, J = 7.0 Hz, 2 H), 2.42-2.36 (m, 2 H), 2.22-2.18 (m, 2 H), 1.89-1.84 (m, 2 H), 
1.83-1.78 (m, 2 H), 1.67-1.61 (m, 2 H), 1.19 (t, J = 7.0 Hz, 3 H), 0.19 (s, 6 H); 13C-NMR 
(125 MHz, CDCl3) δ 168.5, 157.7, 141.7, 139.8, 133.1, 132.3, 121.1, 120.1, 112.1, 67.5, 
63.8, 58.4, 30.1, 28.5, 27.2, 25.8, 25.5, 18.5, -2.4; HRMS (ESI-TOF) calcd. for 
C20H30O4Si [M+Na]+ 385.18056, found 385.19580. 
 
 
5-(Dimethyl(phenyl)silyl)hex-5-en-1-yl 2-(pent-4-en-1-yloxy)benzoate (12e’) 
Yield 93% (colorless oil); IR (neat, cm-1) 3069, 2949, 1728, 1641, 1601, 1491, 1452, 
1430, 1387, 1302, 1251, 1164, 1133, 1078, 1050, 1015; 1H-NMR (500 MHz, CDCl3) δ 
7.75-7.73 (m, 1 H), 7.51-7.49 (m, 2 H), 7.44-7.40 (m,1 H), 7.34-7.32 (m, 3 H), 6.97-6.93 
(m, 2 H), 5.84 (ddt, J = 17.0, 10.0, 6.8 Hz, 1 H), 5.70-5.69 (m, 1 H), 5.42-5.42 (m, 1 H), 
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5.06-5.03 (m, 1 H), 4.99 (d, J = 10.5 Hz, 1 H), 4.21 (t, J = 7.0 Hz, 2 H), 4.03 (t, J = 6.5 
Hz, 2 H), 2.26 (dt, J = 7.2, 7.2 Hz, 2 H), 2.17 (t, J = 7.5 Hz, 2 H), 1.91 (tt, J = 6.9, 6.9 Hz, 
2 H), 1.68 (tt, J = 7.1, 7.1 Hz, 2 H), 1.52-1.46 (m, 2 H), 0.36 (s, 6 H); 13C-NMR (125 
MHz, CDCl3) δ 166.6, 158.4, 149.8, 138.2, 137.7, 133.8, 133.1, 131.5, 128.9, 127.7, 
126.0, 120.8, 120.0, 115.2, 113.0, 67.9, 64.7, 35.4, 30.0, 28.4, 28.3, 25.1, -3.0; HRMS 
(ESI-TOF) calcd. for C26H34O3Si [M+H]+ 423.23500, found 423.23601. 
 
 
(E)-6-(Dimethyl(phenyl)silyl)-3,4,7,8,9,10-
hexahydrobenzo[b][1,5]dioxacyclotetradecin-12(2H)-one (12e) 
RCM reaction of the previous compound (18e’) gave rise to an inseparable mixture of 
product and styrene derivative together with unreacted starting material.  The NMR yield 
was calculated to be 71% based on analysis of crude 1H NMR spectrum. After the first 
column chromatography to get rid of the unreacted starting materials, the mixture of 
product and styrene derivative was subjected to HPLC separation that gave rise to 25 mg 
pure product (54% yield) as pale yellow oil. HPLC condtions: compound was dissolved 
in a 1 ml volume of DMSO.  The separation was executed on an XBridge 19x100 mm 5 
µm columns at a flow rate of 44 ml/min.  Aqueous mobile phase A consisted of 0.1% 
formic acid in water, and organic mobile phase B was 0.1% formic acid in 
acetonitrile.  Purification fractions were immediately frozen at -50°C and lyophilized for 
24hrs using the Genesis Virtis.  After lyophilization the compound was transferred to a 
preweighed vial using dichloromethane.  IR (neat, cm-1) 3067, 2954, 2860, 1703, 1602, 
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1490, 1452, 1429, 1383, 1302, 1250, 1165, 1131, 1050, 1023, 992; 1H-NMR (500 MHz, 
CDCl3) δ 7.78-7.76 (m, 1 H), 7.53-7.51 (m, 2 H), 7.44-7.40 (m, 1 H), 7.36-7.33 (m, 3 H), 
6.97 (dd, J = 7.5, 7.5 Hz, 1 H), 6.92 (d, J = 7.5 Hz, 1 H), 5.91 (t, J = 8.0 Hz, 1 H), 4.38 
(t, J = 5.2 Hz, 2 H), 4.06 (t, J = 5.0 Hz, 2 H), 2.42-2.37 (m, 2 H), 2.18-2.15 (m, 2 H), 
1.89-1.84 (m, 2 H), 1.73-1.68 (m, 2 H), 1.59-1.52 (m, 2 H), 0.35 (s, 6 H); 13C-NMR (125 
MHz, CDCl3) δ 168.5, 157.7, 141.7, 139.4, 138.8, 134.0, 133.1, 132.2, 128.8, 127.7, 
121.1, 120.0, 112.1, 67.5, 63.8, 30.1, 28.4, 28.2, 25.9, 25.7, -3.1; HRMS (ESI-TOF) 
calcd. for C24H30O3Si [M+Na]+ 417.18564, found 417.18593. 
 
 
5-(Triethylsilyl)hex-5-en-1-yl 2-(pent-4-en-1-yloxy)benzoate (12f’) 
Yield 38% (colorless oil); IR (neat, cm-1) 3077, 3048, 2951, 2911, 2875, 1729, 1704, 
1641, 1601, 1582, 1491, 1453, 1416, 1385, 1301, 1250, 1164, 1133, 1078, 1050, 1013; 
1H-NMR (500 MHz, CDCl3) δ 7.78-7.76 (m, 1 H), 7.44-7.41 (m, 1 H), 6.97-6.94 (m, 2 
H), 5.85 (ddt, J = 17.0, 10.0, 6.8 Hz, 1 H), 5.65-5.64 (m, 1 H), 5.32-5.31 (m, 1 H), 5.08-
5.04 (m, 1 H), 4.99 (d, J = 10.0 Hz, 1 H), 4.30 (t, J = 6.5 Hz, 2 H), 4.04 (t, J = 6.5 Hz, 2 
H), 2.27 (dt, J = 7.2, 7.2 Hz, 2 H), 2.14 (t, J = 7.8 Hz, 2 H), 1.93 (tt, J = 7.0, 7.0 Hz, 2 H), 
1.76 (tt, J = 7.1, 7.1 Hz, 2 H), 1.60-1.54 (m, 2 H), 0.92 (t, J = 8.0 Hz, 6 H), 0.60 (q, J = 
8.0 Hz, 9 H); 13C-NMR (125 MHz, CDCl3) δ 166.6, 158.4, 148.5, 137.7, 133.1, 131.5, 
125.3, 120.8, 120.0, 115.2, 113.1, 68.0, 64.8, 35.7, 30.0, 28.6, 28.3, 25.1, 7.3, 2.9; HRMS 
(ESI-TOF) calcd. for C24H38O3Si [M+H]+ 403.26630, found 403.26630. 
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 and  
RCM reaction of compound 12f’ gave rise to an inseparable mixture of product 12f and 
styrene derivative. Unreacted starting material and acyclic dimer were also observed.  
The NMR yield was calculated to be 10% based on analysis of crude 1H NMR spectrum. 
 
 
5-(Diethoxy(phenyl)silyl)hex-5-en-1-yl 2-(hex-5-en-1-yloxy)benzoate (13b’) 
Yield 76% (colorless oil); IR (neat, cm-1) 3071, 2973, 2938, 1729, 1704, 1640, 1601, 
1583, 1491, 1470, 1453, 1430, 1389, 1301, 1250, 1164, 1119, 1102, 1079, 997, 952; 1H-
NMR (500 MHz, CDCl3) δ 7.75-7.73 (m, 1 H), 7.64-7.62 (m, 2 H), 7.44-7.33 (m, 4 H), 
6.96-6.93 (m, 2 H), 5.85-5.77 (m, 2 H), 5.67-5.66 (m, 1 H), 5.04-5.00 (m, 1 H), 4.96 (d, J 
= 10.0 Hz, 1 H), 4.22 (t, J = 7.0 Hz, 2 H), 4.02 (t, J = 6.2 Hz, 2 H), 3.81 (q, J = 7.0 Hz, 4 
H), 2.22 (t, J = 7.8 Hz, 2 H), 2.11 (dt, J = 5.5, 5.5 Hz, 2 H), 1.83 (tt, J = 7.0, 7.0 Hz, 2 H), 
1.70 (tt, J = 7.2, 7.2 Hz, 2 H), 1.62-1.52 (m, 4 H), 1.23 (t, J = 7.2 Hz, 6 H); 13C-NMR 
(125 MHz, CDCl3) δ 166.6, 158.5, 145.5, 138.5, 134.6, 133.3, 133.1, 131.5, 130.0, 129.4, 
127.7, 120.9, 119.9, 114.7, 113.0, 68.6, 64.8, 58.7, 35.2, 33.4, 28.6, 28.4, 25.2, 25.1, 
18.3; HRMS (ESI-TOF) calcd. for C29H40O5Si [M+Na]+ 519.25372, found 519.25541. 
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 and  
RCM reaction of compound 13b’ gave rise to an inseparable mixture of product 13b and 
styrene derivative 13b’-s as well as acyclic dimers and unreacted starting material. The 
NMR yield was calculated to be 35% based on analysis of crude 1H NMR spectrum. 
 
 
5-(Diethoxy(methyl)silyl)hex-5-en-1-yl 2-(hex-5-en-1-yloxy)benzoate (13c’) 
Yield 79% (colorless oil); IR (neat, cm-1) 3076, 2972, 2940, 1729, 1705, 1641, 1601, 
1491, 1452, 1389, 1301, 1252, 1164, 1103, 1079, 996, 951; 1H-NMR (500 MHz, CDCl3) 
δ 7.78-7.76 (m, 1 H), 7.44-7.40 (m, 1 H), 6.96-6.93 (m, 2 H), 5.82 (ddt, J = 17.0, 10.5 , 
6.5 Hz, 1 H), 5.69-5.69 (m, 1 H), 5.57-5.56 (m, 1 H), 5.05-5.01 (m, 1 H), 4.97 (d, J = 
10.5 Hz, 1 H), 4.30 (t, J = 6.8 Hz, 2 H), 4.03 (t, J = 6.5 Hz, 2 H), 3.76 (q, J = 7.0 Hz, 4 
H), 2.21 (t, J = 7.5 Hz, 2 H), 2.13 (dt, J = 7.2, 7.2 Hz, 2 H), 1.84 (tt, J = 7.1, 7.1 Hz, 2 H), 
1.76 (tt, J = 7.2, 7.2 Hz, 2 H), 1.63-1.57 (m, 4 H), 1.21 (t, J = 7.0 Hz, 6 H), 0.19 (s, 3 H); 
13C-NMR (125 MHz, CDCl3) δ 166.6, 158.5, 147.1, 138.5, 133.1, 131.5, 127.6, 120.8, 
119.9, 114.7, 113.0, 68.6, 64.8, 58.2, 35.1, 33.4, 28.6, 28.5, 25.2, 25.1, 18.3, -4.6; HRMS 
(ESI-TOF) calcd. for C24H38O5Si [M+Na]+ 457.23807, found 457.24010. 
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(E)-7-(Diethoxy(methyl)silyl)-4,5,8,9,10,11-hexahydro-2H-
benzo[b][1,5]dioxacyclopentadecin-13(3H)-one (13c) 
Yield 76% (pale yellow oil); IR (neat, cm-1) 2969, 2928, 1700, 1602, 1491, 1452, 1387, 
1302, 1251, 1165, 1130, 1103, 1078, 1016, 952; 1H-NMR (500 MHz, CDCl3) δ 7.76-7.74 
(m, 1 H), 7.42-7.39 (m, 1 H), 6.96 (dd, J = 7.5, 7.5 Hz, 1 H), 6.92 (d, J = 7.5 Hz, 1 H), 
6.13 (t, J = 7.5 Hz, 1 H), 4.40 (t, J = 5.5 Hz, 2 H), 4.08 (t, J = 5.0 Hz, 2 H), 3.74 (q, J = 
6.8 Hz, 4 H), 2.25-2.21 (m, 4 H), 1.87-1.76 (m, 4 H), 1.68-1.56 (m, 4 H), 1.21 (t, J = 6.8 
Hz, 6 H), 0.17 (s, 3 H); 13C-NMR (125 MHz, CDCl3) δ 168.2, 157.7, 143.5, 137.5, 132.9, 
131.7, 121.2, 120.0, 112.3, 68.3, 64.6, 58.1, 28.9, 28.8, 28.6, 28.0, 26.9, 26.7, 18.3, -4.6; 
HRMS (ESI-TOF) calcd. for C22H34O5Si [M+Na]+ 429.20677, found 429.20692. 
 
 and  
Hydrosilylation reaction gave rise to a 14.3:1 mixture of two regioisomers with the 
desired regio isomer 19d’ being the major one.  Yield 89% (colorless oil). 
 
 and  
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RCM reaction of the mixture 13d’ and 13d’’ gave rise to an inseparable mixture of 
product 13d and styrene derivative as well as acyclic dimer and unreacted starting 
material. The NMR yield was calculated to be 62% based on analysis of crude 1H NMR 
spectrum. 
 
 
5-(Dimethyl(phenyl)silyl)hex-5-en-1-yl 2-(hex-5-en-1-yloxy)benzoate (13e’) 
Yield 74% (colorless oil); IR (neat, cm-1) 3069, 2945, 1728, 1703, 1641, 1601, 1491, 
1452, 1430, 1388, 1301, 1250, 1164, 1133, 1077, 1049, 996; 1H-NMR (500 MHz, 
CDCl3) δ 7.75-7.73 (m, 1 H), 7.51-7.49 (m, 2 H), 7.44-7.40 (m, 1 H), 7.34-7.31 (m, 3 H), 
6.96-6.93 (m, 2 H), 5.81 (ddt, J = 16.8, 10.2, 6.5 Hz, 1 H), 5.70-5.69 (m, 1 H), 5.43-5.42 
(m, 1 H), 5.04-5.00 (m, 1 H), 4.96 (d, J = 9.5 Hz, 1 H), 4.21 (t, J = 6.5 Hz, 2 H), 4.02 (t, J 
= 6.2 Hz, 2 H), 2.17 (t, J = 7.8 Hz, 2 H), 2.11 (dt, J = 7.2, 7.2 Hz, 2 H), 1.83 (tt, J = 7.0, 
7.0 Hz, 2 H), 1.67 (tt, J = 7.0, 7.0 Hz, 2 H), 1.58 (tt, J = 7.5, 7.5 Hz, 2 H), 1.52-1.46 (m, 2 
H), 0.37 (s, 6 H); 13C-NMR (125 MHz, CDCl3) δ 166.6, 158.5, 149.9, 138.5, 138.2, 
133.8, 133.1, 131.5, 128.9, 127.7, 126.0, 120.8, 119.9, 114.7, 113.0, 68.6, 64.7, 35.4, 
33.4, 28.6, 28.4, 25.2, 25.1, -3.0; HRMS (ESI-TOF) calcd. for C27H36O3Si [M+H]+ 
437.25065, found 437.25057. 
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(E)-7-(dimethyl(phenyl)silyl)-4,5,8,9,10,11-hexahydro-2H-
benzo[b][1,5]dioxacyclopentadecin-13(3H)-one (13e) 
Yield 32% (pale yellow oil); IR (neat, cm-1) 3067, 2952, 2859, 1698, 1601, 1490, 1452, 
1429, 1383, 1302, 1249, 1165, 1132, 1108, 1049, 1015, 963; 1H-NMR (500 MHz, 
CDCl3) δ 7.77-7.75 (m, 1 H), 7.51-7.49 (m, 2 H), 7.43-7.39 (m, 1 H), 7.34-7.33 (m, 3 H), 
6.95 (dd, J = 7.8, 7.8 Hz, 1 H), 6.92 (d, J = 9.0 Hz, 1 H), 5.94 (t, J = 7.2 Hz, 1 H), 4.34 
(t, J = 5.5 Hz, 2 H), 4.08 (t, J = 5.2 Hz, 2 H), 2.25-2.18 (m, 4 H), 1.87-1.82 (m, 2 H), 
1.70-1.61 (m, 4 H), 1.46 (tt, J = 7.9 Hz, 2 H), 0.34 (s, 6 H); 13C-NMR (125 MHz, C6D6) δ 
168.2, 157.7, 142.2, 139.8, 139.0, 134.0, 133.0, 131.8, 128.8, 127.6, 121.1, 120.0, 112.3, 
68.3, 64.6, 29.0, 28.9, 28.9, 28.8, 27.0, 27.0, -2.6; HRMS (ESI-TOF) calcd. for 
C25H32O3Si [M+Na]+ 431.20129, found 431.20247. 
 
 
5-(Triethylsilyl)hex-5-en-1-yl 2-(hex-5-en-1-yloxy)benzoate (13f’) 
Yield 56% (colorless oil); IR (neat, cm-1) 3076, 3047, 2951, 2911, 2874, 1730, 1704, 
1641, 1601, 1583, 1491, 1453, 1416, 1385, 1301, 1249, 1164, 1132, 1077, 1049, 1017, 
959; 1H-NMR (500 MHz, CDCl3) δ 7.78-7.76 (m, 1 H), 7.44-7.41 (m, 1 H), 6.97-6.94 (m, 
2 H), 5.82 (ddt, J = 17.0, 10.0, 6.8 Hz, 1 H), 5.65-5.64 (m, 1 H), 5.32-5.31 (m, 1 H), 5.05-
5.01 (m, 1 H), 4.98-4.96 (m, 1 H), 4.30 (t, J = 6.8 Hz, 2 H), 4.03 (t, J = 6.8 Hz, 2 H), 
2.16-2.11 (m, 4 H), 1.85 (tt, J = 7.0, 7.0 Hz, 2 H), 1.76 (tt, J = 7.0, 7.0 Hz, 2 H), 1.63-
1.54 (m, 4 H), 0.92 (t, J = 8.0 Hz, 6 H), 0.60 (q, J = 8.0 Hz, 9 H); 13C-NMR (125 MHz, 
CDCl3) δ 166.7, 158.5, 148.6, 138.5, 133.1, 131.5, 125.3, 120.8, 120.0, 114.7, 113.1, 
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68.6, 64.8, 35.7, 33.4, 28.6, 28.6, 25.2, 25.1, 7.3, 2.9; HRMS (ESI-TOF) calcd. for 
C25H40O3Si [M+Na]+ 439.26389, found 439.26459. 
 
 
RCM reaction of compound 13f’ gave rise to less than 2% product based on analysis of 
crude 1H NMR spectrum.  Styrene derivative 13f’-s, unreacted starting material and 
acyclic dimer were observed. 
 
E. RCM of various vinylsiloxane substrates and protodesilylation of the alkenyl 
siloxane products 
The RCM reactions were performed under optimized reaction conditions (see before). 
 
Protodesilylation: adapted from the literature procedure,165 the alkenyl siloxane product 
(1 equiv.) from the RCM reaction was dissolved in a anhydrous THF to a final 
concentration of 0.25 M. AgF (0.5 equiv.) was added to the solution immediately 
followed by acetic acid (1.5 equiv.) and TBAF (2.5 equiv., 1 M solution in THF).  The 
reaction was kept in dark and stirred for 2 hours.  The resulting mixture was filtered with 
celite, concentrated in vacuo and the residue was purified by silica gel column 
chromatography using Hexanes/EtOAc as eluent. 
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N-(3-(Diethoxy(methyl)silyl)but-3-enyl)-4-methyl-N-(pent-4-
enyl)benzenesulfonamide (4c’) 
Yield 70% (colorless oil); IR (neat, cm-1) 3051, 2974, 2926, 2878, 1641, 1599, 1494, 
1444, 1390, 1342, 1306, 1258, 1159, 1103, 1079, 955; 1H-NMR (500 MHz, CDCl3) δ 
7.70 (d, J = 7.8 Hz, 2 H), 7.28 (d, J = 7.8 Hz, 2 H), 5.77 (ddt, J = 17.2, 10.2, 6.5 Hz, 1 H), 
5.70 (d, J = 1.2 Hz, 1 H), 5.58 (d, J = 1.2 Hz, 1 H), 5.01 (d, J = 17.2 Hz, 1 H), 4.97 (d, J 
= 10.2 Hz, 1 H), 3.74 (q, J = 7.0 Hz, 4 H), 3.22-3.19 (m, 2 H), 3.14 (t, J = 7.8 Hz, 2 H), 
2.41 (s, 3 H), 2.35 (t, J = 8.0 Hz, 2 H), 2.06 (dt, J = 7.0, 7.0 Hz, 2 H), 1.69-1.63 (m, 2 H), 
1.20 (t, J = 7.0 Hz, 6 H), 0.18 (s, 3 H); 13C-NMR (125 MHz, CDCl3) δ 144.1, 142.9, 
137.5, 137.2, 130.0, 129.5, 127.1, 115.2, 58.3, 48.0, 47.8, 35.1, 30.8, 27.7, 21.4, 18.3, -
4.9; HRMS (ESI-TOF) calcd. for C21H35NO4SSi [M+Na]+ 448.19483, found 448.19573. 
 
 
(E)-6-(Diethoxy(methyl)silyl)-1-tosyl-1,2,3,4,7,8-hexahydroazocine (4c) 
Yield 75% (pale yellow oil); IR (neat, cm-1) 2972, 2926, 1615, 1455, 1389, 1338, 1292, 
1257, 1158, 1079, 1050, 1017, 995; 1H-NMR (500 MHz, CDCl3) δ 7.68 (d, J = 8.2 Hz, 2 
H), 7.28 (d, J = 8.2 Hz, 2 H), 6.28 (t, J = 8.2 Hz, 1 H), 3.72 (q, J = 7.2 Hz, 4 H), 3.15 (bs, 
2 H), 3.02 (t, J = 5.5 Hz, 2 H), 2.44 (t, J = 5.0 Hz, 2 H), 2.41 (s, 3 H), 2.32 (dt, J = 6.8, 
6.8 Hz, 2 H), 1.79-1.74 (m, 2 H), 1.19 (t, J = 7.0 Hz, 6 H), 0.15 (s, 3 H); 13C-NMR (125 
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MHz, CDCl3) δ 143.8, 142.8, 137.0, 137.0, 129.6, 126.8, 58.2, 50.8, 48.2, 29.2, 29.1, 
24.8, 21.4, 18.3, -4.9; HRMS (ESI-TOF) calcd. for C19H31NO4SSi [M+H]+ 398.18159, 
found 398.27160. 
 
 
(Z)-1-tosyl-1,2,3,4,7,8-hexahydroazocine (33-Z) 
Yield 72% (colorless oil); IR (neat, cm-1) 3018, 2933, 2858, 1598, 1494, 1456, 1369, 
1333, 1304, 1289, 1157, 1112, 1091, 1060, 1038, 991; 1H-NMR (500 MHz, CDCl3) δ 
7.67 (d, J = 8.5 Hz, 2 H), 7.27 (d, J = 8.5 Hz, 2 H), 5.74-5.66 (m, 2 H), 3.14 (t, J = 5.0 
Hz, 2 H), 3.08 (t, J = 5.5 Hz, 2 H), 2.40 (s, 3 H), 2.31-2.28 (m, 2 H), 2.22 (dt, J = 6.9, 6.9 
Hz, 2 H), 1.76-1.72 (m, 2 H); 13C-NMR (125 MHz, CDCl3) δ 142.9, 136.9, 131.3, 129.5, 
128.2, 126.8, 50.8, 48.2, 29.4, 28.1, 23.3, 21.4; HRMS (ESI-TOF) calcd. for C14H19NO2S 
[M+H]+ 266.12093, found 266.12097. 
 
 
Diethoxy(methyl)(3-((1S,2S)-2-(pent-4-enyloxy)cyclohexyloxy)prop-1-en-2-yl)silane 
and its enantiomer (15’) 
Yield 62% (colorless oil); IR (neat, cm-1) 3077, 2974, 2934, 2865, 1641, 1449, 1390, 
1366, 1295, 1257, 1164, 1104, 1083, 992, 951; 1H-NMR (500 MHz, CDCl3) δ 6.00-5.98 
(m, 1 H), 5.82 (dddd, J = 17.0, 10.0, 6.5, 6.5 Hz, 1 H), 5.64-5.63 (m, 1 H), 5.03-4.99 (m, 
1 H), 4.96-4.93 (m, 1 H), 4.24-4.23 (m, 2 H), 3.77 (q, J = 7.0 Hz, 4 H), 3.59-3.50 (m, 2 
 
 
73 
H), 3.26-3.18 (m, 2 H), 2.14-2.10 (m, 2 H), 1.97-1.94 (m, 2 H), 1.68-1.62 (m, 4 H), 1.35-
1.19 (m, 10 H), 0.22 (s, 3 H); 13C-NMR (125 MHz, CDCl3) δ 144.8, 138.5, 126.9, 114.5, 
81.1, 80.6, 72.4, 69.1, 58.3, 30.4, 29.8, 29.8, 29.5, 23.3, 23.3, 18.3, -4.3; HRMS (ESI-
TOF) calcd. for C19H36O4Si [M+Na]+ 379.22751, found 379.22440. 
 
 
 ((8aS,12aS,E)-2,5,6,7,8a,9,10,11,12,12a-Decahydrobenzo[b][1,4]dioxecin-3-
yl)diethoxy(methyl)silane and its enantiomer (15) 
Yield 87% (pale yellow oil); IR (neat, cm-1) 2972, 2932, 2862, 1615, 1451, 1390, 1364, 
1256, 1165, 1113, 1082, 1009, 952; 1H-NMR (500 MHz, CDCl3) δ 6.22 (dd, J = 10.2, 6.8 
Hz, 1 H), 4.33 (d, J = 10.5 Hz, 1 H), 4.26 (d, J = 10.5 Hz, 1 H), 3.81-3.76 (m, 4 H), 3.72-
3.68 (m, 1 H), 3.62-3.57 (m, 1 H), 3.22-3.17 (m, 1 H), 3.02-2.97 (m, 1 H), 2.68-2.60 (m, 
1 H), 2.18-2.12 (m, 1 H), 2.00-1.98 (m, 1 H), 1.94-1.92 (m, 1 H), 1.90-1.82 (m, 1 H), 
1.66-1.65 (m, 2 H), 1.54-1.48 (m, 1 H), 1.26-1.12 (m, 10 H), 0.21 (s, 3 H); 13C-NMR 
(125 MHz, CDCl3) δ 146.8, 136.6, 83.2, 83.1, 67.6, 66.7, 58.3, 31.8, 31.8, 28.6, 25.1, 
24.7, 24.5, 18.3, -4.4; HRMS (ESI-TOF) calcd. for C17H32O4Si [M+Na]+ 351.19621, 
found 351.19793. 
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 (8aS,12aS,Z)-2,3,4,7,8a,9,10,11,12,12a-decahydrobenzo[b][1,4]dioxecine and its 
enantiomer (34-Z) 
Yield 86% (colorless oil); IR (neat, cm-1) 3012, 2930, 2858, 1451, 1360, 1315, 1239, 
1206, 1117, 1086, 1051, 1026, 970; 1H-NMR (500 MHz, CDCl3) δ 5.79 (ddd, J = 10.0, 
10.0, 5.0 Hz, 1 H), 5.55 (ddd, J = 10.7, 10.7, 6.5 Hz, 1 H), 4.31 (dd, J = 10.5, 10.5 Hz, 1 
H), 4.19 (dd, J = 10.7, 5.2 Hz, 1 H), 3.70-3.67 (m, 1 H), 3.53-3.49 (m, 1 H), 3.20-3.15 
(m, 1 H), 2.96-2.92 (m, 1 H), 2.65-2.59 (m, 1 H), 1.94-1.80 (m, 4 H), 1.64-1.63 (m, 2 H), 
1.43-1.37 (m, 1 H), 1.22-1.10 (m, 4 H); 13C-NMR (125 MHz, CDCl3) δ 131.7, 128.8, 
84.7, 83.2, 67.3, 66.9, 32.2, 31.6, 28.1, 24.6, 24.5, 22.6; HRMS (ESI-TOF) calcd. for 
C12H20O2 [M+H]+ 197.15361, found 197.15343. 
 
 
Diethoxy(3-((1S,2S)-2-(hex-5-enyloxy)cyclohexyloxy)prop-1-en-2-yl)(methyl)silane 
and its enantiomer (16’) 
Yield 64% (colorless oil); IR (neat, cm-1) 3076, 2974, 2934, 2863, 1641, 1451, 1390, 
1366, 1295, 1257, 1164, 1104, 1083, 993, 951; 1H-NMR (500 MHz, CDCl3) δ 5.99-5.98 
(m, 1 H), 5.80 (dddd, J = 17.0, 10.5, 7.0, 7.0 Hz, 1 H), 5.64-5.62 (m, 1 H), 5.01-4.98 (m, 
1 H), 4.94-4.92 (m, 1 H), 4.23-4.23 (m, 2 H), 3.77 (q, J = 7.0 Hz, 4 H), 3.58-3.49 (m, 2 
H), 3.25-3.18 (m, 2 H), 2.08-2.04 (m, 2 H), 1.97-1.93 (m, 2 H), 1.65-1.62 (m, 2 H), 1.60-
1.54 (m, 2 H), 1.48-1.42 (m, 2 H), 1.35-1.19 (m, 10 H), 0.22 (s, 3 H); 13C-NMR (125 
MHz, CDCl3) δ 144.8, 138.8, 126.9, 114.4, 81.1, 80.6, 72.4, 69.6, 58.3, 33.6, 29.8, 29.8, 
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25.6, 23.3, 23.3, 18.3, -4.3; HRMS (ESI-TOF) calcd. for C20H38O4Si [M+Na]+ 
393.24316, found 393.24372. 
 
 
((9aS,13aS,E)-5,6,7,8,9a,10,11,12,13,13a-Decahydro-2H-
benzo[b][1,4]dioxacycloundecin-3-yl)diethoxy(methyl)silane and its enantiomer (16) 
Yield 36% (pale yellow oil); IR (neat, cm-1) 2971, 2929, 2860, 1618, 1450, 1389, 1371, 
1255, 1191, 1165, 1104, 1079, 1044, 1003, 951; 1H-NMR (500 MHz, CDCl3) δ 6.23 (dd, 
J = 10.0, 6.0 Hz, 1 H), 4.24 (d, J = 10.2 Hz, 1 H), 4.14 (d, J = 10.2 Hz, 1 H), 3.85-3.82 
(m, 1 H), 3.77 (q, J = 7.0 Hz, 4 H), 3.54-3.51 (m, 1 H), 3.14-3.09 (m, 1 H), 3.00-2.97 (m, 
1 H), 2.66-2.58 (m, 1 H), 2.24-2.18 (m, 1 H), 2.10-2.08 (m, 1 H), 2.00-1.98 (m, 1 H), 
1.75-1.66 (m, 4 H), 1.59-1.52 (m, 1 H), 1.44-1.39 (m, 1 H), 1.23-1.08 (m, 10 H), 0.19 (s, 
3 H); 13C-NMR (125 MHz, CDCl3) δ 149.7, 133.4, 84.1, 82.2, 71.9, 66.2, 58.2, 31.5, 
31.1, 28.4, 27.2, 27.0, 24.5, 24.3, 18.3, -4.6; HRMS (ESI-TOF) calcd. for C18H34O4Si 
[M+Na]+ 365.21186, found 365.21302. 
 
 
(9aS,13aS,Z)-3,4,5,8,9a,10,11,12,13,13a-decahydro-2H-
benzo[b][1,4]dioxacycloundecine and its enantiomer (35-Z) 
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Yield 90% (colorless oil); IR (neat, cm-1) 3012, 2930, 2858, 1450, 1370, 1312, 1243, 
1188, 1130, 1102, 999; 1H-NMR (500 MHz, CDCl3) δ 5.65 (ddd, J = 9.5, 9.5, 5.0 Hz, 1 
H), 5.56 (ddd, J = 10.0, 10.0, 5.0 Hz, 1 H), 4.28 (dd, J = 10.0, 10.0 Hz, 1 H), 4.06 (dd, J 
= 10.0, 5.0 Hz, 1 H), 3.70 (dd, J = 10.0, 8.0 Hz, 1 H), 3.47 (dd, J = 11.5, 6.5 Hz, 1 H), 
3.14 (ddd, J = 9.0, 9.0, 5.0 Hz, 1 H), 2.98 (ddd, J = 9.5, 9.5, 5.0 Hz, 1 H), 2.63-2.56 (m, 1 
H), 2.04-2.00 (m, 3 H), 1.73-1.64 (m, 4 H), 1.51-1.45 (m, 1 H), 1.42-1.37 (m, 1 H), 1.19-
1.07 (m, 4 H); 13C-NMR (125 MHz, CDCl3) δ 135.0, 126.1, 84.3, 82.1, 71.0, 66.4, 31.9, 
30.7, 28.2, 26.7, 26.1, 24.5, 24.2; HRMS (ESI-TOF) calcd. for C13H22O2 [M+H]+ 
211.16926, found 211.16944. 
 
 
(1S,2S)-2-((2-(Diethoxy(methyl)silyl)allyl)oxy)cyclohexyl hex-5-enoate and its 
enantiomer (17’) 
Yield 65% (colorless oil); IR (neat, cm-1) 3077, 2973, 2938, 2866, 1736, 1641, 1452, 
1389, 1365, 1254, 1168, 1103, 1080, 1009, 951; 1H-NMR (500 MHz, CDCl3) δ 5.93-5.93 
(m, 1 H), 5.78 (dddd, J = 17.0, 10.5, 6.5, 6.5 Hz, 1 H), 5.62-5.62 (m, 1 H), 5.04-5.00 (m, 
1 H), 4.98 (d, J = 10.0 Hz, 1 H), 4.81 (ddd, J = 8.5, 8.5, 4.5 Hz, 1 H), 4.20 (d, J = 13.0 
Hz, 1 H), 4.10 (d, J = 13.0 Hz, 1 H), 3.76 (q, J = 7.0 Hz, 4 H), 3.32 (ddd, J = 8.5, 8.5, 4.0 
Hz, 1 H), 2.31 (dd, J = 8.0, 8.0 Hz, 2 H), 2.09 (ddd, J = 7.0, 7.0, 7.0 Hz, 2 H), 2.03-1.97 
(m, 2 H), 1.76-1.64 (m, 4 H), 1.44-1.33 (m, 3 H), 1.30-1.20 (m, 7 H), 0.20 (s, 3 H); 13C-
NMR (125 MHz, CDCl3) δ 172.9, 144.4, 137.8, 127.1, 115.2, 78.7, 74.7, 72.0, 58.3, 58.3, 
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33.9, 33.0, 29.6, 29.5, 24.1, 23.1, 23.0, 18.3, -4.3; HRMS (ESI-TOF) calcd. for 
C20H36O5Si [M+Na]+ 407.22242, found 407.22435. 
 
 
(9aS,13aS,E)-7-(Diethoxy(methyl)silyl)-3,4,5,8,9a,10,11,12,13,13a-decahydro-2H-
benzo[b][1,4]dioxacycloundecin-2-one and its enantiomer (17) 
Yield 43% (pale yellow oil); IR (neat, cm-1) 2971, 2932, 2865, 1736, 1614, 1450, 1389, 
1365, 1256, 1225, 1196, 1152, 1084, 1055, 983, 952; 1H-NMR (500 MHz, CDCl3) δ 
6.20-6.17 (m, 1 H), 4.75 (ddd, J = 10.0, 10.0, 5.0 Hz, 1 H), 4.22 (d, J = 12.8 Hz, 1 H), 
3.99 (d, J = 12.8 Hz, 1 H), 3.81-3.73 (m, 4H), 3.21 (ddd, J = 10.0, 10.0, 4.5 Hz, 1 H), 
2.85-2.76 (m, 1 H), 2.37-2.26 (m, 2 H), 2.16-2.12 (m, 2 H), 2.06-1.99 (m, 1 H), 1.95-1.93 
(m, 1 H), 1.83-1.70 (m, 3 H), 1.34-1.16 (m, 10 H), 0.20 (s, 3 H); 13C-NMR (125 MHz, 
CDCl3) δ 173.4, 150.2, 135.5, 79.4, 75.0, 63.3, 58.2, 58.2, 33.3, 30.6, 30.1, 27.1, 24.1, 
23.6, 18.4, 18.3, -4.9; HRMS (ESI-TOF) calcd. for C18H32O5Si [M+H]+ 357.20918, 
found 357.20950. 
 
 
(9aS,13aS,Z)-3,4,5,8,9a,10,11,12,13,13a-decahydro-2H-
benzo[b][1,4]dioxacycloundecin-2-one and its enantiomer (36-Z) 
 78 
Yield 83% (colorless oil); IR (neat, cm-1) 3011, 2936, 2862, 1735, 1451, 1364, 1322, 
1217, 1153, 1087, 1032, 984; 1H-NMR (500 MHz, CDCl3) δ 6.63-6.59 (m, 1 H), 5.54 
(ddd, J = 10.5, 8.0, 8.0 Hz, 1 H), 4.73-4.68 (m, 1 H), 4.20 (dd, J = 13.2, 4.8 Hz, 1 H), 
3.94 (dd, J = 13.2, 7.2 Hz, 1 H), 3.24-3.19 (m, 1 H), 2.50-2.43 (m, 1 H), 2.36-2.26 (m, 2 
H), 2.16-2.03 (m, 2 H), 1.97-1.85 (m, 2 H), 1.82-1.67 (m, 3 H), 1.33-1.13 (m, 4 H); 13C-
NMR (125 MHz, CDCl3) δ 173.2, 134.6, 127.3, 80.1, 75.8, 64.3, 33.9, 30.9, 30.5, 25.9, 
24.0, 23.9, 23.8; HRMS (ESI-TOF) calcd. for C13H20O3 [M+Na]+ 247.13047, found 
247.13070. 
 
 
(1R,2S)-2-((2-(Diethoxy(methyl)silyl)allyl)oxy)cyclohexyl hex-5-enoate and its 
enantiomer (18’) 
Yield 69% (colorless oil); IR (neat, cm-1) 3077, 2973, 2939, 2869, 1733, 1641, 1449, 
1388, 1364, 1255, 1170, 1104, 1082, 951; 1H-NMR (500 MHz, CDCl3) δ 5.94-5.93 (m, 1 
H), 5.78 (dddd, J = 16.8, 10.2, 6.8, 6.8 Hz, 1 H), 5.64-5.63 (m, 1 H), 5.08-5.07 (m, 1 H), 
5.04-5.00 (m, 1 H), 4.98 (d, J = 10.0 Hz, 1 H), 4.14 (d, J = 13.0 Hz, 1 H), 4.10 (d, J = 
13.0 Hz, 1 H), 3.79-3.75 (m, 4 H), 3.49-3.48 (m, 1 H), 2.34 (dd, J = 7.5, 7.5 Hz, 2 H), 
2.09 (ddd, J = 7.0, 7.0, 7.0 Hz, 2 H), 1.93-1.88 (m, 1 H), 1.85-1.78 (m, 1 H), 1.76-1.65 
(m, 3 H), 1.62-1.47 (m, 3 H), 1.43-1.29 (m, 2 H), 1.23-1.20 (m, 6 H), 0.22 (s, 3 H); 13C-
NMR (125 MHz, CDCl3) δ 173.1, 144.4, 137.8, 127.4, 115.2, 76.5, 71.6, 58.3, 33.9, 33.0, 
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27.8, 27.8, 24.2, 22.0, 21.8, 18.3, -4.3; HRMS (ESI-TOF) calcd. for C20H36O5Si [M+Na]+ 
407.22242, found 407.22426. 
 
 
(9aS,13aR,E)-7-(Diethoxy(methyl)silyl)-3,4,5,8,9a,10,11,12,13,13a-decahydro-2H-
benzo[b][1,4]dioxacycloundecin-2-one and its enantiomer (18) 
Yield 36% (pale yellow oil); IR (neat, cm-1) 2970, 2931, 2870, 1730, 1614, 1450, 1390, 
1360, 1246, 1225, 1162, 1110, 1080, 1049, 949; 1H-NMR (500 MHz, CDCl3) δ 6.24 (dd, 
J = 9.8, 6.2 Hz, 1 H), 4.67 (ddd, J = 11.0, 3.8, 3.8 Hz, 1 H), 4.29 (d, J = 11.5 Hz, 1 H), 
3.89 (bs, 1 H), 3.86 (d, J = 11.5 Hz, 1 H), 3.80-3.75 (m, 4 H), 2.45 (ddd, J = 13.2, 8.2, 4.8 
Hz, 1 H), 2.25-2.13 (m, 3 H), 1.94-1.88 (m, 2 H), 1.86-1.78 (m, 2 H), 1.72-1.70 (m, 1 H), 
1.59-1.48 (m, 2 H), 1.42-1.17 (m, 9 H), 0.21 (s, 3 H); 13C-NMR (125 MHz, CDCl3) δ 
173.6, 147.9, 134.7, 75.6, 74.0, 65.8, 58.3, 34.7, 28.6, 27.6, 26.5, 24.9, 23.7, 19.9, 18.3, -
4.6; HRMS (ESI-TOF) calcd. for C18H32O5Si [M+H]+ 357.20918, found 357.21015. 
 
 
(9aS,13aR,Z)-3,4,5,8,9a,10,11,12,13,13a-decahydro-2H-
benzo[b][1,4]dioxacycloundecin-2-one and its enantiomer (37-Z) 
 80 
Yield 92% (colorless oil), inseparable mixture with styrene derivative; IR (neat, cm-1) 
3010, 2937, 2862, 1729, 1448, 1359, 1243, 1212, 1155, 1083, 1051, 1014; 1H-NMR (500 
MHz, CDCl3) δ 5.61-5.52 (m, 2 H), 4.66-4.62 (m, 1 H), 4.50 (dd, J = 12.2, 7.8 Hz, 1 H), 
4.05 (bs, 1 H), 3.93 (dd, J = 12.2, 5.0 Hz, 1 H), 2.33-2.29 (m, 2 H), 2.24-2.10 (m, 2 H), 
1.93-1.79 (m, 4 H), 1.74-1.72 (m, 1 H), 1.59-1.50 (m, 2 H), 1.47-1.27 (m 3 H); 13C-NMR 
(125 MHz, CDCl3) δ 173.5, 133.7, 127.6, 75.5, 72.3, 64.8, 35.0, 30.1, 26.3, 26.1, 24.9, 
24.1, 19.7; HRMS (ESI-TOF) calcd. for C13H20O3 [M+Na]+ 247.13047, found 
247.13029. 
 
 
(±)-1-(2-(((2-(Diethoxy(methyl)silyl)allyl)oxy)methyl)piperidin-1-yl)hept-6-en-1-one 
(19’) 
Yield 54% (pale yellow oil); IR (neat, cm-1) 3075, 2973, 2930, 2865, 1644, 1425, 1390, 
1365, 1257, 1166, 1103, 1081, 1029, 952; 1H-NMR (500 MHz, CDCl3) δ 5.89 and 5.87 
(pair of bs due to rotamers, 1 H), 5.80 (dddd, J = 17.0, 10.0, 6.8, 6.8 Hz, 1 H), 5.64 (bs, 1 
H), 5.01-4.98 (m, 1 H), 4.93 (d, J = 10.0 Hz, 1 H), 4.57 and 3.66 (pair of d due to 
rotamers, J = 13.0 Hz, 1 H), 4.14-4.04 (m, 3 H), 3.76 (q, J = 6.8 Hz, 4 H), 3.61-3.46 (m, 2 
H), 3.11 and 2.57 (pair of dd due to rotamers, J = 13.0, 13.0 Hz, 1 H), 2.43-2.29 (m, 2 
H), 2.07 (ddd, J = 7.2, 7.2, 7.2 Hz, 2 H), 1.86-1.80 (m, 1 H), 1.71-1.49 (m, 6 H), 1.46-
1.33 (m, 3 H), 1.21 (t, J = 7.0 Hz, 6 H), 0.20 (s, 3H); 13C-NMR (125 MHz, CDCl3) δ 
172.4 and 171.8 (due to rotamers), 144.0 and 143.8 (due to rotamers), 138.7, 127.7, 
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114.4, 74.0 and 73.8 (due to rotamers), 68.7 and 68.4 (due to rotamers), 58.3, 52.4, 46.8, 
42.2, 37.0, 33.6 and 33.2 (due to rotamers), 33.6, 28.7, 26.5 and 25.9 (due to rotamers), 
25.2 and 25.1 (due to rotamers), 24.9 and 24.8 (due to rotamers), 19.6 and 19.4 (due to 
rotamers), 18.3, -4.5; HRMS (ESI-TOF) calcd. for C21H39NO4Si [M+H]+ 398.27211, 
found 398.27371. 
 
 
(±)-(E)-4-(Diethoxy(methyl)silyl)-1,6,7,8,9,12,13,14,15,15a-decahydropyrido[2,1-
c][1,4]oxaazacyclododecin-10(3H)-one (19) 
Yield 33% (colorless oil); IR (neat, cm-1) 2970, 2928, 2865, 1634, 1444, 1389, 1366, 
1256, 1165, 1106, 1079, 952; 1H-NMR (500 MHz, CDCl3) δ 6.15 (dd, J = 9.5, 5.5 Hz, 1 
H), 4.65 (d, J = 13.0 Hz, 1 H), 4.40 (bs, 1 H), 4.29 (d, J = 11.2 Hz, 1 H), 3.95 (d, J = 11.2 
Hz, 1 H), 3.79 (dd, J = 9.8, 9.8 Hz, 1 H), 3.73 (q, J = 6.9 Hz, 4 H), 3.33 (dd, J = 11.0, 4.5 
Hz, 1 H), 2.85-2.82 (m, 1 H), 2.59-2.55 (m, 2 H), 1.96-1.92 (m, 2 H), 1.74-1.58 (m, 6 H), 
1.48-1.35 (m, 4 H), 1.19 (dd, J = 6.8, 6.8 Hz, 6 H), 0.16 (s, 3 H); 13C-NMR (125 MHz, 
CDCl3) δ 173.7, 148.0, 132.9, 67.6, 67.4, 58.3 52.0, 36.6, 29.3, 27.3, 27.0, 26.9, 25.3, 
23.8, 19.7, 18.3, 18.3, -4.6; HRMS (ESI-TOF) calcd. for C19H35NO4Si [M+Na]+ 
392.22276, found 392.22352. 
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(±)-(Z)-1,6,7,8,9,12,13,14,15,15a-decahydropyrido[2,1-c][1,4]oxaazacyclododecin-
10(3H)-one (38-Z) 
Yield 90% (colorless oil); IR (neat, cm-1) 3010, 2934, 2861, 1631, 1444, 1419, 1367, 
1327, 1266, 1125, 1078, 1029; 1H-NMR (500 MHz, CDCl3) δ 5.59-5.49 (m, 2 H), 4.61-
4.59 (m, 1 H), 4.36 (bs, 1 H), 4.24-4.20 (m, 1 H), 3.84-3.82 (m, 1 H), 3.76 (dd, J = 9.8, 
9.8 Hz, 1 H), 3.43-3.40 (m, 1 H), 2.74 (bs, 1 H), 2.53 (dd, J = 12.2, 12.2 Hz, 1 H), 2.38 
(bs, 1 H), 1.93-1.92 (m, 2 H), 1.73-1.60 (m, 6 H), 1.44-1.30 (m, 4 H); 13C-NMR (125 
MHz, CDCl3) δ 173.3, 134.9, 125.4, 67.3, 65.5, 51.1, 36.8, 29.5, 26.8, 26.4, 25.2, 25.1, 
23.6, 19.4; HRMS (ESI-TOF) calcd. for C14H23NO2 [M+Na]+ 260.16210, found 
260.16176. 
 
 
Diethoxy(3-(((1S,2S)-2-(hept-6-en-1-yloxy)cyclohexyl)oxy)prop-1-en-2-
yl)(methyl)silane and its enantiomer (20’) 
Yield 59% (colorless oil); IR (neat, cm-1) 3076, 2974, 2933, 2862, 1641, 1451, 1390, 
1366, 1295, 1257, 1164, 1104, 1083, 994, 952; 1H-NMR (500 MHz, CDCl3) δ 5.99-5.98 
(m, 1 H), 5.80 (dddd, J = 17.0, 10.5, 6.8, 6.8 Hz, 1 H), 5.64-5.63 (m, 1 H), 5.01-4.97 (m, 
1 H), 4.94-4.92 (m, 1 H), 4.23-4.23 (m, 2 H), 3.77 (q, J = 7.0 Hz, 4 H), 3.57-3.48 (m, 2 
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H), 3.25-3.18 (m, 2 H), 2.04 (ddd, J = 7.0, 7.0, 7.0 Hz, 2 H), 1.96-1.94 (m, 2 H), 1.65-
1.62 (m, 2 H), 1.59-1.53 (m, 2 H), 1.41-1.19 (m, 14 H), 0.22 (s, 3 H); 13C-NMR (125 
MHz, CDCl3) δ 144.8, 139.0, 126.9, 114.2, 81.1, 80.7, 72.4, 69.8, 58.3, 33.7, 30.2, 29.8, 
29.8, 28.8, 25.7, 23.3, 23.3, 18.3, -4.3; HRMS (ESI-TOF) calcd. for C21H40O4Si [M+Na]+ 
407.25881, found 407.25995. 
 
 
((10aS,14aS,E)-2,5,6,7,8,9,10a,11,12,13,14,14a-
Dodecahydrobenzo[b][1,4]dioxacyclododecin-3-yl)diethoxy(methyl)silane and its 
enantiomer (20) 
Yield 59% (pale yellow oil); IR (neat, cm-1) 2970, 2930, 2859, 1616, 1450, 1389, 1365, 
1254, 1166, 1135, 1111, 1083, 1024, 950; 1H-NMR (500 MHz, CDCl3) δ 6.33 (dd, J = 
8.8, 6.8 Hz, 1 H), 4.35 (d, J = 8.8 Hz, 1 H), 4.07 (d, J = 8.8 Hz, 1 H), 3.92-3.89 (m, 1 H), 
3.79-3.74 (m, 4 H), 3.16-3.12 (m, 1 H), 3.09-3.05 (m, 2 H), 2.62-2.55 (m, 1 H), 2.08-2.03 
(m, 2 H), 2.00-1.94 (m, 1 H), 1.68-1.59 (m, 4 H), 1.56-1.46 (m, 4 H), 1.22-1.08 (m, 10 
H), 0.19 (s, 3 H); 13C-NMR (125 MHz, CDCl3) δ 149.7, 133.7, 84.2, 81.4, 70.0, 66.5, 
58.2, 58.2, 31.2, 30.7, 27.7, 27.4, 27.2, 25.8, 24.5, 24.2, 18.3, -4.5; HRMS (ESI-TOF) 
calcd. for C19H36O4Si [M+Na]+ 379.22751, found 379.22910. 
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(10aS,14aS,Z)-2,3,4,5,6,9,10a,11,12,13,14,14a-
dodecahydrobenzo[b][1,4]dioxacyclododecine and its enantiomer (39-Z) 
Yield 88% (colorless oil), inseparable mixture with styrene derivative; IR (neat, cm-1) 
3014, 2930, 2858, 1451, 1361, 1334, 1313, 1244, 1190, 1130, 1107, 1047, 983, 962; 1H-
NMR (500 MHz, CDCl3) δ 5.73-5.65 (m, 2 H), 4.47 (dd, J = 9.0, 9.0 Hz, 1 H), 3.96 (dd, J 
= 9.2, 4.2 Hz, 1 H), 3.93-3.90 (m, 1 H), 3.16-3.08 (m, 3 H), 2.45-2.38 (m, 1 H), 2.08-2.07 
(m, 1 H), 2.00-1.98 (m, 1 H), 1.90-1.86 (m, 1 H), 1.70-1.60 (m, 3 H), 1.52-1.45 (m, 4 H), 
1.28-1.13 (m, 5 H); 13C-NMR (125 MHz, CDCl3) δ 135.4, 126.3, 84.8, 80.8, 69.6, 66.0, 
31.5, 30.6, 28.1, 27.3, 24.9, 24.6, 24.1, 24.0; HRMS (ESI-TOF) calcd. for C14H24O2 
[M+Na]+ 247.16685, found 247.16800. 
 
 
(1S,2S)-2-((2-(Diethoxy(methyl)silyl)allyl)oxy)cyclohexyl hept-6-enoate and its 
enantiomer (21’) 
Yield 60% (colorless oil); IR (neat, cm-1) 3075, 2973, 2937, 2865, 1736, 1641, 1452, 
1389, 1257, 1166, 1103, 1080, 1008, 952; 1H-NMR (500 MHz, CDCl3) δ 5.93-5.93 (m, 1 
H), 5.79 (dddd, J = 17.0, 10.5, 6.5, 6.5 Hz, 1 H), 5.62-5.62 (m, 1 H), 5.02-4.98 (m, 1 H), 
4.95 (d, J = 10.0 Hz, 1 H), 4.81 (ddd, J = 8.2, 8.2, 4.5 Hz, 1 H), 4.21 (d, J = 13.2 Hz, 1 
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H), 4.10 (d, J = 13.2 Hz, 1 H), 3.76 (q, J = 7.0 Hz, 4 H), 3.32 (ddd, J = 8.5, 8.5, 4.0 Hz, 1 
H), 2.30 (dd, J = 8.0, 8.0 Hz, 2 H), 2.08-1.96 (m, 4 H), 1.71-1.61 (m, 4 H), 1.45-1.39 (m, 
3 H), 1.34 (dd, J = 9.5, 9.5 Hz, 2 H), 1.30-1.20 (m, 7 H), 0.21 (s, 3 H); 13C-NMR (125 
MHz, CDCl3) δ 173.0, 144.4, 138.4, 127.1, 114.6, 78.7, 74.6, 72.0, 58.3, 58.3, 34.5, 33.4, 
29.6, 29.5, 28.3, 24.4, 23.1, 23.0, 18.3, -4.3; HRMS (ESI-TOF) calcd. for C21H38O5Si 
[M+Na]+ 421.23807, found 421.23885. 
 
 
(10aS,14aS,E)-8-(Diethoxy(methyl)silyl)-3,4,5,6,10a,11,12,13,14,14a-
decahydrobenzo[b][1,4]dioxacyclododecin-2(9H)-one and its enantiomer (21) 
Yield 82% (pale yellow oil); IR (neat, cm-1) 2971, 2936, 2866, 1734, 1617, 1451, 1389, 
1360, 1338, 1256, 1225, 1189, 1150, 1104, 1082, 1036, 996, 950; 1H-NMR (500 MHz, 
CDCl3) δ 6.37 (dd, J = 10.2, 5.8 Hz, 1 H), 4.61 (ddd, J = 10.2, 10.2, 4.5 Hz, 1 H), 4.10 (d, 
J = 9.0 Hz, 1 H), 4.04 (d, J = 9.0 Hz, 1 H), 3.76-3.71 (m, 4 H), 3.22 (ddd, J = 10.0, 10.0, 
4.5 Hz, 1 H), 2.66 (dddd, J = 11.3, 11.3, 11.3, 4.0 Hz, 1 H), 2.47 (ddd, J = 12.5, 12.5, 4.5 
Hz, 1 H), 2.35 (ddd, J = 13.2, 4.8, 4.8 Hz, 1 H), 2.16-2.15 (m, 1 H), 2.07-2.06 (m, 1 H), 
1.96-1.90 (m, 1 H), 1.85-1.78 (m, 1 H), 1.74-1.69 (m, 2 H), 1.65-1.56 (m, 2 H), 1.33-1.18 
(m, 11 H), 0.17 (s, 3 H); 13C-NMR (125 MHz, CDCl3) δ 173.8, 151.1, 132.6, 80.4, 76.5, 
65.4, 58.3, 58.2, 33.3, 31.0, 30.2, 27.9, 27.7, 24.9, 24.1, 24.0, 18.3, -4.9; HRMS (ESI-
TOF) calcd. for C19H34O5Si [M+H]+ 371.22483, found 371.22556. 
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(10aS,14aS,Z)-3,4,5,6,10a,11,12,13,14,14a-
decahydrobenzo[b][1,4]dioxacyclododecin-2(9H)-one and its enantiomer (40-Z) 
Yield 91% (colorless oil); IR (neat, cm-1) 3019, 2937, 2862, 1732, 1451, 1354, 1278, 
1222, 1150, 1107, 1085, 1034, 989; 1H-NMR (500 MHz, CDCl3) δ 5.84 (ddd, J = 10.0, 
10.0, 5.5 Hz, 1 H), 5.65 (ddd, J = 10.0, 7.0, 7.0 Hz, 1 H), 4.62 (ddd, J = 10.0, 10.0, 5.0 
Hz, 1 H), 4.06 (dd, J = 8.5, 8.5 Hz, 1 H), 3.98 (dd, J = 9.5, 6.5 Hz, 1 H), 3.22 (ddd, J = 
10.0, 10.0, 4.0 Hz, 1 H), 2.55 (dddd, J = 11.5, 11.5, 11.5, 4.0 Hz, 1 H), 2.46 (ddd, J = 
12.5, 12.5, 4.0 Hz, 1 H), 2.35 (ddd, J = 13.0, 5.0, 5.0 Hz, 1 H), 2.11-2.06 (m, 2 H), 1.94-
1.87 (m, 1 H), 1.76-1.67 (m, 3 H), 1.65-1.55 (m, 2 H), 1.34-1.17 (m, 5 H); 13C-NMR (125 
MHz, CDCl3) δ 173.6, 138.1, 124.6, 80.6, 76.7, 65.2, 33.1, 30.9, 30.6, 28.2, 25.9, 24.6, 
24.2, 23.9; HRMS (ESI-TOF) calcd. for C14H22O3 [M+Na]+ 261.14612, found 
261.14610. 
 
 
(1R,2S)-2-((2-(Diethoxy(methyl)silyl)allyl)oxy)cyclohexyl hept-6-enoate and its 
enantiomer (22’) 
Yield 66% (colorless oil); IR (neat, cm-1) 3076, 2972, 2938, 2866, 1734, 1641, 1449, 
1388, 1364, 1257, 1169, 1104, 1081, 992, 951; 1H-NMR (500 MHz, CDCl3) δ 5.94-5.93 
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(m, 1 H), 5.79 (dddd, J = 17.0, 10.5, 6.5, 6.5 Hz, 1 H), 5.64-5.63 (m, 1 H), 5.08-5.06 (m, 
1 H), 5.02-4.98 (m, 1 H), 4.94 (d, J = 10.0 Hz, 1 H), 4.14 (d, J = 13.0 Hz, 1 H), 4.10 (d, J 
= 13.0 Hz, 1 H), 3.79-3.75 (m, 4 H), 3.49-3.48 (m, 1 H), 2.33 (dd, J = 7.2, 7.2 Hz, 2 H), 
2.06 (ddd, J = 7.2, 7.2, 7.2 Hz, 2 H), 1.93-1.87 (m, 1 H), 1.85-1.78 (m, 1 H), 1.70-1.47 
(m, 6 H), 1.46-1.29 (m, 4 H), 1.21 (dd, J = 7.0, 7.0 Hz, 6 H), 0.22 (s, 3 H); 13C-NMR 
(125 MHz, CDCl3) δ 173.2, 144.4, 138.5, 127.4, 114.6, 76.5, 71.6, 58.3, 34.5, 33.4, 28.3, 
27.8, 27.8, 24.5, 22.0, 21.9, 18.3, -4.3; HRMS (ESI-TOF) calcd. for C21H38O5Si [M+Na]+ 
421.23807, found 421.23931. 
 
 
(10aS,14aR,E)-8-(Diethoxy(methyl)silyl)-3,4,5,6,10a,11,12,13,14,14a-
decahydrobenzo[b][1,4]dioxacyclododecin-2(9H)-one and its enantiomer (22) 
Yield 46% (pale yellow oil); IR (neat, cm-1) 2970, 2935, 2864, 1730, 1616, 1449, 1389, 
1353, 1256, 1224, 1156, 1105, 1079, 984, 952; 1H-NMR (500 MHz, CDCl3) δ 6.26 (dd, J 
= 8.2, 6.8 Hz, 1 H), 5.02-5.00 (m, 1 H), 4.06-4.01 (m, 2 H), 3.78-3.73 (m, 4 H), 3.61-3.60 
(m, 1 H), 2.40-2.28 (m, 2 H), 2.27-2.15 (m, 2 H), 1.96-1.90 (m, 1 H), 1.88-1.78 (m, 2 H), 
1.75-1.68 (m, 1 H), 1.67-1.54 (m, 6 H), 1.40-1.29 (m, 2 H), 1.22-1.19 (m, 6 H), 0.18 (s, 3 
H); 13C-NMR (125 MHz, CDCl3) δ 174.3, 149.6, 133.3, 75.0, 71.9, 63.6, 58.3, 58.2, 34.9, 
29.7, 28.6, 27.9, 27.7, 27.6, 24.4, 22.1, 21.7, 18.3, -4.8; HRMS (ESI-TOF) calcd. for 
C19H34O5Si [M+Na]+ 393.20677, found 393.20690. 
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(10aS,14aR,Z)-3,4,5,6,10a,11,12,13,14,14a-
decahydrobenzo[b][1,4]dioxacyclododecin-2(9H)-one and its enantiomer (41-Z) 
Yield 97% (colorless oil); IR (neat, cm-1) 2935, 2859, 1729, 1449, 1352, 1219, 1147, 
1081, 1047; 1H-NMR (500 MHz, CDCl3) δ 5.71 (ddd, J = 10.5, 8.0, 8.0 Hz, 1 H), 5.61 
(ddd, J = 10.5, 6.5, 6.5 Hz, 1 H), 5.07-5.06 (m, 1 H), 4.09-4.00 (m, 2 H), 3.65-3.63 (m, 1 
H), 2.43-2.38 (m, 1 H), 2.34-2.29 (m, 1 H), 2.26-2.18 (m, 1 H), 2.10-2.03 (m, 1 H), 1.99-
1.94 (m, 1 H), 1.83-1.72 (m, 3 H), 1.71-1.50 (m, 6 H), 1.42-1.28 (m, 2 H); 13C-NMR (125 
MHz, CDCl3) δ 174.3, 136.3, 125.4, 74.3, 71.9, 62.8, 34.6, 28.7, 28.3, 27.5, 26.1, 23.9, 
22.2, 21.6; HRMS (ESI-TOF) calcd. for C14H22O3 [M+Na]+ 261.14612, found 
261.14045. 
 
 
(1S,2S)-2-(Allyloxy)cyclohexyl 6-(diethoxy(methyl)silyl)hept-6-enoate and its 
enantiomer (23’) 
Yield 82% (colorless oil); IR (neat, cm-1) 3075, 2973, 2937, 2865, 1736, 1641, 1452, 
1389, 1364, 1257, 1166, 1102, 1080, 1008, 994, 952; 1H-NMR (500 MHz, CDCl3) δ 
5.91-5.84 (m, 1 H), 5.67 (bs, 1 H), 5.55-5.55 (m, 1 H), 5.25 (d, J = 17.5 Hz, 1 H), 5.13 (d, 
J = 10.0 Hz, 1 H), 4.80-4.76 (m, 1 H), 4.09 (dd, J = 12.8, 5.2 Hz, 1 H), 4.01 (dd, J = 12.8, 
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5.2 Hz, 1 H), 3.76 (q, J = 7.0 Hz, 4 H), 3.32-3.28 (m, 1 H), 2.31 (dd, J = 7.8, 7.8 Hz, 2 
H), 2.16 (dd, J = 7.8, 7.8 Hz, 2 H), 2.00-1.97 (m, 2 H), 1.71-1.62 (m, 4 H), 1.52-1.46 (m, 
2 H), 1.41-1.20 (m, 10 H), 0.19 (s, 3 H); 13C-NMR (125 MHz, CDCl3) δ 173.0, 147.1, 
135.4, 127.5, 116.2, 78.4, 74.7, 70.4, 58.2, 35.1, 34.6, 29.9, 29.7, 28.2, 24.9, 23.2, 23.2, 
18.3, -4.6; HRMS (ESI-TOF) calcd. for C21H38O5Si [M+Na]+ 421.23807, found 
421.24013. 
 
 
(10aS,14aS,E)-7-(Diethoxy(methyl)silyl)-3,4,5,6,10a,11,12,13,14,14a-
decahydrobenzo[b][1,4]dioxacyclododecin-2(9H)-one and its enantiomer (23) 
Yield 79% (pale yellow oil); IR (neat, cm-1) 2971, 2937, 2866, 1733, 1450, 1390, 1353, 
1339, 1256, 1227, 1146, 1103, 1081, 1036, 996, 951; 1H-NMR (500 MHz, CDCl3) δ 6.21 
(dd, J = 7.0, 7.0 Hz, 1H), 4.65-4.60 (m, 1 H), 4.20 (dd, J = 8.5, 8.5 Hz, 1 H), 3.98 (dd, J = 
9.0, 6.0 Hz, 1 H), 3.76-3.72 (m, 4 H), 3.23 (ddd, J = 10.0, 10.0, 4.0 Hz, 1 H), 2.58 (ddd, J 
= 12.5, 12.5, 3.5 Hz, 1 H), 2.54-2.48 (m, 1 H), 2.34 (ddd, J = 13.0, 5.0, 5.0 Hz, 1 H), 2.10 
(bs, 2 H), 1.95-1.87 (m, 2 H), 1.76-1.69 (m, 3 H), 1.64-1.57 (m, 1 H), 1.33-1.18 (m, 11 
H), 0.18 (s, 3 H); 13C-NMR (125 MHz, CDCl3) δ 173.7, 146.5, 136.5, 80.7, 77.1, 65.8, 
58.2, 58.2, 33.4, 31.0, 30.7, 29.0, 27.8, 25.5, 24.3, 23.9, 18.3, 18.3, -4.7; HRMS (ESI-
TOF) calcd. for C19H34O5Si [M+H]+ 371.22483, found 371.22591. 
 
Protodesilylation of 23 generated 40-Z with 52% yield. 
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(1R,2S)-2-(Allyloxy)cyclohexyl 6-(diethoxy(methyl)silyl)hept-6-enoate and its 
enantiomer (24’) 
Yield 80% (colorless oil); IR (neat, cm-1) 3051, 2971, 2938, 2866, 1733, 1449, 1388, 
1365, 1257, 1238, 1168, 1104, 1081, 950; 1H-NMR (500 MHz, CDCl3) δ 5.92-5.84 (m, 1 
H), 5.68-5.67 (m, 1 H), 5.55-5.54 (m, 1 H), 5.28-5.24 (m, 1 H), 5.15-5.12 (m, 1 H), 5.09-
5.08 (m, 1H), 4.05 (dd, J = 13.0, 5.8 Hz, 1H ), 3.98 (dd, J = 13.2, 5.8 Hz, 1 H), 3.76 (q, J 
= 7.0 Hz, 4 H), 3.49-3.47 (m, 1 H), 2.35 (dd, J = 7.5, 7.5 Hz, 2 H), 2.16 (dd, J = 7.5, 7.5 
Hz, 2 H), 1.91-1.86 (m, 1 H), 1.83-1.76 (m, 1 H), 1.71-1.62 (m, 3 H), 1.60-1.46 (m, 5 H), 
1.43-1.29 (m, 2 H), 1.21 (dd, J = 7.0, 7.0 Hz, 6 H), 0.18 (s, 3 H); 13C-NMR (125 MHz, 
CDCl3) δ 173.3, 174.1, 135.3, 127.5, 116.5, 76.0, 71.0, 69.7, 58.2, 35.1, 34.6, 28.2, 27.9, 
27.8, 24.9, 22.1, 21.7, 18.3, -4.6; HRMS (ESI-TOF) calcd. for C21H38O5Si [M+Na]+ 
421.23807, found 421.23908. 
 
 
(10aS,14aR,E)-7-(Diethoxy(methyl)silyl)-3,4,5,6,10a,11,12,13,14,14a-
decahydrobenzo[b][1,4]dioxacyclododecin-2(9H)-one and its enantiomer (24) 
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Yield 14% (colorless oil); IR (neat, cm-1) 2970, 2935, 2865, 1731, 1449, 1390, 1354, 
1256, 1226, 1149, 1103, 1079, 986, 952; 1H-NMR (500 MHz, CDCl3) δ 6.14 (dd, J = 6.5, 
6.5 Hz, 1 H), 5.06-5.05 (m, 1H), 4.19 (dd, J = 10.8, 6.5 Hz, 1 H), 4.03 (dd, J = 10.8, 6.5 
Hz, 1 H), 3.77-3.72 (m, 4 H), 3.60-3.59 (m, 1 H), 2.46-2.40 (m, 2 H), 2.34 (ddd, J = 13.0, 
5.5, 5.5 Hz, 1 H), 2.08 (ddd, J = 12.2, 12.2, 5.0 Hz, 1 H), 1.98-1.92 (m, 1 H), 1.84-1.71 
(m, 3 H), 1.68-1.54 (m, 5 H), 1.50-1.28 (m, 3 H), 1.20 (dd, J = 7.5, 7.5 Hz, 6 H), 0.18 (s, 
3 H); 13C-NMR (125 MHz, CDCl3) δ 174.0, 144.2, 137.3, 74.8, 72.3, 63.9, 58.2, 34.0, 
29.7, 28.3, 28.1, 28.0, 27.4, 25.1, 22.3, 21.4, 18.3, -4.6; HRMS (ESI-TOF) calcd. for 
C19H34O5Si [M+H]+ 371.22483, found 371.22603. 
 
Protodesilylation of 24 generated 41-Z with 54% yield. 
 
 and  
Hydrosilylation reaction gave rise to a 6.1:1 mixture of two regioisomers with the desired 
regio isomer 25’ being the major one.  Yield 75% (colorless oil). 
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(E)-3-(diethoxy(methyl)silyl)-10-methyl-5,6,7,8-tetrahydro-2H-
benzo[b][1,4]oxaazacy- clododecin-9(10H)-one (25) 
Yield 64% (colorless oil); 1H-NMR (500 MHz, CDCl3) δ 7.34-7.30 (m, 1 H), 7.14-7.12 
(m, 1H), 7.04-7.02 (m, 1 H), 6.99-6.95 (m, 1 H), 4.42-6.38 (m, 1 H), 3.80-3.75 (m, 4 H), 
3.14 (s, 3 H), 2.32-2.26 (m, 1 H), 2.16-2.08 (m, 1 H), 2.00-1.92 (m, 1 H), 1.89-1.83 (m, 2 
H), 1.70-1.62 (m, 1 H), 1.47-1.40 (m, 1 H), 1.33-1.25 (m, 1 H), 1.23-1.20 (m, 6 H), 0.22 
(s, 3 H); 13C-NMR (125 MHz, CDCl3) δ 173.6, 154.4, 153.1, 132.6, 130.0, 129.1, 128.9, 
120.9, 112.5, 64.1, 58.4, 58.3, 36.5, 29.6, 27.5, 26.1, 23.7, 18.3, -5.0. 
 
 
(E)-6-(diethoxy(methyl)silyl)-2,3,4,5,9,10-hexahydrobenzo[b][1,5]dioxacyclotetra- 
decin-12(8H)-one (26) 
Yield 78% (colorless oil); IR (neat, cm-1) 2970, 1704, 1601, 1489, 1453, 1300, 1252, 
1164, 1101, 1078, 1020, 951; 1H-NMR (500 MHz, CDCl3) δ 7.75-7.73 (m, 1 H), 7.43-
7.40 (m, 1H), 7.01-6.96 (m, 2 H), 6.02 (t, J = 7.5 Hz, 1 H), 4.34 (t, J = 5.2 Hz, 2 H), 4.17 
(t, J = 5.5 Hz, 2 H), 3.77-3.73 (m, 6 H), 2.40-2.35 (m, 2 H), 2.22-2.19 (m, 2 H), 1.86-1.77 
(m, 4 H), 1.66-1.61 (m, 2 H), 1.22 (t, J = 6.7 Hz, 6 H), 1.22 (t, J = 6.7 Hz, 6 H), 0.18 (s, 3 
H); 13C-NMR (125 MHz, CDCl3) δ 168.2, 157.4, 143.0, 137.7, 132.9, 131.6, 121.9, 120.2, 
113.1, 66.9 64.1, 58.1, 28.7, 28.4, 27.4, 26.0, 25.0, 18.3, -4.7; HRMS (ESI-TOF) calcd. 
for C21H32O5Si [M+H]+ 393.20918, found 393.21212. 
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 and  
Hydrosilylation reaction gave rise to a 14.3:1 mixture of two regioisomers with the 
desired regio isomer 27’ being the major one.  Yield 82% (colorless oil). 
 
 
(E)-6-(diethoxy(methyl)silyl)-4,5,8,9,10,11-hexahydro-2H-benzo[b][1,5]dioxacyclo-
pentadecin-13(3H)-one (27) 
Yield 58% (colorless oil); IR (neat, cm-1) 2969, 1700, 1602, 1492, 1453, 1388, 1302, 
1253, 1165, 1130, 1078, 952; 1H-NMR (500 MHz, CDCl3) δ 7.75-7.73 (m, 1 H), 7.42-
7.38 (m, 1H), 6.95 (dd, J = 7.2, 7.2 Hz, 1 H), 6.90 (d, J = 8.0 Hz, 1 H), 6.11 (t, J = 7.5 
Hz, 1 H), 4.41 (t, J = 5.7 Hz, 2 H), 4.02 (t, J = 5.2 Hz, 2 H), 3.76-3.72 (m, 4 H), 2.22-2.17 
(m, 4 H), 1.85-1.78 (m, 4 H), 1.68-1.57 (m, 4 H), 1.21 (t, J = 6.2 Hz, 6 H), 0.17 (s, 3 H); 
13C-NMR (125 MHz, CDCl3) δ 168.4, 157.7, 144.0, 136.6, 132.9, 131.6, 121.0, 119.8, 
112.0, 67.9, 64.3, 58.1, 29.4, 28.4, 28.1, 28.1 27.7, 26.0, 18.3, -4.8; HRMS (ESI-TOF) 
calcd. for C22H34O5Si [M+H]+ 407.22483, found 407.22437. 
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(1S,2S)-2-(Hex-5-en-1-yloxy)cyclohexyl 5-(diethoxy(methyl)silyl)hex-5-enoate and its 
enantiomer (29’) 
Yield 73% (colorless oil); IR (neat, cm-1) 3076, 2972, 2938, 2866, 1735, 1641, 1452, 
1389, 1256, 1165, 1109, 1082, 953; 1H-NMR (500 MHz, CDCl3) δ 5.79 (dddd, J = 17.2, 
10.2, 7.0, 7.0 Hz, 1 H), 5.69-5.69 (m, 1 H), 5.58-5.58 (m, 1 H), 5.01-4.97 (m, 1 H), 4.94 
(d, J = 10.0 Hz, 1 H), 4.78-4.74 (m, 1 H), 3.76 (q, J = 7.0 Hz, 4 H), 3.56-3.52 (m, 1 H), 
3.44-3.39 (m, 1 H), 3.24-3.19 (m, 1 H), 2.30 (dd, J = 7.5, 7.5 Hz, 2 H), 2.19 (dd, J = 7.5, 
7.5 Hz, 2 H), 2.05 (ddd, J = 7.0, 7.0, 7.0 Hz, 2 H), 1.98-1.96 (m, 2 H), 1.82-1.76 (m, 2 
H), 1.70-1.64 (m, 2 H), 1.56-1.50 (m, 2 H), 1.45-1.40 (m, 2 H), 1.36-1.31 (m, 3 H), 1.28-
1.20 (m, 7 H), 0.20 (s, 3 H); 13C-NMR (125 MHz, CDCl3) δ 172.9, 146.6, 138.8, 128.1, 
114.4, 78.9, 74.6, 69.3, 58.2, 34.9, 34.2, 33.5, 29.8, 29.7, 29.6, 25.5, 24.1, 23.2, 18.3, -
4.6; HRMS (ESI-TOF) calcd. for C23H42O5Si [M+Na]+ 449.26937, found 449.27061. 
 
 
(12aS,16aS,E)-6-(Diethoxy(methyl)silyl)-4,5,8,9,10,11,12a,13,14,15,16,16a-
dodecahydrobenzo[b][1,4]dioxacyclotetradecin-2(3H)-one and its enantiomer (29) 
Yield 76% (pale yellow oil); IR (neat, cm-1) 2930, 2865, 2733, 1731, 1612, 1452, 1389, 
1367, 1338, 1293, 1252, 1212, 1191, 1165, 1110, 1080, 1020, 989, 951; 1H-NMR (500 
MHz, CDCl3) δ 6.08 (dd, J = 7.0, 7.0 Hz, 1H), 4.76 (ddd, J = 10.0, 10.0, 4.5 Hz, 1 H), 
3.80-3.71 (m, 5 H), 3.28-3.22 (m, 2 H), 2.38-2.12 (m, 6 H), 2.07-1.99 (m, 2 H), 1.88-1.82 
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(m, 1 H), 1.74-1.52 (m, 6 H), 1.43-1.36 (m, 1 H), 1.32-1.18 (m, 10 H), 0.16 (s, 3 H); 13C-
NMR (125 MHz, CDCl3) δ 173.2, 145.5, 135.4, 79.8, 75.2, 67.7, 58.1, 33.4, 30.9, 29.6, 
28.5, 28.3, 27.4, 27.1, 24.4, 24.1, 24.0, 18.3, -4.4; HRMS (ESI-TOF) calcd. for 
C21H38O5Si [M+H]+ 399.25613, found 399.25752.  
 
 
(12aS,16aS,Z)-4,5,8,9,10,11,12a,13,14,15,16,16a-
dodecahydrobenzo[b][1,4]dioxacyclotetradecin-2(3H)-one and its enantiomer (43-Z) 
Yield 60% (colorless oil), inseparable mixture with styrene; IR (neat, cm-1) 3002, 2936, 
2861, 1731, 1452, 1368, 1246, 1207, 1162, 1111, 1022; 1H-NMR (500 MHz, CDCl3) δ 
5.51 (ddd, J = 8.5, 8.5, 8.5 Hz, 1H), 5.24 (ddd, J = 10.0, 10.0, 6.5 Hz, 1H), 4.80 (ddd, J = 
10.0, 10.0, 5.0 Hz, 1 H), 3.78-3.75 (m, 1 H), 3.25-3.20 (m, 2 H), 2.38-2.04 (m, 6 H), 
1.99-1.83 (m, 3 H), 1.76-1.57 (m, 3 H), 1.55-1.37 (m, 4 H), 1.32-1.17 (m, 4 H); 13C-NMR 
(125 MHz, CDCl3) δ 173.1, 131.6, 128.9, 79.8, 74.9, 66.9, 32.1, 30.9, 29.7, 28.3, 26.7, 
26.6, 25.6, 24.1, 23.9, 23.7; HRMS (ESI-TOF) calcd. for C16H26O3 [M+Na]+ 289.17742, 
found 289.17804.  
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(1S,2S)-2-(Hept-6-en-1-yloxy)cyclohexyl 5-(diethoxy(methyl)silyl)hex-5-enoate and 
its enantiomer (30’) 
Yield 79% (colorless oil); IR (neat, cm-1) 3077, 2973, 2937, 2865, 1736, 1641, 1452, 
1389, 1256, 1166, 1110, 1082, 995, 953; 1H-NMR (500 MHz, CDCl3) δ 5.80 (dddd, J = 
17.0, 10.0, 6.8, 6.8 Hz, 1 H), 5.69-5.69 (m, 1 H), 5.58-5.58 (m, 1 H), 5.01-4.97 (m, 1 H), 
4.93 (d, J = 10.0 Hz, 1 H), 4.76 (ddd, J = 8.5, 8.5, 4.5 Hz, 1 H), 3.76 (q, J = 7.0 Hz, 4 H), 
3.53 (ddd, J = 9.0, 6.5, 6.5 Hz, 1 H), 3.41 (ddd, J = 9.5, 7.0, 7.0 Hz, 1 H), 3.21 (ddd, J = 
8.5, 8.5, 4.0 Hz, 1 H), 2.30 (dd, J = 7.2, 7.2 Hz, 2 H), 2.19 (dd, J = 7.8, 7.8 Hz, 2 H), 2.04 
(ddd, J = 7.2, 7.2, 7.2 Hz, 2 H), 1.98-1.96 (m, 2 H), 1.83-1.77 (m, 2 H), 1.70-1.64 (m, 2 
H), 1.55-1.49 (m, 2 H), 1.42-1.20 (m, 14 H), 0.20 (s, 3 H); 13C-NMR (125 MHz, CDCl3) 
δ 172.9, 146.6, 138.9, 128.1, 114.2, 78.9, 74.6, 69.5, 58.2, 34.9, 34.3, 33.7, 30.0, 29.8, 
29.7, 28.7, 25.6, 24.1, 23.2, 18.3, -4.6; HRMS (ESI-TOF) calcd. for C24H44O5Si [M+H]+ 
441.30308, found 441.30151. 
 
 
(13aS,17aS,E)-6-(Diethoxy(methyl)silyl)-3,4,5,8,9,10,11,12,13a,14,15,16,17,17a-
tetradecahydro-2H-benzo[b][1,4]dioxacyclopentadecin-2-one and its enantiomer 
(30) 
Yield 43% (pale yellow oil), Z:E = 8:92, E product was purified and characterized.; IR 
(neat, cm-1) 2935, 2861, 1735, 1613, 1452, 1414, 1365, 1311, 1255, 1218, 1188, 1162, 
1111, 1080, 1017, 988, 952; 1H-NMR (500 MHz, CDCl3) δ 6.08 (dd, J = 10.5, 5.0 Hz, 1 
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H), 4.72 (ddd, J = 10.0, 10.0, 4.3 Hz, 1 H), 3.74 (q, J = 7.0Hz, 4 H), 3.68-3.65 (m, 1 H), 
3.40-3.36 (m, 1 H), 3.15 (ddd, 9.5, 9.5, 4.5 Hz, 1 H), 2.55-2.49 (m, 1 H), 2.38-2.20 (m, 3 
H), 2.12-2.07 (m, 2 H), 2.02-1.89 (m, 3 H), 1.72-1.62 (m, 4 H), 1.40-1.14 (m, 15 H), 0.17 
(s, 3 H); 13C-NMR (125 MHz, CDCl3) δ 173.3, 145.5, 135.3, 80.1, 76.4, 68.9, 58.1, 58.1, 
32.4, 31.1, 31.0, 29.2, 28.8, 27.8, 27.3, 25.5, 24.2, 24.0, 23.5, 18.3, -4.3; HRMS (ESI-
TOF) calcd. for C22H40O5Si [M+H]+ 413.27178, found 413.27159. 
 
 
Protodesilylation of 30 (mixture of Z and E isomers with a ratio of 8:92) gave rise to 44 
as an inseparable mixture of Z and E isomers with a ratio of 90:10 determined by 1H 
NMR analysis. 
 
 
 
(Z)-3,4,7,8,9,10-Hexahydrobenzo[b][1,5]dioxacyclotetradecin-12(2H)-one (14-Z) 
Protodesilylation of 91 mg 12c (0.22 mmol) followed by column chromatography 
(gradient 0 – 20% ethyl acetate/hexane) gave rise to 35 mg of the title compound. Yield 
64% (colorless oil); IR (neat, cm-1) 3009, 2935, 2865, 1703, 1601, 1581, 1490, 1453, 
1384, 1354, 1302, 1250, 1165, 1132, 1097, 1049, 1015, 975; 1H-NMR (500 MHz, 
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CDCl3) δ 7.78-7.76 (m, 1 H), 7.44-7.40 (m, 1 H), 6.98-6.93 (m, 2 H), 5.68 (dt, J = 10.0, 
8.2 Hz, 1 H), 5.48 (dt, J = 10.0, 8.2 Hz, 1 H), 4.43 (t, J = 6.0 Hz, 2 H), 4.09 (t, J = 5.2 Hz, 
2 H), 2.29 (dt, J = 7.8, 7.8 Hz, 2 H), 2.13-2.08 (m, 2 H), 1.85-1.79 (m, 4 H), 1.69-1.63 
(m, 2 H); 13C-NMR (125 MHz, CDCl3) δ 168.5, 157.5, 133.1, 132.2, 130.1, 130.0, 121.3, 
120.0, 112.2, 66.9, 63.8, 29.8, 27.6, 25.7, 25.4, 23.5; HRMS (ESI-TOF) calcd. for 
C16H20O3 [M+H]+ 261.14852, found 261.14455. 
 
 
(Z)-4,5,8,9,10,11-Hexahydro-2H-benzo[b][1,5]dioxacyclopentadecin-13(3H)-one (42-
Z) 
Protodesilylation of 13c (60 mg, 0.14 mmol) followed by column chromatography 
(gradient 0 – 20% ethyl acetate/hexane) gave rise to 17 mg of the title compound. Yield 
46% (colorless oil); IR (neat, cm-1) 3007, 2936, 2862, 1698, 1601, 1491, 1452, 1384, 
1300, 1249, 1164, 1131, 1097, 1050, 958; 1H-NMR (500 MHz, CDCl3) δ 7.71-7.69 (m, 1 
H), 7.42-7.38 (m, 1 H), 6.97-6.94 (m, 1 H), 6.91 (d, J = 8.0 Hz, 1 H), 5.55 (dt, J = 10.8, 
7.4 Hz, 1 H), 5.50 (dt, J = 10.8, 7.4 Hz, 1 H), 4.40 (t, J = 6.0 Hz, 2 H), 4.04 (t, J = 5.2 Hz, 
2 H), 2.14-2.09 (m, 4 H), 1.85-1.77 (m, 4 H), 1.65-1.59 (m, 2 H), 1.58-1.52 (m, 2 H); 13C-
NMR (125 MHz, CDCl3) δ 168.3, 157.6, 132.7, 131.2, 130.3, 129.8, 121.5, 120.0, 112.3, 
68.3, 64.5, 28.6, 27.9, 27.1, 26.9, 26.4, 26.0; HRMS (ESI-TOF) calcd. for C17H22O3 
[M+Na]+ 297.14612, found 297.14667. 
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F. Synthesis of compound 31 and 32 and determination of stereoselectivity 
Following the reported procedure,8 the alkyne substrates were synthesized.  
Hydrosilylation of the alkynes gave rise to the corresponding alkenyl siloxane 31’ and 
32’, which were subjected to the RCM reaction. 
 
Note: The 1H and 13C NMR spectra of many of these compounds were extremely 
complicated owing to the various combinations of rotamers, and conformers. Efforts to 
completely coalesce the resonances through variable temperature NMR (up to 110 oC) 
were unsuccessful. Despite their complexity, all spectra are for single compounds that 
were larger than 95% pure by LC/MS. 
 
 
tert-Butyl (2R,3R)-2-(2-(diethoxy(methyl)silyl)allyloxy)-4-(2-(hex-5-enyloxy)-N-((S)-
1-(4-methoxybenzyloxy)propan-2-yl)-5-nitrobenzamido)-3-
methylbutyl(methyl)carbamate (31’) 
Yield 69% (pale yellow oil); IR (neat, cm-1) 2973, 2932, 1693, 1640, 1612, 1588, 1516, 
1458, 1391, 1365, 1341, 1272, 1251, 1160, 1078, 1036, 952; HRMS (ESI-TOF) calcd. 
for C43H67N3O11Si [M+Na]+ 852.44371, found 852.44396; [α]D21 = -25.5 (c = 2.2, 
CHCl3). 
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tert-Butyl ((10R,11R,E)-7-(diethoxy(methyl)silyl)-13-((S)-1-(4-
methoxybenzyloxy)propan-2-yl)-11-methyl-16-nitro-14-oxo-2,3,4,5,8,10,11,12,13,14-
decahydrobenzo[b][1,9,5]dioxaazacyclohexadecin-10-yl)methyl(methyl)carbamate 
(31) 
Z/E ratio is less than 1:99. Yield 47% (pale yellow oil); IR (neat, cm-1) 2972, 2934, 1692, 
1633, 1614, 1588, 1516, 1468, 1392, 1365, 1341, 1302, 1271, 1251, 1159, 1105, 1080, 
1036, 1010, 986, 953; HRMS (ESI-TOF) calcd. for C41H63N3O11Si [M+Na]+ 824.41241, 
found 824.41263; [α]D21 = -16.4 (c = 7.6, CHCl3). 
 
 
 
tert-Butyl ((2R,3R)-2-(allyloxy)-4-(2-((5-(diethoxy(methyl)silyl)hex-5-en-1-yl)oxy)-N-
((S)-1-((4-methoxybenzyl)oxy)propan-2-yl)-5-nitrobenzamido)-3-
methylbutyl)(methyl)carbamate (32’) 
Yield 69% (pale yellow oil); IR (neat, cm-1) 2973, 2934, 1694, 1940, 1612, 1588, 1516, 
1457, 1391, 1365, 1340, 1272, 1252, 1162, 1078, 1036, 952; HRMS (ESI-TOF) calcd. 
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for C43H67N3O11Si [M+Na]+ 852.44371, found 852.44378; [α]D20 = -32.3 (c = 2.4, 
CHCl3). 
 
 
tert-Butyl (((10R,11R,E)-6-(diethoxy(methyl)silyl)-13-((S)-1-((4-
methoxybenzyl)oxy)propan-2-yl)-11-methyl-16-nitro-14-oxo-2,3,4,5,8,10,11,12,13,14-
decahydrobenzo[b][1,9,5]dioxaazacyclohexadecin-10-yl)methyl)(methyl)carbamate 
(32) 
Z/E ratio is 14:86. Yield 44% (pale yellow oil); IR (neat, cm-1) 2972, 2934, 1689, 1636, 
1612, 1588, 1515, 1463, 1391, 1365, 1340, 1273, 1252, 1164, 1104, 1078; HRMS (ESI-
TOF) calcd. for C41H63N3O11Si [M+H]+ 802.43046, found 802.42662; [α]D22 = -29.8 (c = 
3.2, CHCl3). 
 
The simple diolefinic substrate was synthesized and subjected to RCM reaction using 
catalyst A. A mixture of both stereoisomers was obtained.  The Z/E ratio was analyzed to 
be 36:64 using SFC/MS chromatography (Figure I-4, first trace). SFC: Chiralpak® AD-H 
column; 25% iPrOH, 75% sfCO2, 10 minutes run length, tR(Z) = 3.77 min, area = 36%, 
tR(E) = 5.12 min, area = 64%. 
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Figure I-4. SFC/MS chromatography of product 45 obtained from different route. 
 
First trace: RCM of simple diolefinic substrate; second trace: protodesilylation of 
compound 32; third trace: protodesilylation of compound 31.   
 
In order to confirm the geometry of the double bond within alkenyl siloxane products 31 
and 32, protodesilylation reaction was performed to generate the simple olefins. The Z/E 
ratio of desilylated product 45-Z from compound 31 was larger than 99:1 (Figure I-4, 
third trace, tR(Z) = 3.70 min, area = 100%). Due to highly rotameric nature of compound 
45-Z, VT NMR was performed in C6D6 at 80 °C. The coupling constant was measured to 
be 10.5 Hz, characteristic of Z olefin. Since the protodesilylation reaction is 
stereospecific, the configuration of compound 31 was E. The Z/E ratio of desilylated 
product from compound 32 was 86:14 (Figure I-4, second trace, tR(Z) = 3.83 min, area = 
86%, tR(E) = 5.33 min, area = 14%), which indicated that the Z/E ratio of compound 32 is 
14:86. In both cases, the siloxyl group was able to overcome the intrinsic selectivity 
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favoring the formation of the E olefin. However, the positions of the siloxyl group had 
different influences on the selectivity of the olefin geometry within the product. 
 
 
tert-Butyl (((10R,11R,Z)-13-((S)-1-((4-methoxybenzyl)oxy)propan-2-yl)-11-methyl-
16-nitro-14-oxo-2,3,4,5,8,10,11,12,13,14-
decahydrobenzo[b][1,9,5]dioxaazacyclohexadecin-10-yl)methyl)(methyl)carbamate 
(45-Z) 
Yield 86% (pale yellow oil); IR (neat, cm-1) 2936, 2862, 1690, 1633, 1588, 1515, 1464, 
1392, 1366, 1341, 1272, 1250, 1159, 1104, 1036, 979; HRMS (ESI-TOF) calcd. for 
C36H51N3O9 [M+Na]+ 692.35175, found 692.35064; [α]D21 = -9.9 (c = 4.6, CHCl3). 
 
Protodesilylation of 32 generated 45 with 60% yield 
 
G. Influence of the silyl group on the specificity and stereoselectivity of RCM 
reactions 
RCM of simple di-olefinic substrates: substrate (1 equiv.) was dissolved in anhydrous 
toluene (or other solvent when indicated) at a concentration of 2 mM under argon. 
Catalyst A (20 mol%) or Grubbs II 10 mol%, and 20 mol% 1,4-benzoquinone was added 
to the solution. High vacuum was applied to the reaction flask for 5 min and charged with 
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argon. This operation cycle was repeated for 5 times. The reaction was then heated up to 
35 °C and left for 12 hours.  The resulting mixture was concentrated in vacuo and the 
residue was analyzed by 1H NMR or purified by silica gel column chromatography using 
Hexanes/EtOAc as eluent. 
 
Simple di-olefinic substrates were synthesized and subjected to two different reaction 
conditions:  I, 20 mol% cat. A, 20 mol% 1,4-benzoquinone, toluene, 2 mM, 35 °C, 12 
hours; II, 10 mol% Grubbs II, 20 mol% 1,4-benzoquinone, toluene, 2 mM, 35 °C, 12 
hours.  The reaction outcome was analyzed by proton NMR study of the crude mixture 
using CDCl3 or C6D6 as solvent.  Since the outcomes under both conditions are very 
similar, only expanded region of the proton NMR spectrum from condition II was shown 
here.  The resonance of the olefinic proton corresponding to the cis olefin was known 
from the protodesilylation of alkenyl siloxane intermediate. The resonance of the olefinic 
proton corresponding to the trans olefin was rigorously analyzed when the reaction is 
trans selective 
 
 
N-(but-3-en-1-yl)-4-methyl-N-(pent-4-en-1-yl)benzenesulfonamide (33’) 
IR (neat, cm-1) 3077, 2977, 2929, 2869, 1641, 1599, 1494, 1458, 1340, 1158, 1091, 993, 
958; 1H-NMR (500 MHz, CDCl3) δ 7.68 (d, J = 8.0 Hz, 2 H), 7.28 (d, J = 8.0 Hz, 2 H), 
5.80-5.66 (m, 2 H), 5.06-4.96 (m, 4 H), 3.16 (t, J = 7.5 Hz, 2 H), 3.11 (t, J = 7.5 Hz, 2 
H), 2.41 (s, 3 H), 2.28 (dt, J = 7.3, 7.3 Hz, 2 H), 2.04 (dt, J = 7.1, 7.1 Hz, 2 H), 1.63 (tt, J 
= 7.5, 7.5 Hz, 2 H); 13C-NMR (125 MHz, CDCl3) δ 143.0, 137.4, 136.9, 134.6, 129.6, 
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127.1, 117.0, 115.2, 47.9, 47.7, 33.3, 30.7, 27.8, 21.4; HRMS (ESI-TOF) calcd. for 
C16H23NO2S [M+Na]+ 316.13417, found 316.13501. 
 
 
(1S,2S)-1-(allyloxy)-2-(pent-4-en-1-yloxy)cyclohexane and its enantiomer (34’) 
IR (neat, cm-1) 3078, 2934, 2861, 1642, 1450, 1366, 1315, 1271, 1243, 1208, 1161, 1106, 
993; 1H-NMR (500 MHz, CDCl3) δ 5.97-5.89 (m, 1 H), 5.86-5.78 (m, 1 H), 5.29-5.26 (m, 
1 H), 5.14-5.12 (m, 1 H), 5.04-5.00 (m, 1 H), 4.96-4.94 (m, 1 H), 4.16-4.10 (m, 2 H), 
3.60-3.52 (m, 2 H), 3.23-3.14 (m, 2 H), 2.15-2.11 (m, 2 H), 1.98-1.95 (m, 2 H), 1.68-1.62 
(m, 4 H), 1.31-1.17 (m, 4 H); 13C-NMR (125 MHz, CDCl3) δ 138.5, 135.8, 116.1, 114.5, 
81.5, 80.8, 71.0, 69.2, 30.4, 30.2, 29.5, 23.6, 23.6; HRMS (ESI-TOF) calcd. for C14H24O2 
[M+Na]+ 247.16685, found 247.16675. 
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Figure I-5. 1H NMR spectrum (expansion of 3.0 to 6.5ppm) of reaction mixture of 33’ 
under condition II. 
 
 
Figure I-6. 1H NMR spectrum (expansion of 3.0 to 6.5ppm) of reaction mixture of 34’ 
under condition II. 
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(1S,2S)-1-(allyloxy)-2-(hex-5-en-1-yloxy)cyclohexane and its enantiomer (35’) 
IR (neat, cm-1) 3077, 2933, 1642, 1450, 1366, 1244, 1098; 1H-NMR (500 MHz, CDCl3) δ 
5.97-5.89 (m, 1 H), 5.85-5.77 (m, 1 H), 5.29-5.26 (m, 1 H), 5.14-5.12 (m, 1 H), 5.01-4.98 
(m, 1 H), 4.95-4.93 (m, 1 H), 4.16-4.08 (m, 2 H), 3.59-3.51 (m, 2 H), 3.22-3.14 (m, 2 H), 
2.06 (ddd, J = 7.0, 7.0, 7.0 Hz, 2 H), 1.97-1.95 (m, 2 H), 1.64-1.55 (m, 4 H), 1.49-1.43 
(m, 2 H), 1.31-1.17 (m, 4 H); 13C-NMR (125 MHz, CDCl3) δ 138.9, 135.8, 116.1, 114.4, 
81.5, 80.8, 71.1, 69.8, 33.4, 30.4, 30.2, 29.8, 25.5, 23.6, 23.6; HRMS (ESI-TOF) calcd. 
for C15H26O2 [M+Na]+ 261.18250, found 261.18388. 
 
Figure I-7. 1H NMR spectrum (expansion of 3.0 to 6.5ppm) of reaction mixture of 35’ 
under condition II. 
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The monocyclized Z-alkene compound 35-Z (corresponding to what would be the 
monocyclized product of the RCM of 35’) obtained from protodesilylation of compound 
16 was subjected to reaction condition II using second generation Grubbs catalyst. It was 
almost completely consumed to generate dimers and oligomers (Figure I-8). 
 
Figure I-8. 1H NMR spectrum (expansion of 3.0 to 6.5ppm) of reaction mixture of 35-Z 
under condition II. 
 
 
 
(1S,2S)-2-(allyloxy)cyclohexyl hex-5-enoate and its enantiomer (36’) 
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IR (neat, cm-1) 3078, 2938, 2863, 1734, 1642, 1453, 1367, 1246, 1175, 1101, 994; 1H-
NMR (500 MHz, CDCl3) δ 5.90-5.74 (m, 2 H), 5.26-5.23 (m, 1 H), 5.13-5.11 (m, 1 H), 
5.04-4.96 (m, 2 H), 4.80-4.75 (m, 1 H), 4.10-4.06 (m, 1 H), 4.02-3.98 (m, 1 H), 3.29 
(ddd, J = 8.5, 8.5, 4.0 Hz, 1 H), 2.31 (dd, J = 7.2, 7.2 Hz, 2 H), 2.09 (ddd, J = 7.0, 7.0, 7.0 
Hz, 2 H), 2.00-1.97 (m, 2 H), 1.76-1.63 (m, 4 H), 1.40-1.20 (m, 4 H); 13C-NMR (125 
MHz, CDCl3) δ 172.9, 137.8, 135.3, 116.2, 115.2, 78.4, 74.8, 70.4, 33.9, 33.0, 29.9, 29.8, 
24.1, 23.2; HRMS (ESI-TOF) calcd. for C15H24O3 [M+Na]+ 275.16177, found 
275.16271. 
 
Figure I-9. 1H NMR spectrum (expansion of 3.0 to 6.5ppm) of reaction mixture of 36’ 
under condition II. 
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Figure I-10. 1H NMR spectrum of purified monocyclized product mixture from reaction 
of 36’ for ratio determination. 
 
 
 
(1R,2S)-2-(allyloxy)cyclohexyl hex-5-enoate and its enantiomer (37’) 
IR (neat, cm-1) 3078, 2939, 2861, 1732, 1642, 1450, 1363, 1247, 1175, 1089, 994; 1H-
NMR (500 MHz, CDCl3) δ 5.91-5.83 (m, 1 H), 5.80-5.73 (m, 1 H), 5.27-5.23 (m, 1 H), 
5.14-5.11 (m, 1 H), 5.10-5.08 (m, 1 H), 5.03-4.96 (m, 2 H), 4.04 (dd, J = 13.0, 5.5 Hz, 1 
H), 3.97 (dd, J = 13.0, 5.7 Hz, 1 H), 3.47-3.46 (m, 1 H), 2.34 (dd, J = 7.5, 7.5 Hz, 2 H), 
2.11-2.07 (m, 2 H), 1.90-1.85 (m, 1 H), 1.81-1.64 (m, 4 H), 1.60-1.46 (m, 3 H), 1.42-1.27 
(m, 2 H); 13C-NMR (125 MHz, CDCl3) δ 173.1, 137.8, 135.2, 116.5, 115.2, 76.0, 70.9, 
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69.6, 33.9, 33.0, 27.9, 27.8, 24.2, 22.1, 21.6; HRMS (ESI-TOF) calcd. for C15H24O3 
[M+Na]+ 275.16177, found 275.16316. 
 
 
(9aR,13aS,E)-3,4,5,8,9a,10,11,12,13,13a-decahydro-2H-
benzo[b][1,4]dioxacycloundecin-2-one and its enantiomer (37-E) 
Yield 73% (colorless oil); IR (neat, cm-1) 2934, 2858, 1725, 1443, 1363, 1256, 1210, 
1159, 1139, 1109, 1089, 1073, 1047, 980; 1H-NMR (500 MHz, CDCl3) δ 5.64 (ddd, J = 
15.0, 10.5, 4.0 Hz, 1 H), 5.42 (ddd, J = 15.0, 10.2, 5.5 Hz, 1 H), 4.44-4.40 (m, 1 H), 4.23-
4.20 (dd, J = 13.0, 4.2 Hz, 1 H), 3.77 (bs, 1 H), 3.40 (dd, J = 12.5, 11.0 Hz, 1 H), 2.38-
2.29 (m, 2 H), 2.12-2.07 (m, 1 H), 1.99-1.70 (m, 6 H), 1.56-1.47 (m, 2 H), 1.41-1.23 (m, 
3 H); 13C-NMR (125 MHz, CDCl3) δ 174.9, 132.0, 132.0, 75.1, 74.9, 72.2, 34.4, 33.6, 
30.6, 25.8, 24.5, 24.2, 19.4; HRMS (ESI-TOF) calcd. for C13H20O3 [M+H]+ 225.14852, 
found 225.16079. 
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Figure I-11. 1H NMR spectrum (expansion of 3.0 to 6.5ppm) of reaction mixture of 37’ 
under condition II (the major product was purifiable and is reported as 37-E). 
 
 
 
(1S,2S)-1-(allyloxy)-2-(hept-6-en-1-yloxy)cyclohexane and its enantiomer (39’) 
IR (neat, cm-1) 3077, 2932, 2859, 1642, 1451, 1365, 1314, 1270, 1244, 1208, 1161, 1107, 
994; 1H-NMR (500 MHz, CDCl3) δ 5.97-5.89 (m, 1 H), 5.84-5.76 (m, 1 H), 5.29-5.25 (m, 
1 H), 5.14-5.12 (m, 1 H), 5.01-4.97 (m, 1 H), 4.94-4.91 (m, 1H), 4.16-4.08 (m, 2 H), 
3.59-3.50 (m, 2 H), 3.22-3.13 (m, 2 H), 2.07-2.03 (m, 2 H), 1.96-1.95 (m, 2 H), 1.65-1.54 
(m, 4 H), 1.44-1.33 (m, 4 H), 1.30-1.15(m, 4 H); 13C-NMR (125 MHz, CDCl3) δ 139.0, 
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135.8, 116.0, 114.2, 81.6, 80.8, 71.1, 69.9, 33.7, 30.4, 30.2, 30.2, 28.8, 25.7, 23.6, 23.6; 
HRMS (ESI-TOF) calcd. for C16H28O2 [M+Na]+ 275.19815, found 275.19975. 
 
Figure I-12. 1H NMR spectrum (expansion of 3.0 to 6.5ppm) of reaction mixture of 39’ 
under condition II. 
 
 
 
(1S,2S)-2-(allyloxy)cyclohexyl hept-6-enoate and its enantiomer (40’) 
IR (neat, cm-1) 3078, 2937, 2863, 1735, 1641, 1453, 1353, 1174, 1101, 994; 1H-NMR 
(500 MHz, CDCl3) δ 5.90-5.74 (m, 2 H), 5.26-5.23 (m, 1 H), 5.13-5.11 (m, 1 H), 5.01-
4.98 (m, 1 H), 4.95-4.93 (m, 1 H), 4.77 (ddd, J = 8.5, 8.5. 5.0 Hz, 1 H), 4.08 (dd, J = 7.8, 
 114 
5.0 Hz, 1 H), 4.00 (dd, J = 7.8, 5.0 Hz, 1 H), 3.29 (ddd, J = 8.5, 8.5, 4.0 Hz, 1 H), 2.30 
(dd, J = 7.2, 7.2 Hz, 2 H), 2.08-2.04 (m, 2 H), 1.99-1.97 (m, 2 H), 1.70-1.61 (m, 4 H), 
1.46-1.20 (m, 6 H); 13C-NMR (125 MHz, CDCl3) δ 173.0, 138.4, 135.3, 116.2, 114.6, 
78.5, 74.8, 70.4, 34.5, 33.4, 29.9, 29.8, 28.3, 24.5, 23.2; HRMS (ESI-TOF) calcd. for 
C16H26O3 [M+Na]+ 289.17742, found 289.17766. 
 
Figure I-13. 1H NMR spectrum (expansion of 3.0 to 6.5ppm) of reaction mixture of 40’ 
under condition II. 
 
 
 
(1R,2S)-2-(allyloxy)cyclohexyl hept-6-enoate and its enantiomer (41’) 
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IR (neat, cm-1) 3078, 2938, 2860, 1732, 1642, 1450, 1362, 1236, 1174, 1089, 994; 1H-
NMR (500 MHz, CDCl3) δ 5.91-5.75 (m, 2 H), 5.27-5.23 (m, 1 H), 5.14-5.08 (m, 2 H), 
5.02-4.98 (m, 1 H), 4.95-4.93 (m, 1 H), 4.04 (dd, J = 8.0, 5.5 Hz, 1 H), 3.98 (dd, J = 8.0, 
5.5 Hz, 1 H), 3.48-3.46 (m, 1 H), 2.34 (dd, J = 7.2, 7.2 Hz, 2 H), 2.08-2.04 (m, 2 H), 
1.90-1.85 (m, 1 H), 1.81-1.75 (m, 1 H), 1.70-1.28 (m, 10 H); 13C-NMR (125 MHz, 
CDCl3) δ 173.2, 138.5, 135.2, 116.5, 114.6, 76.0, 71.0, 69.6, 34.5, 33.4, 28.3, 27.9, 27.8, 
24.5, 22.1, 21.7; HRMS (ESI-TOF) calcd. for C16H26O3 [M+Na]+ 289.17742, found 
289.17867. 
 
Figure I-14. 1H NMR spectrum (expansion of 3.0 to 6.5ppm) of reaction mixture of 41’ 
under condition II. 
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Figure I-15. 1H NMR spectrum of purified monocyclized product mixture from reaction 
of 41’ for identification of trans isomer. 
 
 
 
(±)-1-(2-((allyloxy)methyl)piperidin-1-yl)hept-6-en-1-one (38’) 
IR (neat, cm-1) 3076, 2934, 2859, 1642, 1426, 1357, 1243, 1178, 1134, 1104, 1057, 1028, 
992; The 1H and 13C NMR spectra of many of this compound was complicated owing to 
the combination of rotamers. HRMS (ESI-TOF) calcd. for C16H27NO2 [M+Na]+ 
288.19340, found 288.19396. 
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Figure I-16. 1H NMR spectrum (expansion of 3.0 to 6.5ppm) of reaction mixture of 38’ 
under condition II. 
 
 
 
(1S,2S)-2-(hex-5-en-1-yloxy)cyclohexyl hex-5-enoate and its enantiomer (43’) 
IR (neat, cm-1) 3077, 2936, 2862, 1734, 1641, 1453, 1369, 1175, 1111; 1H-NMR (500 
MHz, CDCl3) δ 5.83-5.74 (m, 2 H), 5.04-4.92 (m, 4 H), 4.75 (ddd, J = 9.0, 9.0, 4.5 Hz, 1 
H), 3.54 (ddd, J = 9.0, 6.5, 6.5 Hz, 1 H), 3.40 (ddd, J = 9.0, 6.5, 6.5 Hz, 1 H), 3.21 (ddd, J 
= 8.5, 8.5, 4.0 Hz, 1 H), 3.32-2.29 (m, 2 H), 2.11-2.02 (m, 4 H), 2.00-1.95 (m, 2 H), 1.76-
1.63 (m, 4 H), 1.56-1.50 (m, 2 H), 1.46-1.38 (m, 2 H), 1.37-1.19(m, 4 H); 13C-NMR (125 
MHz, CDCl3) δ 172.9, 138.8, 137.8, 115.2, 114.4, 79.0, 74.7, 69.3, 33.9, 33.5, 33.0, 29.8, 
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29.6, 25.5, 24.2, 23.3; HRMS (ESI-TOF) calcd. for C18H30O3 [M+Na]+ 317.20872, found 
317.20928. 
 
Figure I-17. 1H NMR spectrum (expansion of 3.0 to 6.5ppm) of reaction mixture of 43’ 
under condition II. 
 
 
 
Hex-5-en-1-yl 2-(pent-4-en-1-yloxy)benzoate (14’) 
IR (neat, cm-1) 3077, 2976, 2940, 2870, 1728, 1704, 1641, 1601, 1583, 1491, 1469, 1452, 
1416, 1386, 1302, 1251, 1164, 1133, 1080, 1049, 1013, 995; 1H-NMR (500 MHz, 
CDCl3) δ 7.78-7.76 (m, 1 H), 7.44-7.41 (m, 1 H), 6.98-6.94 (m, 2 H), 5.89-5.77 (m, 2 H), 
5.08-4.95 (m, 4 H), 4.30 (t, J = 7.0 Hz, 2 H), 4.04 (t, J = 6.5 Hz, 2 H), 2.30-2.25 (m, 2 H), 
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2.14-2.09 (m, 2 H), 1.96-1.90 (m, 2 H), 1.80-1.74 (m, 2 H), 1.58-1.52 (m, 2 H); 13C-NMR 
(125 MHz, CDCl3) δ 166.7, 158.4, 138.4, 137.7, 133.1, 131.5, 120.9, 120.0, 115.2, 114.8, 
113.1, 68.0, 64.7, 33.3, 30.0, 28.3, 28.2, 25.3; HRMS (ESI-TOF) calcd. for C18H24O3 
[M+Na]+ 311.16177, found 311.16440. 
 
Figure I-18. 1H NMR spectrum of purified monocyclized product mixture from reaction 
of 43’ for ratio determination. 
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Figure I-19. 1H NMR spectrum (expansion of 3.0 to 6.5ppm) of reaction mixture of 14’ 
under condition II. 
 
 
 
(1S,2S)-2-(hept-6-en-1-yloxy)cyclohexyl hex-5-enoate and its enantiomer (44’) 
IR (neat, cm-1) 3077, 2934, 2861, 1734, 1641, 1452, 1417, 1369, 1247, 1175, 1111, 1026, 
994; 1H-NMR (500 MHz, CDCl3) δ 5.83-5.74 (m, 2 H), 5.04-4.91 (m, 4 H), 4.75 (ddd, J 
= 9.0, 9.0, 4.5 Hz, 1 H), 3.53 (ddd, J = 9.5, 6.5, 6.5 Hz, 1 H), 3.39 (ddd, J = 9.0, 7.0, 7.0 
Hz, 1 H), 3.20 (ddd, J = 9.0, 9.0, 4.0 Hz, 1 H), 2.32-2.29 (m, 2 H), 2.11-2.07 (m, 2 H), 
2.05-2.01 (m, 2 H), 1.99-1.95 (m, 2 H), 1.76-1.63 (m, 4 H), 1.54-1.49 (m, 2 H), 1.41-1.19 
(m, 8 H); 13C-NMR (125 MHz, CDCl3) δ 172.9, 138.9, 137.8, 115.2, 114.2, 79.0, 74.8, 
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69.5, 33.9, 33.7, 33.0, 30.0, 29.8, 28.7, 25.6, 24.2, 23.3; HRMS (ESI-TOF) calcd. for 
C19H32O3 [M+H]+ 309.24242, found 309.24229. 
 
Figure I-20. 1H NMR spectrum (expansion of 3.0 to 6.5ppm) of reaction mixture of 44’ 
under condition II. 
 
 
 
Hex-5-en-1-yl 2-(hex-5-en-1-yloxy)benzoate (42’) 
IR (neat, cm-1) 3076, 2937, 2862, 1728, 1704, 1640, 1601, 1583, 1491, 1469, 1453, 1386, 
1302, 1250, 1164, 1133, 1079, 1049, 995, 953; 1H-NMR (500 MHz, CDCl3) δ 7.78-7.76 
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(m, 1 H), 7.44-7.41 (m, 1 H), 6.97-6.94 (m, 2 H), 5.87-5.78 (m, 2 H), 5.05-5.01 (m, 2 H), 
4.98-4.96 (m, 2 H), 4.30 (t, J = 6.8 Hz, 2 H), 4.03 (t, J = 6.5 Hz, 2 H), 2.15-2.10 (m, 4 H), 
1.85 (tt, J = 7.1, 7.1 Hz, 2 H), 1.77 (tt, J = 7.2, 7.2 Hz, 2 H), 1.63-1.52 (m, 4 H); 13C-
NMR (125 MHz, CDCl3) δ 166.7, 158.4, 138.5, 138.4, 133.1, 131.5, 120.8, 120.0, 114.8, 
114.7, 113.0, 68.6, 64.7, 33.4, 33.3, 28.6, 28.2, 25.3, 25.2; HRMS (ESI-TOF) calcd. for 
C19H26O3 [M+Na]+ 325.17742, found 325.17910. 
 
Figure I-21. 1H NMR spectrum (expansion of 3.0 to 6.5ppm) of reaction mixture of 42’ 
under condition II. 
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H. Further transformation of macrocyclic alkenylsiloxanes 
 
tert-Butyl (((10R,11R)-13-((S)-1-((4-methoxybenzyl)oxy)propan-2-yl)-11-methyl-16-
nitro-7,14-dioxo-2,3,4,5,6,7,8,10,11,12,13,14-
dodecahydrobenzo[b][1,9,5]dioxaazacyclohexadecin-10-
yl)methyl)(methyl)carbamate (47) 
Adapted from the reported procedure,244 to a stirred solution of compound 31 (78.0 mg, 
0.097 mmol) in tetrahydrofuran/methanol (1:1, 2.0 mL, 50 mM), was added anhydrous 
potassium fluoride (17.0 mg, 0.29 mmol), potassium bicarbonate (29.0 mg, 0.15 mmol), 
and 30% hydrogen peroxide (110 mg, 0.97 mmol).  The reaction was stirred at 23 °C for 
3 h. The suspension was then filtered through a Celite pad and the filtrate was dried with 
sodium sulfate and concentrated in vacuo.  The residue was purified by column 
chromatography (gradient 40 – 60% ethyl acetate/hexane) to give compound 47 as a 
white solid (50.0 mg, 0.073 mmol). 
Yield 75%; IR (neat, cm-1) 3055, 2936, 2870, 1729, 1689, 1634, 1613, 1588, 1516, 1489, 
1462, 1392, 1366, 1340, 1302, 1271, 1152, 1109, 1035; HRMS (ESI-TOF) calcd. for 
C36H51N3O10 [M+Na]+ 708.34667, found 708.34659; [α]D19 = -17.5 (c = 2.2, CHCl3). 
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tert-Butyl (((10R,11R,E)-7-iodo-13-((S)-1-((4-methoxybenzyl)oxy)propan-2-yl)-11-
methyl-16-nitro-14-oxo-2,3,4,5,8,10,11,12,13,14-
decahydrobenzo[b][1,9,5]dioxaazacyclohexadecin-10-yl)methyl)(methyl)carbamate 
(48) 
To a stirred solution of compound 31 (60.0 mg, 0.075 mmol) in dimethylformamide (3.7 
mL, 20 mM), was added anhydrous potassium fluoride (8.7 mg, 0.15 mmol), potassium 
carbonate (15.0 mg, 0.15 mmol), and iodine (95.0 mg, 0.37 mmol).  The reaction was 
heated to 50 °C and left for 18 hours.  Then another portion of potassium fluoride (8.7 
mg, 0.15 mmol), potassium carbonate (15.0 mg, 0.15 mmol), and iodine (95.0 mg, 0.37 
mmol) was added.  The resulting mixture was allowed to react at 50 °C for another 18 
hours before quenched with 20 mL solution of 10% sodium bisulfite and 10% sodium 
bicarbonate. The aqueous solution was extracted with dichloromethane (15 mL x 3).  The 
combined extracts were dried with sodium sulfate and concentrated in vacuo.  
Purification by column chromatography (gradient 20 – 50% ethyl acetate/hexane) gave 
compound 48 as yellow oil (42.0 mg, 0.053 mmol). 
Yield 70%; IR (neat, cm-1) 2968, 2935, 2866, 1687, 1631, 1613, 1588, 1515, 1466, 1392, 
1365, 1341, 1302, 1272, 1250, 1158, 1110, 1083, 1034; HRMS (ESI-TOF) calcd. for 
C36H50N3O9I [M+H]+ 796.26645, found 796.26655; [α]D24 = -33.1 (c = 4.1, CHCl3). 
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tert-Butyl (((10R,11R,Z)-13-((S)-1-((4-methoxybenzyl)oxy)propan-2-yl)-11-methyl-
16-nitro-14-oxo-7-(3-oxo-1-phenylbutyl)-2,3,4,5,8,10,11,12,13,14-
decahydrobenzo[b][1,9,5]dioxaazacyclohexadecin-10-yl)methyl)(methyl)carbamate 
(50, mixture of diastereomers) 
Adapted from the reported procedure,247,248 to a round bottom flask armed with a 
condenser, was added compound 31 (77.0 mg, 0.096 mmol), anhydrous tetrahydrofuran 
(4.8 mL, 20 mM), trans-4-phenyl-3-buten-2-one (28.1 mg, 0.192 mmol), cyclooctadiene 
rhodium chloride dimer (9.5 mg, 0.019 mmol), and tetra-n-butylammonium fluoride (1.0 
M solution in tetrahydrofuran, 144 µl, 0.14 mmol).  The reaction was stirred under reflux 
for 3 h. The suspension was then concentrated in vacuo and purified by column 
chromatography (gradient 20 – 50% ethyl acetate/hexane) to give compound 50 as yellow 
oil (38.0 mg, 0.047 mmol). 
Yield 48%; IR (neat, cm-1) 2971, 2935, 2866, 1690, 1633, 1613, 1588, 1515, 1482, 1468, 
1454, 1393, 1365, 1341, 1302, 1271, 1250, 1157, 1108, 1079, 1035; HRMS (ESI-TOF) 
calcd. for C46H61N3O10 [M+H]+ 816.44297, found 816.44253; [α]D22 = -31.1 (c = 4.5, 
CHCl3). 
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tert-Butyl (((10R,11R,Z)-7-(4-acetylphenyl)-13-((S)-1-((4-
methoxybenzyl)oxy)propan-2-yl)-11-methyl-16-nitro-14-oxo-
2,3,4,5,8,10,11,12,13,14-decahydrobenzo[b][1,9,5]dioxaazacyclohexadecin-10-
yl)methyl)(methyl)carbamate (49) 
Adapted from the reported procedure,246 to a stirred solution of compound 31 (55.0 mg, 
0.069 mmol) in anhydrous tetrahydrofuran (1.4 mL, 20 mM), was added 1-(4-
iodophenyl)ethanone (21.9 mg, 0.089 mmol), palladium(II) acetate (1.5 mg, 0.007 
mmol), triphenylphosphine (3.6 mg, 0.014 mmol), and tetra-n-butylammonium fluoride 
(1.0 M solution in tetrahydrofuran, 103 µl, 0.10 mmol).  The reaction was stirred at 23 °C 
for 5 h. The suspension was then concentrated in vacuo and purified by column 
chromatography (gradient 20 – 50% ethyl acetate/hexane) to give compound 49 as yellow 
oil (46.0 mg, 0.058 mmol). 
Yield 85%; IR (neat, cm-1) 2970, 2935, 2869, 1681, 1632, 1611, 1589, 1515, 1467, 1393, 
1365, 1341, 1270, 1157, 1081, 1036, 984, 954; HRMS (ESI-TOF) calcd. for 
C44H57N3O10 [M+Na]+ 810.39362, found 810.39373; [α]D22 = -65.1 (c = 3.4, CHCl3). 
 
I. Conversion of alkenyl silanes to α-silyl ketones 
Dihydroxylation: to a solution of vinylsilane (1 equiv.) and 4-methylmorpholine 4-oxide 
(2 equiv.) in mixed solvent (acetone, water, and tert-butyl alcohol, 20:1:1, 0.1 M) was 
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added 0.7% of a 2.5% solution (w/v) of osmium tetroxide in tert-butyl alcohol. The 
reaction mixture was warmed up to 50 °C for 24 h and cooled to room temperature, and 
then aqueous NaHSO3 (20%), was added. The resulting mixture was concentrated on the 
rotary evaporator (room temperature) to remove most of the tert-butyl alcohol and 
acetone, saturated with NaCl, and extracted five times with EA. The extract was then 
concentrated in vacuo and purified by column chromatography (gradient 50 – 100% ethyl 
acetate/hexane). 
 
General procedure for silapinacol rearrangement: to a stirred solution of 
dihydroxylsilane (1 equiv.) in solvent (DCM, toluene or 1,4-dioxane, 25 mM) at 0 °C or 
r.t. was added the corresponding acid (1.2 equiv.). The resulting mixture was warmed up 
to the desired temperature and stirred for 16 hours. The reaction was then quenched with 
aqueous NaHCO3 (saturated), extracted with EA, concentrated in vacuo and purified by 
column chromatography (gradient 20 – 50% ethyl acetate/hexane). 
 
 
(3R,4R)-3-(dimethyl(phenyl)silyl)-1-tosylpyrrolidine-3,4-diol and its enantiomer(56) 
Yield 99% (colorless oil); 1H-NMR (500 MHz, CDCl3) δ 7.65 (d, J = 8.0 Hz, 2 H), 7.52-
7.51 (m, 2 H), 7.44-7.36 (m, 3 H), 7.28 (d, J = 8.0 Hz, 2 H), 7.05 (dd, J = 8.0, 15.5 Hz, 1 
H), 3.46 (dd, J = 7.0, 14.5 Hz, 1 H), 3.40 (d, J = 12.5 Hz, 1 H), 3.33 (d, J = 12.5 Hz, 1 H), 
3.02 (dd, J = 8.0, 9.5 Hz, 1 H), 2.42 (s, 3 H), 2.04 (d, J = 8.0 Hz, 1 H), 1.73 (s, 1 H), 0.39 
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(s, 3 H), 0.38 (s, 3 H); 13C-NMR (125 MHz, CDCl3) δ 143.6, 134.3, 134.1, 133.6, 130.0, 
129.7, 128.2, 127.4, 73.3, 72.2, 56.2, 51.2, 21.5, -5.9, -5.9. 
 
 
(3R,4R)-3-(tert-butyldimethylsilyl)-1-tosylpyrrolidine-3,4-diol and its enantiomer 
(57) 
Yield 94% (colorless oil); 1H-NMR (500 MHz, CDCl3) δ 7.70 (d, J = 8.5 Hz, 2 H), 7.33 
(d, J = 7.5 Hz, 2 H), 4.11(dd, J = 8.0, 16.0 Hz, 1 H), 3.50-3.44 (m, 2 H), 3.37 (d, J = 11.5 
Hz, 1 H), 3.05 (dd, J = 7.5, 10.0 Hz, 1 H), 2.55 (d, J = 8.5 Hz, 1 H), 2.43 (s, 3 H), 1.88 (s, 
1 H), 0.93 (s, 9 H), 0.03 (s, 3 H), -0.04 (s, 3 H); 13C-NMR (125 MHz, CDCl3) δ 143.8, 
133.6, 129.7, 127.5, 74.0, 73.4, 57.0, 51.1, 27.2, 21.5, 17.5, -7.5, -7.6. 
 
 
1-Tosylpyrrolidin-3-one (60) 
1H-NMR (500 MHz, CDCl3) δ 7.72 (d, J = 8.5 Hz, 2 H), 7.38 (d, J = 8.0 Hz, 2 H), 3.54 
(d, J = 7.5 Hz, 2 H), 3.49 (s, 2 H), 2.50 (t, J = 7.5 Hz, 2 H), 2.45 (s, 3 H).  
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(3R,4R)-3-(dimethyl(phenyl)silyl)-1-tosylpiperidine-3,4-diol and its enantiomer (61) 
Yield 82% (colorless oil); 1H-NMR (500 MHz, CDCl3) δ 7.58-7.54 (m, 4 H), 7.42-7.26 
(m, 5 H), 3.53-3.51 (m, 1 H), 3.46-3.41 (m, 2 H), 2.46-2.43 (m, 4 H), 2.36-2.31 (m, 1 H), 
2.14 (s, 1 H), 2.03 (d, J = 9.5 Hz, 1 H), 1.86-1.73 (m, 2 H), 0.46 (s, 3 H), 0.44 (s, 3 H); 
13C-NMR (125 MHz, CDCl3) δ 143.9, 135.2, 134.4, 132.9, 129.8, 129.7, 127.9, 127.6, 
70.4, 66.6, 52.0, 44.2, 28.8, 21.5, -4.6, -5.1. 
 
 
(3R,4R)-3-(tert-butyldimethylsilyl)-1-tosylpiperidine-3,4-diol and its enantiomer (62) 
Yield 92% (colorless oil); 1H-NMR (500 MHz, CDCl3) δ 7.64-7.62 (m, 2 H), 7.35-7.33 
(m, 2 H), 3.80-3.77 (m, 1 H), 3.69-3.64 (m, 1 H), 3.53-3.48 (m, 1 H), 2.51 (d, J = 12.0 
Hz, 1 H), 2.45 (s, 3 H), 2.20 (s, 1 H), 1.99 (d, J = 11.0 Hz, 1 H), 1.87-1.80 (m, 2 H), 0.95 
(s, 9 H), 0.13-0.08 (m, 6 H). 
 
 
1-Tosylpiperidin-3-one (65) 
1H-NMR (500 MHz, CDCl3) δ 7.67 (d, J = 9.0 Hz, 2 H), 7.35 (d, J = 8.0 Hz, 2 H), 3.60 
(s, 2 H), 3.29 (t, J = 6.7 Hz, 2 H), 2.44 (s, 3 H), 2.36 (t, J = 6.7 Hz, 2 H), 2.04-1.99 (m, 2 
H). 
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Racemic 4-(tert-butyldimethylsilyl)-1-tosylpiperidin-3-one (64) 
1H-NMR (500 MHz, CDCl3) δ 7.65 (d, J = 8.0 Hz, 2 H), 7.35 (d, J = 8.5 Hz, 2 H), 3.62 
(d, J = 17.0 Hz, 2 H), 3.46-3.39 (m, 2 H), 2.99-2.94 (m, 2 H), 2.44-2.42 (m, 4 H), 2.22-
2.06 (m, 2 H), 0.91 (s, 9 H), 0.11 (s, 3 H), 0.01 (s, 3 H). 
 
J. Conversion of alkenylsiloxanes to alkenyl halides 
Dibromination/bromodesilylation: to a stirred solution of alkenylsiloxane (1 equiv.) in 
the corresponding solvent (50 mM) was added Br2 (1.05 equiv.) at -78 °C. After 5 min at 
-78 °C, TBAF (1 M solution in THF, 4 equiv.) was added and the reaction was allowed to 
warm up to r.t. over 15 min and stirred at r.t. for another 15 min. The reaction was then 
quenched with aqueous Na2S2O3 (10 %), extracted with EA. The extract was 
concentrated in vacuo and purified by column chromatography (gradient 0 – 10% ethyl 
acetate/hexane).  
 
Iodination: adapted from reported procedure,284 to a stirred solution of alkenylsiloxane (1 
equiv.) in HFIP (50 mM) was added NIS (1.5 equiv.) at 0 °C. After 40 min at 0 °C, the 
reaction was then quenched with aqueous Na2S2O3 (10 %), extracted with EA. The 
extract was concentrated in vacuo and purified by column chromatography (gradient 0 – 
10% ethyl acetate/hexane). 
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(Z)-6-bromo-3,4,7,8,9,10-hexahydrobenzo[b][1,5]dioxacyclotetradecin-12(2H)-one 
(66-Z) 
Yield 89% (colorless oil); IR (neat, cm-1) 2940, 1698, 1601, 1491, 1452, 1384, 1300, 
1244, 11166, 1133, 1097, 1053; 1H-NMR (500 MHz, CDCl3) δ 7.82-7.80 (m, 1 H), 7.46-
7.43 (m, 1 H), 7.00-6.94 (m, 1 H), 6.26 (t, J = 6.7 Hz, 1 H), 4.38 (t, J = 5.2 Hz, 2 H), 4.16 
(t, J = 5.0 Hz, 2 H), 2.56-2.53 (m, 2 H), 2.44-2.40 (m, 2 H), 2.00-1.96 (m, 2 H), 1.89-1.84 
(m, 2 H), 31.75-1.70 (m, 2 H); 13C-NMR (125 MHz, CDCl3) δ 167.8, 157.6, 133.2, 132.1, 
128.7, 125.6, 1206, 120.1, 112.1, 70.7, 65.0, 38.9, 31.7, 27.7, 25.6, 24.0. 
 
 
(E)-6-iodo-3,4,7,8,9,10-hexahydrobenzo[b][1,5]dioxacyclotetradecin-12(2H)-one (76-
E) 
Yield 93% (colorless oil); IR (neat, cm-1) 2953, 1702, 1601, 1490, 1452, 1384, 1354, 
1302, 1251, 1193, 1164, 1132, 1097, 1052, 979; 1H-NMR (500 MHz, CDCl3) δ 7.77-7.75 
(m, 1 H), 7.44-7.40 (m, 1 H), 6.99-6.92 (m, 2 H), 6.23 (t, J = 7.8 Hz, 1 H), 4.40 (t, J = 5.0 
Hz, 2 H), 4.08 (t, J = 5.2 Hz, 2 H), 2.65-2.62 (m, 2 H), 2.27-2.23 (m, 2 H), 1.84-1.80 (m, 
6 H); 13C-NMR (125 MHz, CDCl3) δ 168.3, 157.1, 140.1, 133.1, 132.2, 121.2, 120.2, 
112.2, 101.6, 66.1, 63.7, 38.7, 28.9, 27.1, 26.6, 24.4. 
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(E)-3-bromo-10-methyl-5,6,7,8-tetrahydro-2H-benzo[b][1,4]oxaazacyclododecin-
9(10H)-one (71-E) 
Yield 79% (colorless oil); 1H-NMR (500 MHz, CDCl3) δ 7.35-7.31 (m, 1 H), 7.18-7.16 
(m, 1 H), 7.03-7.00 (m, 1 H), 6.93-6.92 (m, 1 H), 6.23-6.19 (m, 1 H), 4.96 (d, J = 12.5 
Hz, 1 H), 4.73 (d, J = 13.0 Hz, 1 H), 3.20 (s, 3 H), 2.26-2.20 (m, 1 H), 2.01-1.84 (m, 4 
H), 1.54-1.37 (m, 3 H). 
 
 
(Z)-6-bromo-4,5,8,9,10,11-hexahydro-2H-benzo[b][1,5]dioxacyclopentadecin-
13(3H)-one (74-Z) 
Yield 97% (colorless oil); 1H-NMR (500 MHz, CDCl3) δ 7.69-7.67 (m, 1 H), 7.43-7.40 
(m, 1 H), 7.00-6.97 (m, 2 H), 5.73 (t, J = 7.0 Hz, 1 H), 4.30 (t, J = 5.5 Hz, 2 H), 4.02 (t, J 
= 7.0 Hz, 2 H), 2.50 (t, J = 6.0 Hz, 2 H), 2.27-2.24 (m, 2 H), 1.91-1.85 (m, 2 H), 1.94-
1.78 (m, 2 H), 1.74-1.69 (m, 2 H), 1.64-1.59 (m, 2 H). 
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(E)-6-iodo-4,5,8,9,10,11-hexahydro-2H-benzo[b][1,5]dioxacyclopentadecin-13(3H)-
one (77-E) 
Yield 87% (colorless oil); 1H-NMR (500 MHz, CDCl3) δ 7.73-7.71 (m, 1 H), 7.43-7.40 
(m, 1 H), 6.97 (dd, J = 8.0, 8.0 Hz, 1 H), 6.91 (d, J = 8.0 Hz, 1 H), 6.27 (t, J = 8.2 Hz, 1 
H), 4.38 (t, J = 6.0 Hz, 2 H), 4.06 (t, J = 5.2 Hz, 2 H), 2.57 (t, J = 7.8 Hz, 2 H), 2.11-2.07 
(m, 2 H), 1.92-1.86 (m, 2 H), 1.83-1.75 (m, 4 H), 1.60-1.54 (m, 2 H); 13C-NMR (125 
MHz, CDCl3) δ 168.2, 157.5, 140.7, 132.9, 131.5, 121.2, 120.1, 112.3, 101.9, 67.8, 64.5, 
39.4, 30.2, 27.9, 27.7, 26.3, 25.7. 
 
K. Enyne RCM reactions 
Alkyne silylation and enyne RCM (un-optimized conditions): to a stirred solution of 91 
(100 mg, 0.27 mmol) in 2.7 mL THF (0.1 M) at -78 °C was added 0.14 mL butyllithium 
(2 M in hexane, 0.28 mmol) followed by chlorotriethoxysilane (108 mg, 0.54 mmol). The 
reaction was stirred for 1 hour at -78 °C and warmed up to room temperature. THF was 
removed on the rotary evaporator (room temperature). Without workup or purification, 
the crude reaction mixture was charged with anhydrous toluene (2.7 mL) and 51 mg 
(0.082 mmol) HG-II, purged with ethylene gas, and left at room temperature for 
overnight. The reaction was then quenched with aqueous NaHCO3 (saturated), extracted 
with EA, concentrated in vacuo and purified by column chromatography (gradient 20 – 
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50% ethyl acetate/hexane) to give compound 92 as yellow oil (20 mg, 0.038 mmol, 20% 
yield). 
 
(R)-2-benzyl-1-tosyl-6-(1-(triethoxysilyl)vinyl)-2,3,4,7-tetrahydro-1H-azepine (92) 
Yield 20% (colorless oil); 1H-NMR (500 MHz, CDCl3) δ 7.68 (d, J = 8.5 Hz, 2 H), 7.30-
7.27 (m, 2 H), 7.24-7.17 (m, 5 H), 5.91-5.90 (m, 1 H), 5.78-5.78 (m, 1 H), 5.72-5.71 (m, 
1 H), 4.63 (d, J = 18.5 Hz, 1 H), 4.01-3.95 (m, 1 H), 3.80 (q, J = 7.0 Hz, 7 H), 3.03 (dd, J 
= 13.0, 3.5 Hz, 1 H), 2.75 (dd, J = 13.0, 4.5 Hz, 1 H), 2.37 (s, 3 H), 2.03-1.96 (m, 1 H), 
1.70-1.58 (m, 2 H), 1.45-1.39 (m, 1 H), 1.22 (t, J = 7.0 Hz, 9 H).  
 
L. CM reactions 
General reaction conditions for cross metathesis: to a stirred to solution of vinylsiloxane 
or alkenylsiloxane (1 equiv.) in toluene (0.1 M) was added the simple olefin (allyl 
acetate, methyl acrylate, or methylvinlylketone, 1 to 5 equiv.) and the catalyst (Cat. A, G-
I, G-II, or HG-II, 20 mol%). The resulting mixture was warmed up to 50 °C and stirred 
for 16 hours. The crude reaction was then concentrated in vacuo and analyzed by 1H 
NMR. 
 
 
Benzyl 5-(triethoxysilyl)hex-5-enoate (94a) 
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Yield 58% (colorless oil); 1H-NMR (300 MHz, CDCl3) δ 7.36-7.31 (m, 5 H), 5.72-5.71 
(m, 1 H), 5.67-5.66 (m, 1 H), 5.12 (s, 2 H), 3.81 (q, J = 6.9 Hz, 6 H), 2.37 (t, J = 7.2 Hz, 
2 H), 2.19 (t, J = 7.5 Hz, 2 H), 1.84 (tt, J = 6.9, 6.9 Hz, 2 H), 1.22 (t, J = 6.9 Hz, 9 H).  
 
 
Benzyl 5-(diethoxy(methyl)silyl)hex-5-enoate (94c) 
Yield 52% (colorless oil); 1H-NMR (300 MHz, CDCl3) δ 7.36-7.31 (m, 5 H), 5.68-5.66 
(m, 1 H), 5.58-5.57 (m, 1 H), 5.12 (s, 2 H), 3.75 (q, J = 7.2 Hz, 4 H), 2.37 (t, J = 7.8 Hz, 
2 H), 2.18 (t, J = 7.8 Hz, 2 H), 1.82 (tt, J = 7.8, 7.8 Hz, 2 H), 1.20 (t, J = 6.9 Hz, 6 H), 
0.19 (s, 3 H).  
 
Scheme I-22. Synthesis of 95e and 95a. 
 
 The synthesis of 95e started from hydrosilylation of oct-2-yn-1-ol (Scheme I-22). 
Following the general hydrosilylation procedure with acetone as solvent instead of DCM, 
compound 97 was obtained with 85% yield. Allylation of 97 gave rise to compound 95e 
with moderate yield. Surprisingly, hydrosilylation with HSi(OEt)3 did not work. Instead, 
1-(allyloxy)oct-2-yne was subjected to the hydrosilylation reaction. However, the 
reaction yielded the undesired regioisomer 96a as the major product that is not separable 
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from the desired product 95a. Cross metathesis reactions with 95e or mixture of 95a and 
96a were performed following the general procedure, but failed to generate any 
detectable amount of products. 
  
 
(Z)-(1-(allyloxy)oct-2-en-3-yl)dimethyl(phenyl)silane (95e) 
Yield 65% (colorless oil); 1H-NMR (500 MHz, CDCl3) δ 7.53-7.50 (m, 2 H), 7.36-7.32 
(m, 3 H), 6.20 (t, J = 6.5 Hz, 1 H), 5.82-5.75 (m, 1 H), 5.18-5.14 (m, 1 H), 5.11-5.08 (m, 
1 H), 3.82 (d, J = 7.0 Hz, 2 H), 3.74-3.73 (m, 2 H), 2.15 (t, J = 8.5 Hz, 2 H), 1.40-1.34 
(m, 2 H), 1.31-1.23 (m, 4 H), 0.87 (t, J = 7.0 Hz, 3 H), 0.39 (s, 6 H).  
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Chapter II-1. Introduction 
The use of small-molecule probes to shed light on both normal and disease-associated 
biological phenomena is a powerful approach in chemical biology.1-4 With respect to 
disease biology, such probes serve as useful starting points to produce new medicines. 
Technological advances have made high-throughput screening (HTS) the predominant 
mechanism through which these probes are discovered.5-11 The success of such an 
approach is inextricably linked to the identity and the quality of the screening 
collection.12,13 Synthetic organic chemistry has played a pivotal role in generating large 
collections of small molecules to be screened in various HTS campaigns. However, even 
the largest conceivable compound collections have fallen far short of sampling the 
chemical diversity space (an estimated to be upward of 1060 molecules containing up to 
30 non-hydrogen atoms).14 Compounding the problem is the fact that most small 
molecule screening collections have substantial overlap, leading to a dearth of new 
chemical entities being discovered.15,16 Clearly, sources of chemicals with greater 
diversity are needed and alternative approaches toward probe development are warranted.  
 
Fragment-based drug discovery (FBDD) is a complementary strategy to HTS, and is a 
well-validated approach toward generating small-molecule leads.17-23 The central theme 
underlying FBDD is the screening of a library of low molecular weight compounds 
(typically less than 250 g/mol),24 or “fragments,” against a specific biological target. The 
number of potential fragments with up to 12 heavy atoms (not including three- and four-
membered ring structures) has been estimated at 107.25 As a result, fragment libraries 
though substantially smaller, are still able to sample a higher percentage of the chemical 
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space compared to HTS screening collections.24-26 Because fragment molecules are small 
in size, they typically bind with lower affinity to a target protein (micromolar to 
millimolar range) compared with drug-like molecules (nanomolar to micromolar range). 
Consequently, the binding of a fragments is mostly captured by very sensitive 
biophysical techniques capable of picking up such weak interactions.27 Although the 
binding affinity of a fragment is low, it usually has high ligand efficiency which makes it 
a good starting point.21 After an appropriate fragment hit has been identified, it then 
serves as a constructive chemical anchor for the generation of a more potent ligand. This 
can be achieved by synthetically “growing” or “linking” the bound fragments.28-35 FBDD 
approaches are most efficiently executed when an X-ray or NMR structure of the target is 
available, giving critical binding information.36-45 With structural information in hand, 
follow-up chemistry is guided in a rational manner requiring fewer analogs to be made 
toward a potent lead compound. 
 
The increasing popularity of fragment-based screening has led to an increase in the 
number of commercial vendors selling fragments. However, most fragment libraries used 
to date have been limited to aromatic heterocycles with an underrepresentation of chiral, 
enantiopure sp3-rich compounds.46 These traditional planar sp2-rich fragments have 
undoubtedly led to the generation of unique and high-quality starting points.22,47,48 In 
order to explore more difficult biological targets without well-defined binding pockets 
(e.g. transcription factors), more emphasis should be placed upon developing compounds 
with different structural motifs. 
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Additionally, there have been several recent studies demonstrating the benefits of 
increasing the saturation content in drug-like compounds.49-51 The increased sp2 content 
of a molecule was found to negatively correlate with the aqueous solubility, while 
positively correlating with lipophilicity, serum albumin binding, and CyP450 inhibition, 
suggesting that drug candidates with fewer aromatic rings were more “developable” than 
the lead compounds with more aromatic rings.50 The importance of sp3-rich lead 
compounds in these studies can be extended to fragments, which support the hypothesis 
that sp3-rich fragments can serve as higher-quality starting points in terms of 
physicochemical properties. 
 
In addition to insufficient chemical diversity, buying fragments from various commercial 
vendors does not allow for efficient structure-activity relationship (SAR) determination. 
Because compounds were not selected on the basis of synthetic availability of their 
analogs, the chemistry to optimize hits from commercial collections can often be 
challenging and problematic. However, through proactively synthesizing a fragment 
collection, analogues with different regiochemical, stereochemical, and skeletal 
properties can be easily accessed to facilitate a rapid optimization after the primary 
screen.  
 
The modification of fragments is another important step in the entire FBDD process. 
Guided by the structural information of the fragment binding against the macromolecule, 
positions and directions for “growing” or “linking” can be determined. The growth vector 
from sp2 atoms (carbon or nitrogen) of traditional planar fragments is confined to the 
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plane of the ring. On the contrary, sp3 atoms provide different geometric vectors off of a 
fragment, which enables orientation-dependent modifications of fragments into pockets 
of an active site that might otherwise be inaccessible to planar aromatic fragments. 
Researchers at Eli Lilly have recently demonstrated this notion (Figure II-1) by showing 
that the rigid bicyclic scaffold benzothiazine failed to afford optimal vectors for fragment 
growth into an adjacent pocket.52 The problem was solved by deplanarizing the 
aminothiazine, and introducing a quaternary methyl group to both exploit this topology 
and enhance chemical stability. 
 
Figure II-1. Deplanarization of bicyclic fragment to enhance occupancy of S1 pocket of 
BACE1 and provide vector for introduction of an S3 binding element to increase 
affinity.52 
 
 
Taken together, these examples sufficiently show the benefits of putting an upfront effort 
into the synthesis of a diverse fragment collection. A fragment collection comprised of 
molecules that can be accessed using modular syntheses would circumvent downstream 
challenges. In an effort to generate such a library, a diversity-oriented synthesis (DOS) 
approach was undertaken. 
 
After several years of exploration in the area of DOS, a build/couple/pair strategy (B/C/P) 
has recently emerged, which has been proven successful in producing molecules suitable 
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for HTS.53-69 In a recent paper, Dr. Alvin W. Hung, Mr. Alex Ramek, and I have 
demonstrated the application of this concept toward the generation of low molecular 
weight fragments. Short and efficient synthetic pathways following the logic of B/C/P 
were used to generate fragments that were structurally diverse and rich in sp3-content.   
 
In addition to shape diversity and higher sp3 content, the notion of synthetic accessibility 
of analogues was also incorporated into the design of fragments. In an ideal situation, one 
would like to have the ability of making modifications at every single atom of the 
scaffold. To achieve this goal, special attention was paid toward the synthetic 
accessibility and commercial availability of derivatives of the starting building blocks. 
Functional groups that have the potential to be diversified are also incorporated (see 
Chapter II-2-2). Another advantage of generating DOS fragments from the B/C/P 
strategy is the potential access to all possible stereoisomers including enantiomers and 
diastereomers in their enantiopure forms. Such a fragment library would enable the 
exploration of stereochemical structure-activity relationships, and more importantly allow 
for the differentiation between specific binders versus nonspecific binders. Such 
information is not included in commercial vendor collections. 
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Chapter II-2. Design and Synthesis of Diversity-Oriented 
Synthetic Fragment Libraries 
1. Proline-based fragment library 
Together with Dr. Alvin Hung, we designed a synthetic pathway starting with proline 
building blocks 1-3 (Scheme II-1). One factor for selecting these compounds was the 
readily available enantiomerically pure versions of all stereoisomers.70-72 Another benefit 
of using proline building blocks includes the extensive amount of chemistry focusing on 
the generation of pyrrolidine-based scaffolds.73 This information is constructive given 
that, if binders are found, numerous substituted pyrrolidines can be generated in the 
follow-up chemistry phase from a variety of known methods. 
 
Scheme II-1. Application of a B/C/P approach to make bicyclic compounds starting from 
building blocks 1-3. 
 
 
With compounds 1-3 in hand, we proceeded to the couple and pair phases of our 
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pathway. Scheme II-1 illustrates the implementation of this strategy. Intermolecular 
coupling reactions based around the building blocks yielded more densely functionalized 
pyrrolidine molecules (compounds 4’-11’),70,74,75 which were then paired under various 
conditions such as RCM, lactam formation, Michael addition, etc. Skeletally diverse 
bicyclic fragments that have 5,5, 5,6, 5,7, 5,8, and 5,9 fused ring systems were generated.  
 
Scheme II-2. Using a B/C/P approach to obtain the full matrix of all possible 
diastereomeric products. 
 
 
The devised B/C/P strategy not only created a small library of fragments of diverse 
skeletal structures, but also one rich in stereochemical variation. The mixing and 
matching of various stereogenic building blocks followed by versatile RCM pairing 
reactions generated a complete set of all possible diastereomers (Scheme II-2). The 
difference between various stereoisomers might be significantly large enough to 
completely obliterate binding. Therefore having a complete set of stereoisomers would 
facilitate the identification of the more potent stereoisomer and provided insights on 
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further design of a better inhibitor.  
 
Scheme II-3. Reducing the olefin groups in a post-pairing phase to generate a new set of 
fragments. 
 
 
In addition to structural and stereochemical diversity, we designed a third diversity 
element into our library: a “postpairing phase”. Fragments, because of their low 
molecular weight usually display weak binding affinities. Consequently, the particular 
functional groups within a given fragment are critical to the observation of a binding 
event. Subtle changes in functionalities and shape of fragments can result in significant 
changes to binding affinities. Accordingly, we determined that it would be imperative to 
take the scaffolds that were assembled in the B/C/P strategy and perform functional 
group interconversion reactions on them to produce new fragments (Scheme II-3). The 
result of these modifications would be to generate “functional group diversity” within the 
fragment library. Methyl esters were hydrolyzed to the carboxylic acids to give fragments 
32, 33, and 34. These functional interconversions would have a significant impact on the 
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overall electronic properties of the fragments. The reduction of olefins in the fragments 
was also performed (Scheme II-3), resulting in increased sp3 carbon atom content and a 
different conformational profile for the reduced fragments. 
 
Scheme II-4. Synthesis of spirocyclic compounds. 
 
 
Besides the design of the proline-based fragment library, my contribution to the 
execution of the synthesis was focused on the generation of spirocyclic fragments. 
Commercially available starting material 3’ (derivative of compound 3, see Scheme II-1) 
was coupled with allylamine (Scheme II-4). The RCM of 35 failed to generate the 
cyclized product because the thermodynamically favored rotamer of the secondary amide 
causes the two allyl groups to be positioned away from each other. To overcome this 
problem, 35 was methylated yielding the tertiary amide 36, which allowed for the two 
rotamers to be isothermic and interconvertable. The subsequent RCM of 36 gave rise to 
two enamides, a major product 37 and a minor product 38. In both products, migration of 
the double bond was observed, which is indicative of isomerization during the RCM 
reaction, presumably catalyzed by ruthenium hydride species.76,77 Formation of the 6-
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membered enamide 38 can be rationalized on grounds that the migration of the double 
bond occurred before the RCM releasing propene (instead of ethylene) to generate 38. 
However, migration of the double bond in situ could happen in the RCM of tertiary 
amide 42, but was not extensively studied. The desired spirocyclic product 43 was 
obtained with moderate yield (Scheme II-4). 
 
2. Fragment library based on RCM of vinylsiloxanes 
In addition to the proline-based fragment library mentioned above, a fragment library 
focusing on nitrogen-containing heterocycles was designed taking advantages of the 
RCM of vinylsiloxanes. The synthetic pathway (Scheme II-5) started from both 
enantiomers of allylglycine and propargylglycine, which are commercially available. 
Coupling of the Boc-protected amino acids with the corresponding propargylamine or 
allylamine gave rise to the tertiary amide with both alkene and alkyne functionality in it. 
After hydrosilylation of the alkyne, the vinylsiloxanes were subjected to the optimized 
RCM conditions described in Chapter I-2-2. The R group must be an alkyl group or 
sulfonyl group for the RCM reaction to orrur. The presence of a N-aryl group did not 
permit RCM. It is rational that the N,N-phenylalkyl amide will adopt a different 
conformation than a N,N-bisalkyl amide, which may cause the dramatic change in the 
rates of the ring-closing reaction. If a m-nitrophenylsulfonyl (nosyl) group is used, it can 
be removed to release the secondary amide that has different hydrogen bonding ability 
compared to the sulfonamide or the tertiary amide. The switch between the alkene and 
alkyne enables the incorporation of silyl groups at either of the two sp2-olefinic carbons 
in the RCM product so that both regioisomers are accessible.  
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Scheme II-5. Proposed synthetic pathway towards a 7-membered nitrogen-containing 
fragment library starting from amino acids and preliminary results. 
 
 
Once the RCM product was obtained, a one-step transformation of the alkenylsiloxane 
moiety yielded either the ketone, alkenyl iodide, or the aryl-substituted alkene. 
Furthermore, an additional step would generate different functionalities from the parent 
fragments such as the secondary alcohol, substituted oxazole,78 or the saturated version of 
the 7-membered ring. Preliminary results have shown that both regioisomers 45 and 52 
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can be closed successfully with similar reaction outcome (Scheme II-5). Subsequent 
cross-coupling reactions can be executed from product 46 directly using Hiyama 
coupling79 or from the alkenyl iodide 48 using Suzuki coupling.80 In addition, the nosyl-
protected amide 50 afforded the cyclized product with good yield. The synthesis of this 
library is currently being performed by Mr. Evan Liang. 
 
Figure II-2. Substrates that failed to be closed under optimal RCM conditions (ring sizes 
of the desired products in parentheses). 
 
 
To understand the generality of building up libraries around alkene- or alkyne-containing 
amino acids and amino alcohols, several other substrates were also prepared and 
subjected to the optimal RCM conditions. However, proline-bsaed vinylsiloxanes failed 
to generate the 7- to 9-membered products with a conversion larger than 5% (Figure II-2, 
first row). Substrates based on protected allyl glycines or amino alcohols to provide 8-
membered products also failed to be cyclized (Figure II-2, second row). This reflects the 
challenge of cyclizing medium size rings from 7- to 9-members due to high intrinsic ring 
strain as well as the constraint of the introduction of the silyl group.  
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Scheme II-6. Proposed synthetic pathway towards a nitrogen-containing fragment library 
starting from chiral amines. 
 
 
Although the RCM of vinylsiloxanes to form rings larger than 7 is dependent on the 
nature of the substrates, it has been shown that the reaction is quite general towards the 
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formation of 5- and 6-membered rings in Chapter I-1-4 and I-2-1. We designed another 
pathway to access a diverse set of linked-bicyclic compounds and cyclic ketones with 
different ring sizes, stereoisomers, regioisomers, and various aromatic groups (Scheme 
II-6). Though the complete set of proposed 7-membered rings may not be fully 
accessible, I have explored the synthesis of 59 to test the feasibility of this approach 
(Scheme II-7). Starting with the (S)-amino alcohol 54, the tosyl-protected aziridine 55 
was obtained in a one-pot transformation. The aziridine 55 was then opened with 
allylcyanocuprate reagent to install the terminal alkene. Propargylation of compound 56 
gave rise to the alkenyl alkyne 57 with excellent yield. Hydrosilylation and RCM of 57 
completed the synthesis of 7-membered alkenylsiloxane 59 in acceptable yields. The 
other starting chiral amines shown in Scheme II-6 are either commercially available or 
easily accessible from ring opening of chiral aziridines following the similar route to 
compound 56. 
 
Scheme II-7. Preliminary results on RCM to form a 7-membered product. 
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Chapter II-3. Screen the Synthetic Fragment Library  
against GSK3β  
1. Initial biophysical screening using thermal shift assay 
The glycogen synthase kinase (GSK3β) was selected as the proof-of-concept target for 
screening the DOS fragments. GSK3β is a well-characterized target that is involved in a 
range of developmental and homeostatic cellular biology.  Signaling abnormalities in the 
pathway involving this protein have been linked to a variety of human diseases. 
Pertaining to neuropsychiatric disease, growing evidence from human genetic studies 
implicates aberrant GSK3β signaling, including the discovery of the schizophrenia risk 
gene DISC1 as a direct binder and inhibitor of GSK3β,81 and the bHLH transcription 
factor TCF4 (ITF-2) as a GSK3β/B-catenin target gene82 making it a target of interest 
within the Stanley Center for Psychiatric Disease at the Broad Institute. To convincingly 
portray the role of GSK3β in neuropsychiatric disorders, a small-molecule ligand with 
exquisite potency and selectivity is required. To date, it has been difficult to obtain a 
small-molecule with such properties based on HTS. Therefore, a fragment-based 
approach has the potential to be impactful in an area where more conventional methods 
have not succeeded. 
 
A florescence thermal shift assay83 was used to screen the entire fragment library against 
GSK3β. This method of screening has the advantage of robust throughput (96 well per 
0.5 hour), enabling it for use as a primary screen against GSK3β. Our collaborator Dr. 
Steve Haggarty, of the Stanley Center and the Chemical Biology Platform had extensive 
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experience on using thermal shift with GSK3β. Accordingly, significant thermal shifts of 
6-8 °C had been observed by them for known (nonselective) inhibitors of GSK3β. This 
would be beneficial, as it would translate into higher sensitivity when screening for 
fragments. 
 
Optimization of the thermal shift assay against GSK3β was performed together with Dr. 
Alvin W. Hung and Mr. Alexander Ramek. Different combinations of protein 
concentration and dye concentration were tested until a good fluorescence curve was 
obtained with minimal amount of protein. Next the DMSO tolerance of GSK3β was 
determined. Given that high concentrations of fragment are required for the initial 
screening, we wanted to use a high percentage of DMSO in order to solubilize the ligand. 
However, higher concentration of DMSO can also interfere with the protein and 
eventually denature it. After several experiments, the optimal condition was determined 
to be 0.12 mg/mL GSK3β, 1:400 dilution of Sypro Orange from the original stock, and 
2.5% DMSO. The assay was performed in 384-well plate format with final volume of 5 
µL using a buffer solution containing 50 mM HEPES (pH 7.5) and 150 mM NaCl. 
 
Next, known binders of the protein were tested under the optimized assay conditions to 
determine whether the assay was working as well as its sensitivity. In the GSK3β case, 
several known inihibitors were tested and all were discovered to give a positive thermal 
shift (Figure II-3). GW8510, an inhibitor of cyclin-dependent kinase-2, also inhibits T. 
brucei GSK-3 short protein with an IC50 of 1 nM.84 When tested at 20 µM, it showed a 6 
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°C positive thermal shift. Another inhibitor BRD4003 found by our collaborators, which 
has a KD of 130 nM (measured by SPR) also showed a shift around 3 °C. It will be 
interesting to note the correlation of thermal shift with Kd in future experiments, when the 
whole set of data is collected. 
 
Figure II-3. Thermal shift experiments on GSK3β with positive controls. 
 
Top traces: fluorescence level over temperature; bottom traces: first derivative of 
fluorescence level over temperature. Blue: DMSO control; green: compound BRD4003; 
pink: compound GW8510. 
 
ATP is a cofactor of GSK3β and can also bind to the protein. As an additional control, 
we desired to determine whether the binding of ATP would stabilize the protein or not. 
To our surprise, when tested at 240 µM of ATP, the melting point of the protein was 
unchanged, suggestive of no interaction. By checking our assay conditions carefully, we 
found out that the assay buffer did not contain Mg(II), which is required for the activity 
of the protein. We then retested ATP in the presence of 10 mM MgCl2, and a 2.0 °C 
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thermal shift was observed. Therefore, Mg(II) is required for ATP binding but not for the 
positive controls we had tested. We decided to screen our compound collection with and 
without Mg(II) in order to compare the results. 
 
The screening of our fragment collection without Mg(II) yield 6 compounds that showed 
a positive thermal shift value larger than 0.4 °C (Figure II-4). Compound 60, 61, and 62 
gave no shift when the assay was performed in the presence of Mg(II). However 
compound 63, 64, and 65 showed slight increases in their shift values when Mg(II) was 
present. We speculate that Mg(II) binding causes a conformational change of the protein 
that disfavors the binding of the first 3 compounds but favors the binding of others. This 
suggests to us that the first three compounds have distinct binding modes that might be 
interesting to study. However, we decided to follow up with the compounds that bind to 
the protein both with and without Mg(II). 
 
Figure II-4. Hits from thermal shift assays against GSK3β in the absence (red value) or 
presence (blue value) of Mg(II). 
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2. Initial SAR of several analogues and their inhibitory activities 
Compounds 63-65 were synthesized via a tandem Ullmann reaction/cyclodehydration 
sequence85 from different starting materials (Scheme II-8). Specifically, the sequence 
involves a one-pot reaction involving an intermolecular cross-coupling reaction between 
an amino group of the amino acid and an aryl bromide, followed by an intramolecular 
cyclization reaction that forms the amide bond. There are several desirable features of 
this reaction. First, aryl bromides with different substitutions can be used including the 
pyridyl bromide. Second, the other building block of this reaction is an amino acid. 
Various amino acids, either naturally occurring or non-naturally occurring, are 
commercially available with both enantiomers. Rapid access to analogues and 
stereoisomers will enable efficient growth of the fragment once a hit is identified, which 
also facilitates the study of (stereochemical) structure-activity relationships. Third, the 
free amine group can be easily modified, and the secondary amide moiety can be reduced 
to the corresponding amine. Last, starting with a secondary amine (R2 = alkyl), the 
tertiary amide can be accessed that has totally different hydrogen bonding ability and 
sterics compared to the secondary amide. 
 
Scheme II-8. Versatility of the Ullmann reaction/cyclodehydration sequence. 
 
 
However, there are several notable problems associated with this reaction. First, the 
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reaction is performed at 120 °C. Under such harsh conditions, epimerization of the chiral 
center within the amino acid occurs potentially at any stage of the reaction. Second, the 
use of aryl-substituted glycines leads to serious decomposition without isolation of 
desired product. Third, certain products can be further oxidized to the imine in solution at 
room temperature, eliminating the chiral center and posing challenges for storage of such 
compounds in a stock solution. To overcome the third limitation, small aliquots of each 
compound (mostly crystalline powders) were prepared and stored at -20 °C. Before 
running the assays, each compound was made freshly and discarded at the end of the day. 
 
Enabled by the efficient Ullmann reaction, analogues were easily accessed. Thermal 
shifts of these compounds were obtained and listed in Figure II-5. At this point, we were 
interested in whether these compounds will inhibit the kinase activity of GSK3β. An 
ADP-GloTM assay was adopted for this purpose. We measured the inhibitory activity of 
the compounds at a single concentration of 1 mM whenever soluble. The results are 
shown in Figure II-5.  
 
Figure II-5. Results of thermal shift assay and inhibition assay with several analogues. 
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If the inhibitory activity is caused by non-specific aggregation of the compound, both 
enantiomers will have the same activity since enantiomers have the same 
physicochemical properties. Our results showed that the (R)-enantiomer 66 is more active 
than the (S)-enantiomer 65, which suggests the binding interaction and inhibitory activity 
are real and not due to promiscuous interactions. Other results also showed that the 
position of the pyridyl nitrogen matters. Among the four regioisomers 66-69, compound 
66 with nitrogen atom adjacent to the amide yielded the optimal scaffold. Interestingly, 
when the pyridyl nitrogen is adjacent to the amine, the (R)-enantiomer 69 is less active 
than the (S)-enantiomer 70. The reversion of stereochemical SAR indicated that the 
binding modes of the two scaffolds (65, 66 versus 69, 70) are probably different from 
each other. 
 
3. Identification of the key binding motif of a particular scaffold 
We chose to follow up with the enantiomeric pair 65 and 66 first. It has been reported 
that a pyridylamide moiety is able to form a hydrogen-bonding network with the 
backbone carbonyl and amide hydrogen of the peptide through the amide hydrogen and 
pyridyl nitrogen.86-88 We hypothesized that this moiety is a key interaction for the small 
fragment. To test our hypothesis, perturbations of the moiety or the pattern were achieved 
synthetically (Figure II-6). The secondary amide of compound 65 was reduced to 
generate the secondary amine 76, thereby deleting the carbonyl oxygen that previously 
served as a hydrogen bond accepter, and abolishing the binding interaction. Starting from 
N-methyl bromopyridylamine, tertiary amide 77 was obtained which not only removed 
the hydrogen bond donor ability but also increase the steric hindrance of the amide; and 
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again the binding interaction was abolished. A 7-membered analogue 79 was made to 
disturb the dihedral angle between the pyridyl group and the amide moiety, and it is also 
inactive compared to the parent compound. However, changes that have little interference 
with the key binding motif retain activity to some degree such as compound 75 
(commercially available) and 78 (accessed via oxidation of 65). 
 
Figure II-6. Key binding interaction probed by perturbations of compound 65 and 66. 
 
 
4. Growth of the fragment to improve potency and confirmation by NMR and ITC 
After the recognition of the key binding motif, we pursued the question of where to grow 
compound 66 to increase potency (Figure II-7). Increased potency of compound 73 and 
74 indicated that there might be a pocket at the position where the substituent is pointing. 
 
Figure II-7. Growth of fragment 66 to increase potency. 
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The geminal-dimethyl analogue 80 and cyclobutenyl analogue 81 were synthesized and 
shown to be less potent. The oxidized product 78 also displays less potency. Taken all 
together, these results indicated that the orientation of the substituent is important for 
picking up the favorable interactions, and there might be a hydrophobic pocket. 
Therefore, several analogues containing substituted alkyl, gem-dialkyl, benzyl, 
hydroxybenzyl, and heteroaromatic substituents from the corresponding amino acids 
were synthesized and tested using the thermal shift assay. Generally speaking, 
compounds that have heteroaromatic groups increase the binding interaction, among 
which the indole analogue 91 was found to be the most potent one.  
 
STD and WaterLOGSY experiments41,44 were performed to confirm the binding 
interaction between compounds 66, 74, and 91 with GSK3β. The results are shown in 
Figure II-8. Using 5 µM of GSK3β and 500 µM of compound 74 or 91 for the NMR 
experiment, binding interactions of both were clearly shown in either experiment 
indicated by the increase of ligand signal in the presence of GSK3β. For compound 66, 
the binding interaction was also observed at 5 µM of GSK3β. However, the results 
shown in Figure II-8 were performed with 20 µM of GSK3β and 500 µM ligand in order 
to increase the signal/noise ratio. Next, an ATP competition assay was performed to 
determine whether compound 66 is an ATP-competitive binder or not. When ATP was 
added to the solution with both protein and compound 66 at a final concentration of 500 
µM in the presence of 10 mM MgCl2, signals corresponding to ATP were observed, 
which can be more clearly seen in the WaterLOGSY experiment. Interestingly, decreases 
of ligand signals in both experiments were observed indicating that ATP was competing 
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with compound 66. 
 
Figure II-8. STD and WaterLOGSY NMR experiment of compound 74 (top left), 91 
(top right), and 66 (bottom two). 
 
 
ITC experiments were then performed to measure the binding constant of compounds 66, 
74, and 91 (Figure II-9). The Kd of each compound was determined to be 0.9 mM, 80 
µM, 14 µM respectively, which correlate well with their thermal shift values.  
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Figure II-9. ITC results of compound 66 (top left), 74 (top right), and 91 (bottom). 
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5. Current exploration and future directions 
X-Ray crystallography studies are being performed in Prof. Steve Almo’s group, which 
will help us to capture the binding interactions and guide further optimization of the 
inhibitor in a rational way. 
 
Until all the experiments mentioned above were completed, the enantiopurity of some 
compounds was measured by chiral SFC analysis. The enantiomeric excess (ee) of 
compound 66 is 62%, of 67 is 98%, of 68 is 98%, of 69 is 80%, of 70 is 28%, of 91 is 
34%. These results indicate that the racemization of the chiral center during the Ullmann 
reaction is a serious problem. Without enantiomerically pure forms of these compounds, 
the comparison between them is invalid, and Kd or IC50 values of the grown fragments 
are not accurate.  
 
We explored ways to make the enantiopure compounds either by recrystallization or via a 
different synthetic route for compounds that cannot be easily recrystallized. It was found 
that the ee of compound 66 was improved by about 5-10% after one round of 
recrystallization from an initial ee of around 50%. At the same time, a different synthetic 
route was explored according to a reported procedure.89 As shown in Scheme II-9, 3-
fluoro-2-nitropyridine underwent a SNAr reaction with an amino ester to generate 
compound 93. The one-pot reduction/cyclization under transfer-hydrogenation conditions 
was low yielding. Nevertheless, the ee of isolated product 66n is determined to be 98%. 
To improve yield of this reaction, classical hydrogenation condition with H2 and Pd/C 
was adopted. The reduction of the nitro group in compound 94 was finished after 3 hours. 
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However, the cyclization did not proceed efficiently. Ammonium formate was then added 
to the reaction mixture after removal of H2 from the flask. The reaction went to 
completion after 12 hours at 40 °C, yielding the desired product 65n with 55% yield and 
98% ee. This new route did lead to a remarkable improvement of enantiopurity compared 
to the Ullmann reaction. Patrick Sheehan is currently resynthesizing several key 
compounds with high enantiopurity so that a valid comparison can be made and accurate 
binding affinities can be determined. 
 
Another way of solving the enantiopurity issue is to run the Ullmann reaction with α-
disubstituted amino acids. By having a α-methyl group instead of the α-H in compound 
91, both the epimerization and oxidation can be prevented at the same time. 
 
Scheme II-9. Synthetic route towards enantiopure aza-quinoxalinone. 
 
 
 
 
 
 
 281 
Chapter II-4. Conclusion and Future Directions 
The concept of DOS was applied to the synthesis of novel fragment libraries to expand 
into the chemical space not covered by traditional fragments. The DOS fragment library 
was designed to have higher sp3 content and more stereochemical and skeletal diversity 
compared to commercial fragment libraries. Modular synthetic pathways following the 
logic of B/C/P has enabled the access of all possible stereoisomers in their enantiopure 
forms. The inclusion of all stereoisomers provided primary SSAR information that was 
used to distinguish between specific binders from nonspecific binders and guide 
modification of the initial hit. Synthetic accessibility of derivatives of building blocks and 
pre-imbedded versatile functional groups allowed rapid access of analogues to gain SAR 
information and optimization of the initial hit. Such efforts can be made to increase the 
potency of the initial hit prior to the gathering of structural information from X-Ray 
crystallography studies. 
 
To evaluate the DOS fragments that have been synthesized, GSK3β was selected as the 
proof-of-concept target. After initial hits were identified by thermal shift screenings, 
analogues were made efficiently via the Ullmann reaction and evaluated by thermal shift 
assays and biochemical assays. The KD was rapidly improved from 0.9 mM to 14 µM as 
determined by ITC experiments. However, the enantiopurity of analogues accessed by 
the Ullmann reaction are not consistently high, which complicated the comparison 
between different analogues and the determination of binding affinities of these 
compounds. The experience so far taught us that the design of synthetic pathways and the 
quality of the compounds within a library are very important for the success and 
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efficiency of the fragment-based approach and are worth the proactive effort. Progress is 
currently being made to solve the enantiopurity issue of the analogues. In addition, 
various DOS fragments from different synthetic pathways including the ones mentioned 
before are being made to increase the size of our library. These novel libraries will be 
screened against a broad array of biological targets to evaluate their biological activities. 
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Experimental Section 
1. Material and Methods 
Except as otherwise noted, reactions were carried out under argon. All reaction solvents 
except acetone and pyridine were dispensed from a solvent purification system wherein 
solvents are passed through a packed activated alumina column. Acetone was Aldrich 
99.5+% histological grade. Pyridine was Aldrich 99.8% histological grade. NMR spectra 
were recorded at 500 MHz or 300 MHz using a Varian I-500 or M-300 instrument. 
Chemical shifts for proton NMR spectra are reported in parts per million downfield from 
tetramethylsilane and were referenced to residual protonated solvent (CHCl3: d 7.26, 
C6H6: d 7.15, CH3OH: 3.34, DMSO: 2.54). Chemical shifts for carbon NMR spectra are 
reported in parts per million downfield from tetramethylsilane and referenced to 
protonated solvent (CHCl3: d 77.0, C6H6: d 128.0, CH3OH: 49.9, DMSO: 39.5). Data are 
represented as follows: chemical shift (multiplicity [bs = broad singlet, s = singlet, d = 
doublet, t = triplet, q = quartet, m = multiplet], coupling constants in Hertz, integration). 
High-resolution mass spectra were obtained through the Harvard University mass 
spectrometry facility. Infrared spectra were obtained with a Nicolet IR100 FTIR from 
Thermo Scientific. Optical rotations were obtained using digital polarimeter Autopol IV 
(Rudolph research Analytical) with a 1 mL cell and a 1 dm path length. All reactions 
were magnetically stirred and monitored by thin-layer chromatography (TLC) using E. 
Merck silica gel 60 F254 precoated plates (0.25 mm). Flash chromatography was 
performed either with the indicated solvent on E. Merck silica gel 60 (230-400 mesh) or 
using a CombiFlash companion system (Teledyne ISCO, Inc.) with pre-packed FLASH 
silica gel columns (Teledyne ISCO, Inc.). SFC/MS chromatography was performed with 
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a Berger analytic SFC (Waters ZQ Mass Spectometer) using CO2 and isopropanol as the 
mobile phase and using a Chiralpak® AD-H column purchased from Chiral Technology 
Inc. (column length: 4.6x250mm, particle size: 5um).  
 
2. Experimental procedures 
A. Synthesis of proline-based fragment library 
The syntheses and characterizations of compounds 1-34 can be found in the paper (Proc. 
Natl. Acad. Sci. U.S.A. 2011, 108, 6799). The synthetic procedures of compounds 35-44 
(Scheme II-4) are described as followings. 
 
To a stirred solution of proline derivative 3’ (0.200 g, 0.78 mmol), allyamine (0.067 g, 
1.18 mmol), ethyl(hydroxyimino)cyanoacetate (0.167 g, 1.18 mmol) and 1-ethyl-3-(3-
dimethylaminopropyl)carbodiimide hydrochloride (0.225 g, 1.18 mmol) in 
dichloromethane (16 mL) was added triethylamine (0.328 mL, 2.35 mmol). The reaction 
was stirred for 4 h at 23 °C.  Saturated aqueous sodium bicarbonate (15 mL) was added 
to the reaction mixture and the aqueous phase was extracted with dichloromethane (3 x 
15 mL). The combined extracts were dried over sodium sulfate and concentrated in 
vacuo. Purification by column chromatography (gradient 20 – 30% ethyl acetate/hexane) 
gave the ally amide 35 as colourless oil (0.210 g, 91%). 
 
To a stirred solution of ally amide 35 (0.066 g, 0.22 mmol) in anhydrous 
dimethylformamide (4.5 mL), methyl iodide (0.64 g, 4.5 mmol) was added.  The 
resulting solution was cooled to 0 °C and sodium hydride (60% in mineral oil, 26.9 mg, 
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0.67 mmol) was added. The reaction was stirred for 4 h at 0 °C.  Saturated aqueous 
ammonium chloride (20 mL) was added to the reaction mixture and the aqueous phase 
was extracted with dichloromethane (3 x 15 mL). The combined extracts were dried over 
sodium sulfate and concentrated in vacuo. Purification by column chromatography 
(gradient 20 – 30% ethyl acetate/hexane) gave 36 as colourless oil (0.050 g, 72%). 
 
To a stirred mixture of 36 (0.070 g, 0.23 mmol) in anhydrous toluene (23 mL) was added 
Grubbs 2nd generation catalyst (0.019 g, 0.02 mmol). The reaction mixture was heated to 
50 °C for 4 h followed by the addition of another portion of Grubbs 2nd generation 
catalyst (0.019 g, 0.02 mmol). After another 12 hours at 50 °C, ethylvinylether (0.327 g, 
4.5 mmol) was added to the reaction and then the solvent was removed in vacuo. 
Purification by column chromatography (gradient 25 – 60% ethyl acetate/hexane) gave 
product 37 as yellow oil (0.038 g, 60%) and product 38 (0.005 g, 8%) as yellow oil. 
Deprotection of the Boc group on either product was performed in 2 ml neat 
trifluoroacetic acid for 5 minutes. The reaction was then concentrated in vacuo. The 
remaining TFA was quenched with anhydrous Na2CO3. The extracts were extracted with 
DCM and concentrated in vacuo respectively to give product 39 and 40 (quantitative).  
 
 
(S)-7-methyl-1,7-diazaspiro[4.6]undec-8-en-6-one (39) 
1H-NMR (500 MHz, CDCl3) δ 5.86 (d, J = 9.5 Hz, 1 H), 5.36 (ddd, J = 9.5, 4.5, 4.5 Hz, 1 
H), 3.65-3.60 (m, 1 H), 3.42-3.37 (m, 1 H), 3.17 (s, 3 H), 2.65-2.61 (m, 1 H), 2.51-2.46 
 286 
(m, 1 H), 2.40-2.22 (m, 4H), 2.19-2.14 (m, 1 H), 1.87-1.79 (m, 1 H); 13C-NMR (125 
MHz, CDCl3) δ 170.8, 128.4, 117.1, 73.0, 45.5, 37.9, 31.9, 31.9, 23.8, 23.6; HRMS (ESI-
TOF) calcd. for C10H16N2O [M+H]+ 181.13354, found 181.13419. 
 
 
(R)-7-methyl-1,7-diazaspiro[4.5]dec-8-en-6-one (40) 
1H-NMR (500 MHz, CDCl3) δ 6.00-5.98 (m, 1 H), 5.16-5.12 (m, 1 H), 3.25-3.21 (m, 1 
H), 3.09 (s, 3 H), 3.08-3.04 (m, 1 H), 2.53-2.49 (m, 1 H), 2.33 (dd, J = 17.0, 6.0 Hz, 1 H), 
1.93-1.80 (m, 4 H); 13C-NMR (125 MHz, CDCl3) δ 167.6, 130.5, 104.7, 66.9, 46.8, 35.0, 
34.5, 29.7, 23.3; HRMS (ESI-TOF) calcd. for C9H14N2O [M+Na]+ 189.09983, found 
189.09997. 
 
 
(S)-7-methyl-1,7-diazaspiro[4.6]undecan-6-one (22) 
A solution of  39 (0.007 g, 0.039 mmol) and palladium hydroxide (20 wt.% Pd on carbon, 
wet, 0.011 g) in methanol (8 mL) was stirred at 25 oC under an atmosphere of hydrogen 
gas for 16 h. The suspension was then filtered through a Celite pad and the filtrate was 
concentrated in vacuo to give compound 22 as a yellow solid (0.006 g, 90%). 1H-NMR 
(500 MHz, CDCl3) δ 9.46 (bs, 1H), 3.60-3.54 (m, 2H), 3.36-3.31 (m, 1H), 3.29-3.25 (m, 
1H), 3.08 (s, 3H), 2.35-2.30 (m, 2H), 2.25-2.15 (m, 2H), 2.03-1.85 (m, 4H), 1.72-1.63 
 287 
(m, 1H), 1.53-1.45 (m, 1H); 13C-NMR (125 MHz, CDCl3) δ 171.7, 73.4, 51.1, 45.1, 39.0, 
32.0, 31.8, 26.9, 25.0, 24.6; HRMS (ESI-TOF) calcd. for C10H18N2O [M+H]+ 183.14919, 
found 183.14985. 
 
To a stirred solution of proline derivative 3’ (0.110 g, 0.43 mmol), (S)-methyl 2-
aminopent-4-enoate trifluoroacetic acid (0.125 g, 0.52 mmol), 
ethyl(hydroxyimino)cyanoacetate (0.092 g, 0.65 mmol) and 1-ethyl-3-(3-
dimethylaminopropyl)carbodiimide hydrochloride (0.124 g, 0.65 mmol) in 
dichloromethane (16 mL) was added triethylamine (0.240 mL, 1.72 mmol). The reaction 
was stirred for 4 h at 25 °C.  Saturated aqueous sodium bicarbonate (15 mL) was added 
to the reaction mixture and the aqueous phase was extracted with dichloromethane (15 
mL, 3 times). The combined extracts were dried over sodium sulfate and concentrated in 
vacuo. Purification by column chromatography (gradient 20 – 30% ethyl acetate/hexane) 
gave the ally amide 41 as colourless oil (0.140 g, 89%). 
 
To a stirred solution of the secondary amide 41 (0.140 g, 0.38 mmol) in anhydrous 
dimethylformamide (7.6 mL), methyl iodide (2.17 g, 15.3 mmol) was added.  The 
resulting solution was cooled to 0 °C and sodium hydride (60% in mineral oil, 45.8 mg, 
1.15 mmol) was added. The reaction was stirred for 4 h at 0 °C.  Saturated aqueous 
ammonium chloride (20 mL) was added to the reaction mixture and the aqueous phase 
was extracted with dichloromethane (15 mL, 3 times). The combined extracts were dried 
over sodium sulfate and concentrated in vacuo. Purification by column chromatography 
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(gradient 20 – 30% ethyl acetate/hexane) gave the tertiary amide 42 as colourless oil 
(0.129 g, 89%). 
 
To a stirred mixture of 42 (0.129 g, 0.34 mmol) in anhydrous dichloromethane (16 mL) 
was added Grubbs 2nd generation catalyst (0.058 g, 0.07 mmol). The reaction mixture 
was heated to reflux for 16 h. The solvent was removed in vacuo. Purification by column 
chromatography (gradient 25 – 45% ethyl acetate/hexane) gave product 43 as a white 
solid (0.012 g, 34%). Deprotection of the Boc group on either product with 2 ml neat 
trifluoroacetic acid followed by concentration in vacuo gave the product 44 as yellow oil 
(quantitative).  
 
 
(5R,8S,Z)-methyl 7-methyl-6-oxo-1,7-diazaspiro[4.7]dodec-10-ene-8-carboxylate (44) 
1H-NMR (500 MHz, CDCl3) δ 5.75-5.68 (m, 2 H), 5.20 (dd, J = 10.2, 6.2 Hz, 1 H), 3.78 
(s, 3 H), 3.49 (bs, 2 H), 3.17-3.13 (m, 1 H), 2.87-2.83 (m, 5 H), 2.78-2.71 (m, 1 H), 2.51-
2.47 (m, 1 H), 2.17-2.08 (m, 2 H), 2.03-1.98 (m, 1 H); 13C-NMR (125 MHz, CDCl3) δ 
169.7, 168.9, 129.8, 125.1, 73.0, 59.6, 52.9, 45.8, 36.9, 35.0, 33.9, 28.0, 22.4; HRMS 
(ESI-TOF) calcd. for C13H20N2O3 [M+H]+ 253.15467, found 253.15519. 
 
 
 289 
(5S,8S)-methyl 7-methyl-6-oxo-1,7-diazaspiro[4.7]dodecane-8-carboxylate (27) 
A solution of 44 (0.019 g, 0.075 mmol) and palladium hydroxide (20 wt.% Pd on carbon, 
wet, 0.011 g) in methanol (8 mL) was stirred at 25 °C under an atmosphere of hydrogen 
gas for 2 h. The suspension was then filtered through a Celite pad and the filtrate was 
concentrated in vacuo to give compound 27 as yellow oil (0.016 g, 84%). 1H-NMR (500 
MHz, CDCl3) δ 4.80 (dd, J = 7.5, 7.5 Hz, 1 H), 3.80 (s, 3 H), 3.50-3.43 (m, 2 H), 2.95 (s, 
3 H), 2.63-2.60 (m, 1 H), 2.26-2.16 (m, 2 H), 2.11-2.01 (m, 4 H), 1.98-1.92 (m, 1 H), 
1.83-1.79 (m, 1 H), 1.70-1.61 (m, 2 H), 1.36-1.28 (m, 1H); 13C-NMR (125 MHz, CDCl3) 
δ 172.7, 171.8, 74.7, 61.6, 53.3, 47.8, 39.5, 36.8, 28.6, 23.5, 23.4, 22.5; HRMS (ESI-
TOF) calcd. for C13H22N2O3 [M+H]+ 255.17032, found 255.17059. 
 
B. Synthesis of alkenylsiloxane-based fragment library 
Following the general hydrosilylation and RCM procedures described in Chapter I-7-2, 
compounds 46, 51, and 53 were efficiently synthesized. 
 
 
(R)-tert-butyl (6-(diethoxy(methyl)silyl)-1-methyl-2-oxo-2,3,4,7-tetrahydro-1H-
azepin-3-yl)carbamate (46) 
Yield 62% (colorless oil); 1H-NMR (500 MHz, CDCl3) δ 6.18-6.17 (m, 1 H), 5.79 (d, J = 
5.5 Hz, 1 H), 4.99-4.94 (m, 1 H), 4.43-4.39 (m, 1 H), 3.78-3.69 (m, 4 H), 3.52 (d, J = 
17.5 Hz, 1 H), 3.01 (s, 3 H), 2.79-2.73 (m, 1 H), 2.26-2.20 (m, 1 H), 1.42 (s, 9 H), 1.19 (t, 
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J = 7.0 Hz, 6 H), 0.15 (s, 3 H); 13C-NMR (125 MHz, CDCl3) δ 172.0, 155.1, 142.2, 
133.3, 79.5, 58.4, 49.2, 48.0, 35.7, 35.2, 28.3, 18.2, -5.5. 
 
 
(R)-tert-butyl (6-(diethoxy(methyl)silyl)-1-((2-nitrophenyl)sulfonyl)-2-oxo-2,3,4,7-
tetrahydro-1H-azepin-3-yl)carbamate (51) 
Yield 70% (colorless oil); 1H-NMR (500 MHz, CDCl3) δ 8.46-8.44 (m, 1 H), 7.80-7.75 
(m, 3 H), 6.32 (dd, J = 2.7, 2.7 Hz, 1 H), 5.40 (d, J = 7.0 Hz, 1 H), 5.10-5.06 (m, 1 H), 
4.86 (d, J = 17.0 Hz, 1 H), 4.51-4.47 (m, 1 H), 3.82-3.75 (m, 1 H), 2.88-2.84 (m, 1 H), 
2.48-2.42 (m, 1 H), 1.38 (s, 9 H), 1.27-1.22 (m, 6 H), 0.26 (s, 3 H); 13C-NMR (125 MHz, 
CDCl3) δ 172.5, 154.5, 147.9, 141.7, 134.7, 134.7, 1333.3, 132.9, 132.0, 124.6, 81.1, 
58.6, 58.6, 51.1, 44.2, 35.4, 28.2, 18.2, -5.0. 
 
 
(R)-tert-butyl (6-iodo-1-methyl-2-oxo-2,3,4,7-tetrahydro-1H-azepin-3-yl)carbamate 
(48) 
To a stirred solution of compound 46 (155 mg, 0.42 mmol) in HFIP (6 mL) was added 
NIS (281 mg, 1.25 mmol) at room temperature. The resulting mixture was warmed up to 
50 °C, and stirred for 3 hours. The reaction was then quenched with aqueous Na2S2O3 (10 
%), extracted with EA. The extract was concentrated in vacuo and purified by column 
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chromatography (gradient 10 – 40% ethyl acetate/hexane) to give compound 48 as 
yellowish oil (0.060 g, 61%). 1H-NMR (300 MHz, CDCl3) δ 6.38-6.35 (m, 1 H), 5.73 (d, 
J = 5.7 Hz, 1 H), 4.90-4.72 (m, 2 H), 3.71 (d, J = 18.6 Hz, 1 H), 3.08 (s, 3 H), 2.64-2.54 
(m, 1H), 2.25-2.19 (m, 1 H), 1.39 (s, 9 H). 
 
 
 (R)-tert-butyl (6-(2-chloropyridin-3-yl)-1-methyl-2-oxo-2,3,4,7-tetrahydro-1H-
azepin-3-yl) carbamate (49) 
Following the procedure described in ref. 80, to a stirred solution of compound 48 (80 
mg, 0.22 mmol) in DMF (8 mL) was added (2-chloropyridin-3-yl)boronic acid (52 mg, 
0.33 mmol), DPPF (8.5 mg, 15 µmol), and sodium carbonate solution (0.65 mL, 1 M). 
The resulting mixture was warmed up to 70 °C and stirred for 3 hours. The reaction was 
then cooled to room temperature after 2 hours, quenched with water, extracted with EA 
(3 times). The extract was washed with brine, dried with sodium sulfate, concentrated in 
vacuo and purified by column chromatography (25-55% EA in hexane) to afford the title 
compound as yellowish solid (65 mg, 63%). 1H-NMR (300 MHz, CDCl3) δ 8.31-8.29 (m, 
1 H), 7.48-7.45 (m, 1 H), 7.23-7.19 (m, 1 H), 5.87 (d, J = 6.3 Hz, 1 H), 5.73-5.71 (m, 1 
H), 5.07-4.99 (m, 1 H), 4.87-4.78 (m, 1 H), 3.52 (d, J = 17.4 Hz, 1 H), 3.11 (s, 3 H), 2.88-
2.78 (m, 1 H), 2.39-2.27 (m, 1 H), 1.42 (s, 9 H). 
 
C. Synthesis of GSK3β  inhibitors 
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The syntheses and characterizations of compounds 60 and 61 can be found in the paper 
(Org. Lett. 2011, 13, 5556). 
 
General procedure for Ullmann reaction/cyclodehydration sequence: adapted from the 
reported procedure, in a pressure tube, a suspension of 2-bromoaniline (1 equiv.), amino 
acid (2 equiv.), K3PO4 (2 equiv.), cuprous (I) chloride (2 mol%), and N,N′-
dimethylethylenediamine (DMEDA) (20 mol%) in dry DMSO (0.3 M) was deoxygenated 
with argon and sealed with PTFE plug. The reaction mixture was then stirred at 120oC for 
24 h. The mixture was treated with water (20 mL) and the mixture was extracted three 
times with EtOAc. The combined organic layers were dried over anhydrous sodium 
sulfate. After filtration, solvent was evaporated to give the crude product, which was 
subjected to chromatography on silica gel (hexanes/EtOAc or DCM/MeOH) providind 
the desired compound. 
 
 
(S)-2-methyl-1,2-dihydropyrido[2,3-b]pyrazin-3(4H)-one (65) 
Yield 24% (yellowish solid); 1H-NMR (500 MHz, d6-DMSO) δ 10.7 (s, 1 H), 7.61-7.59 
(m, 1 H), 7.01-7.00 (m, 1 H), 6.84-6.81 (m, 1 H), 6.28 (s, 1 H), 3.92-3.88 (m, 1 H), 1.30 
(d, J = 7.0 Hz, 3 H); 13C-NMR (125 MHz, d6-DMSO) δ 169.1, 140.7, 136.1, 130.2, 
118.9, 118.6, 50.7, 17.7. 
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(R)-2-methyl-1,2-dihydropyrido[2,3-b]pyrazin-3(4H)-one (66) 
Yield 46% (yellowish solid); 1H-NMR (500 MHz, d6-DMSO) δ 10.7 (s, 1 H), 7.61-7.59 
(m, 1 H), 7.01-7.00 (m, 1 H), 6.84-6.81 (m, 1 H), 6.28 (s, 1 H), 3.92-3.88 (m, 1 H), 1.30 
(d, J = 7.0 Hz, 3 H); 13C-NMR (125 MHz, d6-DMSO) δ 169.1, 140.7, 136.1, 130.2, 
118.9, 118.6, 50.7, 17.7. 
 
 
(R)-2-methyl-1,2-dihydropyrido[3,4-b]pyrazin-3(4H)-one (67) 
Yield 6% (brown solid); 1H-NMR (500 MHz, CD3OD) δ 7.79 (d, J = 5.5 Hz, 1 H), 7.75 
(s, 1 H), 6.63(d, J = 5.5 Hz, 1 H), 4.59 (s, 2 H), 4.10 (q, J = 7.0 Hz, 1 H), 1.40 (d, J = 7.0 
Hz, 3 H). 
 
 
(R)-3-methyl-3,4-dihydropyrido[3,4-b]pyrazin-2(1H)-one (68) 
Yield 14% (brown solid); 1H-NMR (500 MHz, CD3OD) δ 7.88 (s, 1 H), 7.79 (d, J = 4.0 
Hz, 1 H), 6.76 (d, J = 5.0 Hz, 1 H), 3.97 (q, J = 6.5 Hz, 1 H), 3.34 (s, 1 H), 1.38 (d, J = 
6.0 Hz, 3 H); 13C-NMR (125 MHz, CD3OD) δ 168.7, 139.7, 134.6, 132.4, 130.9, 109.1, 
50.7, 17.5. 
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(R)-3-methyl-3,4-dihydropyrido[2,3-b]pyrazin-2(1H)-one (69) 
Yield 33% (yellowish solid); 1H-NMR (500 MHz, d6-DMSO) δ 10.4 (s, 1 H), 7.66-7.65 
(m, 1 H), 6.97-6.96 (m, 1 H), 6.85 (s, 1 H), 6.62-6.59 (m, 1 H), 4.05-4.01 (m, 1 H), 1.33 
(d, J = 7.0 Hz, 2 H). 
 
 
(S)-3-methyl-3,4-dihydropyrido[2,3-b]pyrazin-2(1H)-one (70) 
Yield 18% (yellowish solid); 1H-NMR (500 MHz, d6-DMSO) δ 10.4 (s, 1 H), 7.66-7.65 
(m, 1 H), 6.97-6.96 (m, 1 H), 6.85 (s, 1 H), 6.62-6.59 (m, 1 H), 4.05-4.01 (m, 1 H), 1.33 
(d, J = 7.0 Hz, 2 H); 13C-NMR (125 MHz, d6-DMSO) δ 167.5, 147.0, 141.0, 120.8, 
119.9, 113.3, 50.8, 18.5. 
 
 
(R)-2-isopropyl-1,2-dihydropyrido[2,3-b]pyrazin-3(4H)-one (73) 
Yellowish solid; 1H-NMR (500 MHz, CD3OD) δ 7.56 (d, J = 5.0 Hz, 1 H), 7.02 (d, J = 
7.5 Hz, 1 H), 6.81 (dd, J = 7.0, 5.0 Hz, 1 H), 3.76 (d, J = 5.0 Hz, 1 H), 2.13-2.07 (m, 1 
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H), 1.00 (d, J = 7.0 Hz, 3 H), 0.92 (d, J = 7.0 Hz, 3 H); 13C-NMR (125 MHz, CD3OD) δ 
170.5, 140.6, 136.6, 131.8, 120.6, 120.1, 62.8, 33.4, 19.1, 17.8. 
 
 
(R)-2-(4-hydroxybenzyl)-1,2-dihydropyrido[2,3-b]pyrazin-3(4H)-one (74) 
Yellowish solid; 1H-NMR (500 MHz, d6-DMSO) δ 10.6 (s, 1 H), 9.15 (s, 1 H), 7.47-7.46 
(m, 1 H), 6.95-6.93 (m, 3 H), 6.74-6.72 (m, 1 H), 6.61 (d, J = 8.0 Hz, 2 H), 6.04 (s, 1 H), 
4.04-4.01 (m, 1 H), 2.82 (dd, J = 13.5, 4.5 Hz, 1 H), 2.75 (dd, J = 13.5, 7.0 Hz, 1 H); 13C-
NMR (125 MHz, d6-DMSO) δ 167.8, 155.8, 139.9, 135.5, 130.6, 129.5, 126.8, 118.7, 
118.6, 56.9, 37.4. 
 
 
(R)-2,4-dimethyl-1,2-dihydropyrido[2,3-b]pyrazin-3(4H)-one (77) 
Yield 79% (yellowish solid); 1H-NMR (500 MHz, d6-DMSO) δ 7.75-7.74 (m, 1 H), 7.08-
7.06 (m, 1 H), 6.92-6.89 (m, 1 H), 6.38 (s, 1 H), 3.98 (q, J = 6.5 Hz, 1 H), 3.35 (s, 3 H), 
1.32 (d, J = 7.0 Hz, 3 H). 
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2,2-Dimethyl-1,2-dihydropyrido[2,3-b]pyrazin-3(4H)-one (80) 
Yellowish solid; 1H-NMR (500 MHz, d6-DMSO) δ 10.6 (s, 1 H), 7.62-7.61 (m, 1 H), 
7.01-7.00 (m, 1 H), 6.85-6.82 (m, 1 H), 6.25 (s, 1 H), 1.27 (s, 6 H). 
 
 
1'H-spiro[cyclopentane-1,2'-pyrido[2,3-b]pyrazin]-3'(4'H)-one (81) 
Yellowish solid; 1H-NMR (500 MHz, d6-DMSO) δ 10.6 (s, 1 H), 7.62-7.61 (m, 1 H), 
7.05-7.03 (m, 1 H), 6.84-6.82 (m, 1 H), 6.34 (s, 1 H), 2.08-2.03 (m, 2 H), 1.82-1.75 (m, 2 
H), 1.70-1.56 (m, 4 H). 
 
 
(R)-2-((1H-indol-3-yl)methyl)-1,2-dihydropyrido[2,3-b]pyrazin-3(4H)-one (91) 
Yellowish solid; 1H-NMR (500 MHz, d6-DMSO) δ 10.8 (s, 1 H), 10.6 (s, 1 H), 7.50 (d, J 
= 8.0 Hz, 1 H), 7.47-7.46 (m, 1 H), 7.30 (d, J = 8.0 Hz, 1 H), 7.10-7.09 (m, 1 H), 7.04 
(dd, J = 7.0, 7.0 Hz, 1 H), 6.96-6.91 (m, 2 H), 6.71 (dd, J = 7.5, 5.0 Hz, 1 H), 6.05-6.04 
(m, 1 H), 4.15-4.12 (m, 1 H), 3.09 (dd, J = 15.0, 4.0 Hz, 1 H), 2.98 (dd, J = 15.0, 7.5 Hz, 
1 H); 13C-NMR (125 MHz, d6-DMSO) δ 168.2, 140.0, 136.1, 135.5, 129.5, 127.5, 124.1, 
120.8, 118.7, 118.6, 118.3, 118.3, 111.3, 109.1, 56.2, 28.3. 
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2-Methylpyrido[2,3-b]pyrazin-3(4H)-one (78) 
To a solution of 8% aqueous sodium hydroxide (1.0 mL) was added compound 65 (48 
mg, 0.3 mmol) followed by a solution of 30 wt% hydrogen peroxide in water (0.6 mL). 
The reaction mixture was slowly heated to 80 °C and maintained at this temperature for 4 
h. The heating source was removed, and acetic acid (0.5 mL) was added dropwise. The 
suspension was stirred overnight at room temperature and the precipitated solid was 
collected by filtration to afford the desired product 78 as white solid. 1H-NMR (500 
MHz, d6-DMSO) δ 12.7 (bs, 1 H), 8.46 (s, 1 H), 8.10 (d, J = 7.5 Hz, 1 H), 7.33-7.31 (m, 1 
H), 2.40 (s, 3 H); 13C-NMR (125 MHz, d6-DMSO) δ 160.7, 156.2, 149.1, 144.0, 135.8, 
126.8, 119.5, 20.5. 
 
 
2,3-Dihydro-1H-pyrido[2,3-b][1,4]diazepin-4(5H)-one (79) 
A pressure tube was charged with CuI (19 mg, 0.1 mmol), 2-bromoaniline (0.35 g, 2 
mmol), 2-azetidinone (0.17 g, 2.4 mmol), and K2CO3 (0.86 g, 4.1 mmol), evacuated, and 
backfilled with argon. N,N′-Dimethylethylenediamine (DMEDA) (18 mg, 0.10 mmol) 
and DMF (10 mL) were added under argon. The pressure tube was sealed with a PTFE 
plug and the reaction mixture was stirred at 110 °C for 24 h in a preheated oil bath. The 
resulting brown-black suspension was allowed to reach room temperature, filtered 
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through a silica gel plug eluting with 10:1 CH2Cl2/MeOH (50 mL), and the red filtrate 
was concentrated. The oily residue was transferred to a pressure tube, which was then 
evacuated, backfilled with argon, and sealed with a rubber septum. Ti(OiPr)4 (0.2 g, 0.7 
mmol) and toluene (6 mL) was added to the pressure tube and the septum was replaced 
with a PTFE plug under a stream of argon. The sealed pressure tube was placed in an oil 
bath preheated to 120 °C. After being stirred at 120 °C for 24 h, the reaction mixture was 
allowed to reach room temperature and then filtered through a silica gel plug eluting with 
10:1 CH2Cl2/MeOH (50 mL). The filtrate was concentrated, and the residue was purified 
by column chromatography on silica gel (CH2Cl2/MeOH) to provide the desired product 
as yellowish solid. 1H-NMR (500 MHz, d6-DMSO) δ 9.49 (s, 1 H), 7.66-7.53 (m, 1 H), 
7.09 (d, J = 8.0 Hz, 1 H), 6.88-6.86 (m, 1 H), 5.98 (s, 1 H), 3.40 (dt, J = 5.0, 5.0 Hz, 2 H), 
2.56 (t, J = 5.0 Hz, 2 H); 13C-NMR (125 MHz, d6-DMSO) δ 172.1, 138.8, 136.6, 135.2, 
125.3, 119.7, 42.6, 37.5. 
 
 
(S)-2-methyl-1,2,3,4-tetrahydropyrido[2,3-b]pyrazine (76) 
To a stirred solution of compound 65 (22 mg, 0.14 mmol) in THF (1 mL) was added 
BH3⋅THF solution (1 M, 0.67 mL) dropwise. The reaction was monitored by TLC until 
the disappearance of starting materials and then quenched with NaHCO3 solution 
(saturated), extracted with EA (3 times). The extract was washed with brine, dried with 
sodium sulfate, concentrated in vacuo and purified by column chromatography 
(MeOH/DCM) to afford 76 as brown oil (10 mg, 48% yield). 1H-NMR (500 MHz, 
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CDCl3) δ 7.47 (d, J = 5.0 Hz, 1 H), 6.63 (d, J = 7.5 Hz, 1 H), 6.46 (dd, J = 7.5, 5.0 Hz, 1 
H), 4.87 (bs, 1 H), 3.52-3.49 (m, 1 H), 3.43 (dd, J = 11.0, 2.5 Hz, 1 H), 3.17 (dd, J = 10.5, 
8.5 Hz, 1 H), 1.20 (d, J = 6.5 Hz, 3 H). 
 
D. Revised synthetic route 
Adapted from ref. 89. 
General procedure for SNAr: to a stirred solution of 2-Nitro-3-fluoropyridine (1 equiv.) 
and methyl amino ester (or its hydrochloride salt, 2 equiv.) in DMSO (0.5 M) was added 
DIPEA (4 equiv.) at room temperature. The resulting mixture was warmed up to 50 °C 
and stirred for 18 hours. The reaction was then cooled to room temperature, quenched 
with NaHCO3 solution (saturated), extracted with EA (3 times). The extract was washed 
with brine, dried with sodium sulfate, concentrated in vacuo and purified by column 
chromatography (EA/hexane or MeOH/DCM) to afford the uncyclized product. 
 
General procedure for cyclization: a solution of uncyclized nitro-containing compound (1 
equiv.) and palladium on carbon (10 wt.% Pd on carbon, wet, 0.05 equiv.) in solvent 
mixture of EA and ethanol (1:1, 0.1 M) was stirred at 25 °C under an atmosphere of 
hydrogen gas for 4 hours. The reaction flask was then purged with argon to replace 
hydrogen followed by the addition of ammonium formate (1 equiv.). The resulting 
mixture was warmed up to 40 °C and stirred for 18 hours. The suspension was then 
filtered through a Celite pad and the filtrate was concentrated in vacuo and purified by 
column chromatography (EA/hexane or MeOH/DCM) to afford the cyclized product. 
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E. Biochemical and biophysical assays 
Thermal shfit Assay: 
Florescence thermal shift experiments were performed on a 480 Roche Lightcycler in a 
384 well format. The fragments were tested at 2.5 mM with 2.5 % DMSO. The optimal 
condition was determined to be 0.12 mg/mL GSK3β and 1:400 dilution of Sypro Orange 
from the original stock. The assay was performed with final volume of 5 µL using a 
buffer solution containing 50 mM HEPES (pH 7.5) and 150 mM NaCl. Fragments that 
gave a thermal shift greater 0.5 oC were considered hits. 
 
Isothermal Titration Calorimetry: 
ITC experiments were performed on an ITC200 instruments from Microcal Inc. (GE 
Healthcare) at 25  °C. ITC cell was loaded with GSK3 β in concentrations of 50-85  µM 
with 2-5 % DMSO solution. Ligands were tested at 0.5-2 mM concentrations. Typically, 
18 injections of 2.4 µL ligand were performed over a period of 30 min with stirring at 
1000 rpm.    
 
Biochemical assay:  
The assay kit was acquired from Promega V9103, ADP Glo. 
First, 4 µL/well of CABPE, 2 µL of ATP (Promega V9103 component, in AB, 125 mM 
concentration), and 4 µL of ligand (2.5 mM in AB with 5% DMSO), DMSO (5% in AB), 
or positive control (GW8510, 20 µM in AB with 5% DMSO) was dispensed into 
respective wells of a 384-well plate (Corning 3572) to start the reaction. The reaction was 
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incubated at room temperature for 20 minutes. Second, 10 µL/well of ADP-Glo reagent 
was added to terminate the reaction. The plate was incubated at room temperature for 40 
minutes. Last, 20 µL/well of kinase detection reagent was added. After 30 minutes 
incubation at room temperature, luminescence was read on an Envision (PerkinElmer) 
plate reader. 
 
Buffer conditions: AB: 25 mM tris(hydroxymethyl)aminomethane, 10 mM magnesium 
chloride, pH adjusted to 7.5. CABPE (in AB): 12.5 mM dithiothreitol (Sigma 43816), 
0.25 mg/mL bovine serum albumin (Sigma A4503), 0.5 U/mL heparin (Baxter NDC 
0641-2440-41), 8 µM GSM (GSK3 substrate peptide, Millipore 12-533), 9 nM GSK3beta 
(XTAL Biostructures).  
 
NMR experiments: 
All spectra were recorded at 298 K on a Bruker Avance 600 MHz NMR spectrometer 
equipped with z-axis gradients. The data were collected with a sweep width of 12019 Hz 
and 8192 complex points. For each sample 1D 1H, STD,90 and WaterLOGSY91 spectra 
were collected with water suppression using excitation sculpting.92 The 1D 1H spectrum 
was acquired with 128 scans and a relaxation delay of 1.5s. The STD experiment was 
acquired with a 3s saturation period (50ms Gaussian shaped pulse), a recycle delay of 
0.5s and 256 scans each for the on-resonance (0.8ppm) and off-resonance (-25ppm). The 
WaterLOGSY experiment was acquired with 512 scans, a mixing time of 2.3s, and a 
recycle delay of 1.3s. The relaxation-edited experiment was acquired with 256 scans, a 
recycle delay of 2s and a 300ms CPMG spin-lock period. All spectra were processed 
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using nmrPipe93 and prior to Fourier transformation the data were multiplied by and 
shifted sine-bell weighting function and an exponential function with a line broadening of 
0.5Hz. 
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